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1 Introduction 
1.1 VIP and PACAP 
Vasoactive intestine peptide (VIP) was first isolated from porcine small intestine in the 
1790s by Said and Mutt (1970; 1972). Vasoactive intestinal peptide (VIP) and pituiatary 
adenylate cyclase activating polypeptide (PACAP) belong to the same superfamiliy of 
structually releated growth hormone peptides (fig.1). This familiy also includes secretin, 
glucagon, growth hormon releasing factor (GRF) and the glucagon-like peptide-1 and 2 
(GLP-1, GLP-2). This familiy of peptides has a common duplication of an anchestral 
gene, six genes encode nine bioactive hormons (Sherwood et al. 2000). 
Pituitary adenylate cyclase activating peptide (PACAP) was first isolated from ovine 
hypothalamic tissue by Miyata et al. (1989). PACAP consists of 38 amino acids 
residues (PACAP-38) and is C-terminally amidated. It has the ability to stimulate 
adenlyate cyclase in cultured rat anterior pituitary cells.  
 
Figure 1. Human Amino acid sequence of the different members of the PACAP-VIP-GRF-
glucagon superfamily. Underlined residues indicate amino acids different from those of VIP. In 
PACAP-38, GKR (Gly28-Lys29-Arg30) is the internal cleavage- amidation site. [from (Bachem 2005)] 
1.1.1 Cellular synthesis  
VIP is a 28 amino acid long peptide which is synthesied as a precourser peptide of 170 
amino acids containing a VIP-related peptide called PHM (fig.2).  
 
 
 
 
Figure 2. Schematic illustration of human prepro-VIP, and the localisation SP (signal pepide), 
mature PHM and VIP sequences. Amino acid numbers are shown below. [from (Bachem 2005)] 
 
Posttranslational modifications occur in the endoplasmatic reticulum and by signal 
peptidase to a 148 aa pro-VIP. Pro-VIP is cleaved by the trypsin-like peptidase to VIP-
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GRK (prepro-VIP125-155) and PHI/PHM-GRK (prepro-VIP81-110) and these precursers are 
cleaved by carboxypeptidase-B-like enzyme to VIP-G and PHI/PHM-G. Finally the 
peptide fragments are metabolized by an amidation enzyme and results in a biologically 
active C-terminally amidated VIP and PHI/PHM, which is released as a secretory 
vesicle (fig.3).  
 
 
Figure 3. Processing steps from prepro-VIP to 28 amino acids long VIP. The peptides substrates 
and products are indicated on the left and the number of amino acids is indicated in parentheses. The 
processing enzymes are shown on the right. [from (Moody 1996)] 
 
VIP precursers can also be processd by an alternative splicing pathway. In this route the 
normal cleaving site after PHI remains uncleaved, resulting in a C-terminally extended 
form termed PHV (peptide with N-terminal histidine and C-terminal valine).  
PACAP occures in two biological active stages, PACAP-38 and an alternative splice 
variant corresponding to its N-terminal 27 amino acids (PACAP-27). PACAP-38 
sequence contains an internal cleavage-amidation site (Gly
28
-Lys
29
-Arg
30
) which can be 
used to generate PACAP-27 (fig.4). PACAP-38 is the prodominant form, but the 
distribution and ratio of PACAP-38/-27 varies between tissues especially in the central 
nervous system (CNS), adrenal and testis (Sherwood et al. 2000). 
 
 
Figure 4. Schematic illustration of the general organisation of human prepro-PACAP, and the 
localisation of mature PRP; PACAP-27 and PACAP-38 sequence. Amino acid numbers are shown 
below; SP: signal peptide. [from (Bachem 2005)] 
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PACAP is hightly conserved during evolution, its amino acid sequence is identical in 
rat, sheep and human. It differs in frogs and some fishes, but with a complementarity of 
86-92% (Sherwood et al. 2000). In mammals PACAP has a strong similarity with the 
VIP precurser. The posttranslational cleavage site of the 176 amino acid precurser 
(prepro-PACAP) results in the following peptides: PACAP-38, PACAP-27 and the 29 
amino acid PACAP-relates peptide (PRP) which has some structure homology to 
PACAP-27 (fig.4). The N-terminal 28 amino acid sequence of PACAP-38 showes 
considerable sequence homology (68%) with VIP (fig.1), but its adenlyate cyclase 
stimulating activity is 1000 times greater than VIP.  
As shown by circular dichroism and nuclear magnetic resonance, the N-terminus of VIP 
and PACAP-27 is essential for their biological activity (Christophe et al. 1988). The 
analyses of Christophe et al. revealed an alpha-helical structure of the amino acids 15-
28 and two beta-turns at the position 1-4 and 6-10.  
1.1.2 Biological activity 
VIP has many important functions in cellular processes. It acts as neuropeptide in many 
tissues additionally to the intestine. It relaxes smooth muscles in blood vessel and the 
gut. The alternatively spliced peptide is as potent as VIP in relaxing smooth muscle 
(Moody 1996). VIP and PACAP can be a stimulator of mucose secretion. 
In the nervous sytem VIP acts as neuromodulator, it was suggested to be associated with 
the “visceral forebrain system” that influences and temporarily controls cardiovascular, 
respiratory and gastrointestinal functions. In the endocrine system VIP activates 
hormone relase, like VIP released prolactin (PRL), luteinzing hormone (LH) and growth 
hormone (GH) from the pituitary gland. It acts on the pancras to release either insulin or 
glucagon, depending on the glucose level. VIP also functions on the exocrine pancreas 
to increase the bicarbonate output and acts on non-neuronal tissue such as the gonads 
and some immune cells. During embryogenesis, VIP is expressed in the embryonic 
brain and has trophic and mitogenic effects (Sherwood et al. 2000).  
Like VIP, PACAP is involved in multiple biological processes including reproduction, 
development, growth, cardiovascular, respiratory and digestive function, immune 
response and circadian rhythms (Vaudry et al. 2000). 
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1.1.3 Receptors  
VIP and the alternative splicing variants are selectively binding to surface membrane 
receptors. They belong to the large family of class II G-protein coupled receptors 
(GPCR), which have a common structure of seven transmembrane domains (7TM). 
These domains are linked together by three extracellular (EC1, EC2, EC3) and three 
intracellular (IC1, IC2, IC3) oligopeptide loops. The polypeptide has a long amino-
terminal extracellular domain and an intracellular carboxyl terminus. GPCR share 
several important properties, the most important is the large N-terminal extracellular 
domain which contains 10 highly conserved amino acids including six cysteins, a 
putative N-terminal leader sequence and several potential N-glycosylation sites. G-
protein coupled receptors trigger mainly the adenlyate cyclase pathway via stimulatory 
Gs-proteins (Gs). The stimulatory Gq-proteins (Gq) activate the inositol phospholipid 
signalling pathway (PLC/PI). There are three types of receptors which can interact with 
VIP and PACAP. According to the Union of Pharmacology (UIPHAR) the 
nomenclature of these human VPAC receptors (VIP/PACAP) has been classified in 
three subtypes: VPAC1, VPAC2 and PAC1 (Harmar et al. 1998; Laburthe and Couvineau 
2002). 
1.1.3.1 VPAC1 
The first recombinant receptor for VIP and PACAP was isolated from rat lung by 
Ishihara et. al (2002), the human homologue has also been cloned and expressed in cell 
lines. The gene for the VPAC1 is located on human chromosome 3p22, it has 13 exons 
ranging in the size from 42-1400bp. The receptor consists of 457 amino acid residues 
and is also known as VIP1 or VIP/PACAP type II or PVR2. VPAC1 receptor has a high 
affinity for VIP and PACAP (IC50, 1nM), low affinity for PHI, PHV (IC50, 100nM, 
3000nM) and secretin (IC50, 1500nM) which differs from rat VPAC1 affinity. Signal 
transduction primarily occurs via the adenlyate cyclase pathway.  
Splice variants of VPAC1 were recently discovered by Bokaei et al. (2006) where two 
novel human 5TM VPAC receptor isoforms are described. The isoforms are differently 
expressed in peripheral blood mononuclear and cord blood cells and in malignant 
hematopoietic-and epithelial-derived cancer cell lines. Five transmembrane (5TM) 
isoforms lack a G-protein binding site and therefore have a significantly decreased 
lower cAMP response production as to VIP. 
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VPAC1 is found in certain regions in the brain, especially in the cerebral cortex and 
hippocampus and predominantly expressed in the peripheral tissue such as liver, lung 
and intestine (Ishihara et al. 1992; Usdin et al. 1994). VPAC1 is also expressed by 
resting T lymphocytes and peripheral blood monocytes (Delgado et al. 1996). 
1.1.3.2 VPAC2 
A second receptor that responds to VIP and PACAP with high affinity was first cloned 
from the rat olfactory bulb by Lutz et al. (1993). The receptor VPAC2 is also known as 
VIP-R2 or VIP/PACAP type III or PVR3. VPAC2 consists of 460 amino acid residues, 
the gene is located on chromosome 7q36.3 and it contains of 13 exons. Rat and human 
VPAC2 recognize VIP (IC50, 3-4nM), PHI and PHV (IC50, 10-30nM) and PACAP-27 
(IC50, 10nM) and PACAP-38 (IC50, 30mM). The receptors also recognize GRF and 
secretin with a very low affinity (IC50, 5000-30.000nM). Ligand binding to VPAC2 
results in the preferential activation of adenlyate cyclase.  
VPAC2 expression is found in the CNS in high concentrations in the suprachiasmatic 
nucleus (SCN) and thalamus, in lower concentration in the hippocampus, brainstem, 
spinal cord and dorsal root ganglion (Sheward et al. 1995; Usdin et al. 1994). VPAC2 is 
also distributed in several peripheral tissues, including pancreas, skeletal muscle and 
smooth muscles, kidney, stomach, heart and testis (Adamou et al. 1995; Krempels et al. 
1995; Wei and Mojsov 1996). 
1.1.3.3 PAC1 
A third receptor subtype was isolated by Pisegna and Wank (1993) from rat pancreatic 
acinar carcinoma cell line AR4-2J. This PACAP preferring receptor subtype is termed 
PAC1 also known as VIP/PACAP type I or PVR1. The receptor shows a high affinity for 
PACAP-27 and PACAP-38 (IC50, 1nM) but a much lower affinity to VIP (IC50, 
1000nM), with very low affinities it also binds PHI, PHV, secretin and GRF. The PAC1 
gene is located on chromosome 7p14 and encodes 495 amino acids. Unlike to VPAC1 
and VPAC2, PAC1 has several splice variants without systematic nomenclature. PAC1 
receptors prefer both, the adenlyate cyclase (AC) and the phospholipase C (PLC) 
signalling pathway for signal transduction. The alternative splicing variants contain or 
lack two exons (hip and hop) in the third intracellular domain, therefore six alternative 
splice variants can occur. These have different signal transduction pathways. A splice 
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variant of PAC1 in the third cytoplasmatic loop, hop2, was suggested to be involved in 
VIP-related neuroprotection in cell culture. VIP protects cells expressing hop2 from 
oxidative stress and mediates cytoprotective effects (Pilzer and Gozes 2006). 
The receptor is predominantly expressed in the CNS, most abundantly in the olfactory 
bulb, thalamus, hypothalamus and granules cells of the cerebellum (Hashimoto et al. 
1996; Spengler et al. 1993). It is also found in the adrenal medulla (Sundler et al. 1996).  
1.1.3.4 Receptor selectivity 
Site directed mutagenesis studies showed that the N-terminal ectodomain (N-ted) of 
VPAC receptor plays a crucial role in ligand binding. The physical interaction domains 
of VIP and VPAC1 are the side chains at position 6, 22, 24 which are in direct contact 
with amino acids in the receptor´s N-ted domain. Short consensus repeats (SCR) which 
lie towards the N-terminus of the cell surface receptors play a crucial structural role. 
They are involved in ligand recognition. The N-terminal domain of VIP His
1
-Phe
6
 is 
largely disordered in solution whereas the C-terminal Ser
25
-Asn
28
 are very flexible and 
close to a helical conformation state which was discovered by NMR studies (Laburthe 
et al. 2007). The author described a “two domain model” for VPAC receptors binding, 
where VIP is sandwiched between N-ted and the core receptor. The central part and 
carboxyl terminal of VIP bind to the receptor and peptide amino terminal segments 
docks to the heptahelical receptor core. The N-ted domain ensured receptor affinity and 
positions the peptide´s N-terminus to the receptor core for activation. Additional to this 
model a new mechanism “hidden agonist within the N-ted” was suggested recently 
(Dong et al. 2006) where N-ted is still bound to the ligand but exposes a hidden epitope 
that is present within the N-ted domain of receptors. The N-ted epitope becomes an 
agonist by activating the receptor and interacting with the heptahelical core of the 
receptor. 
PAC1 receptors with the N-ted domain are selective and specific for the agonist PACAP, 
while splice variants which delete the N-ted sequence are less specific (Laburthe and 
Couvineau 2002).  
1.1.3.5 Receptor recycling 
Unstimulated cells show slow endocytosis of receptors from the surface into 
endosomes, whereas agonist-stimulated cells dramatically increase their endocytosis 
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rate. After endocytosis and ligand detachment, the receptor can be recycled back to the 
membrane or to a smaller extent it can be routed to lysosomes. G-protein coupled 
receptors are extremely temperature and energy dependent, temperatures below 16°C 
prevents endocytosis. Agonist stimulated accumulation of GPCR occurs in clathrin-
coated pits after budding from the cell surface to form clathrin-coated vesicles. The 
reduction of surface receptors is termed internalisation or sequestration, which occurs 
either as endocytosis or recycling or a combination of both. The receptor density often 
decreases after the agonist concentration has been elevated for some time. Ligand 
binding leads to the phosphorylation at different intracellular sites by G-protein kinases 
(GRK). The kinase recruits the cytosolic protein β-arrestin which uncouples the G-
protein (Gs). The phosphorylations are involved in the receptor desensitisation which is 
very rapidly to generate a second messenger. Early endosomes determine the fate of 
endocytosed receptor, with recycling to the plasma membrane or degradation. 
Desensitisation is described as loss of functional response due to receptor 
internalisation, which can be short-time (seconds-minutes) or long-time (hours). The 
recovery of functional responses after desensitisation is called resensitisation. Also 
ubiquitination in endocytosis and degradation of receptor via lysosomal pathway can 
occur. Usually there is a balance between de-and resensitisation (Koenig and 
Edwardson 1997). 
VPAC1 receptor signalling, desensitisation and sequestration are regulated by 
phosphorylation of GRKs. A dose-depending increase of cAMP occurs within 5-10 min 
and followed by a complete desensitisation after 20min (Laburthe et al. 2002; Shetzline 
et al. 2002). The desensitisation of VPAC receptor activity is associated with a drop of 
the VIP induced cAMP generation. Dependent on time and concentration VIP 
desensitisation occurs, the loss of response to VIP is related to a disappearance of the 
cell surface receptors, this is partly reversible. The internalisation of VIP reaches a 
maximum after 60min, the rate of receptor occupancy increases with VIP concentration 
whereas the rate of internalisation remains constant. The internalised receptor remains 
functionally, undegraded receptors recycle back to the surface within a half-time of 
10min from the endosomal vesicles. The ligand appears degraded in vesicles whereas 
the recycled receptor is coupled again to the adenlyate cyclase components (Rosselin et 
al. 1988). 
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In blood serum VIP has a half-life time of less than one minute (Domschke et al. 1978), 
therefore a new strategy to enhance full length VIP survival for specific targeting was 
developed (fig.5). A [Arg
8
]-VIP-dye analogue is described to increase stability towards 
proteolytic degradation with a longer half-life in vivo (Bhargava et al. 2002).  
Liposomes can be used to deliver helical folded VIP to target destination and release 
free VIP at VPAC cell surface receptors (Rubinstein 2005; Sejourne et al. 1997; Sethi et 
al. 2005; Stark et al. 2007). An advantage for liposome application is the protective 
envelope of liposomes for VIP degradation by proteases.  
 
Figure 5. Schematic model of cell entry behaviour of liposomes, and free VIP. Free random 
coiled VIP can be degraded by proteases. VIP in liposomes is folded in a α-helix, this is the preferred 
form for receptor recognition, it is protected from endogenous proteases in the cytosol. After binding, 
the ligand-receptor complex is internalised into the cell thereby triggering signal transduction via G-
proteins and second messengers. VPAC receptors are recycled back to the cell surface and can be 
again loaded with the ligand. [from (Hajos F 2008)] 
1.1.4 Synthetic VIP analogues  
Several potent VIP analogues were tested in vitro and in vivo. For example a hybrid 
combing a sequence of VIP and a sequence of neurotensin, [neurotensin(6-11)VIP(7-
28)] termed VIPhyb. It acts as an antagonist to VIP (Gozes and Brenneman 1989; Hill et 
al. 1991). (N-steryl,Nle
17
)VIPhyb called (SN)VIPhyb was described as anti-proliferative 
factor in breast cancer cells (Moody et al. 2001). Inhibiting growth promoting actions of 
VIP where shown in mouse embryos (Gressens et al. 1993) and on various cell lines 
(Lilling et al. 1994; Wollman et al. 1993). Gozes et. al (1989; 1991) found other cell 
lines where it is no inhibition. A lipophilic analogue of VIP, (steryl-Nle
17
-VIP), has 
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been reported to enhance survival of neurons in culture with 100-fold greater potency 
than VIP (Gozes et al. 1994) and also to be neuroprotective in animals models of 
Alzheimer´s disease (Gozes et al. 1996). 
1.1.4.1 VPAC1 selective analogues 
Two highly selective agonists have been described, one is the VIP/GFR hybrid 
[Lys
15
,Arg
16
,Leu
27
]VIP(1-7)-GRF(8-27)-NH2 (IC50, 1nM) first designed by Gourlet et 
al. (1997b) as a selective VPAC1 agonist which does not interact with the GRF receptor. 
He also discovered a selective agonist for VPAC1 and secretin receptor if changing 
Ser
16
 to Arg
16
 of secretin, it was used as a highly selective VPAC1 agonist in the brain 
(IC50, 2nM). A VIP analogue, (Ala
11,22,18
)-VIP (Nicole et al. 2000), which was designed 
after a complete alanine-scan of VIP (table 1) is the most potent VPAC1 selective 
agonist to date. Also a selective antagonist for VPAC1 was discovered by Gourlet et. al 
(1997b), [Acetyl-His
1
, D-Phe
2
, Lys
15
, Arg
16
]VIP(3-7)GRF(8-27)-NH2 or PG-97-269, of 
which the antagonistic properties is mostly related to D-Phe at position 2 instead of an 
serine in VIP. 
1.1.4.2 VPAC2 selective analogues  
VPAC2 specificity is also mediated by the receptor´s N-ted domain, but also 
transmembrane segment 5 and extracellular loop 3 are important of peptide agonist 
recognition which was shown by Juarranz et. al (1999). Two highly selective cyclic 
VPAC2 peptides, Ro-25-1553(Gourlet et al. 1997c)1997c) which consist of Ac-
His
1
[Glu
8
, Lys
12
, Nle
17
, Ala
19
, Asp
25
, Leu
26
, Lys
27,28
, Gly
29,30
, Thr
31
]-NH2VIP(cyclo21-
25) and Ro-25-1392 (Xia et al. 1997) which is composed of Ac-His
1
-[Glu
8
,OCH3-
Tyr
10
,Lys
12
,Nle
17
,Ala
19
,Asp
25
,Leu
26
,Lys
27,28
]-VIP (cyclo 21-25), have been described. A 
peptide fragment of VIP, VIP4-28, acts as an endogenous VPAC1 agonist and VPAC2 
antagonist previously described by Goetzl et. al (1989). Recently a selective VPAC2 
antagonist, PG-99-465, has been synthesized and described by Robberecht and his 
group (Grant et al. 2006; Vanneste et al. 2004), which acts on expressed VPAC1 
receptors on the endothelium, VPAC2 on the outer layers and NPR-C receptor 
throughout the artery.  
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1.1.4.3 PAC1 selective analogues 
Maxadilan, a 61 amino acid peptide from sand flies, which has no homology to PACAP, 
activates the PAC1 receptor and has a high binding affinity (IC50, 1-3nM). It is not 
interacting with VPAC1 and VPAC2 receptors (Moro and Lerner 1997). The fragment 
PACAP-27 (aa 6-38) is a potent antagonist for PAC1, it does not interact with VPAC1 
but it has a significant affinity for VPAC2 (Dickinson et al. 1997). 
 
Receptor Agonist Reference Antagonist Reference 
VPAC1 (Ala
11,22,28
)-VIP (Nicole et al. 2000) PG-97-269 (Gourlet et al. 1997a) 
VPAC2 Ro25-1392 (Xia et al. 1997) PG-99-465 (Vanneste et al. 2004) 
PAC1 Maxadilan 
(Moro and Lerner 
1997) 
Maxadilan  
Δ24-42 
Maxadilan 
Δ24-43 
(Moro et al. 1999) 
(Uchida et al. 1998) 
Table 1. Instrumental agonists and antagonists of VPAC receptors. [modified from (Harmar, Arimura 
et al. 1998)]  
1.1.5 Signal transduction pathway 
After the ligand-receptor complex is internalised, signal transduction occurs. Typically 
it alters gene transcription and cellular function. VIP signalling utilizes mainly Gs and 
adenlyate cyclase and cAMP as second messenger. VIP also activates the inositol 
phospholipid signalling pathway (PLC/PI) pathway which releases calcium. PACAP 
mainly stimulates Gq and transduces the signal via the PLC/PI pathway. 
In the unstimulated state, the receptor and the G protein are both inactive. Specific 
binding of an extracellular ligand, changes the conformation of the receptor, this alters 
the conformation of the G protein bound to the receptor. The alteration of the  subunit 
of the G protein allows it to exchange its GDP for GTP. The G protein breaks up into 
two active components, an  subunit and a  complex. Both can regulate the activity of 
target proteins in the plasma membrane. The receptor stays active while the external 
signal molecule is bound to it, and it can therefore catalyze the activation of many 
molecules of G protein. After ligand binding the ligand-receptor complex (VIP-
VPAC1/2; PACAP-PAC1) is engulfed into the cell via endocytosis. The G-protein  
subunit activates its target protein, it shuts itself off by hydrolyzing its bound GTP to 
GDP. This inactivates the  subunit, which dissociates from the target protein and 
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reassociates with a  complex to reform an inactive G protein. Binding to the target 
protein or to a membrane-bound protein usually stimulates the GTPase activity of the  
subunit; this stimulation significantly enhances the inactivation. Gα activates the 
enzyme adenlyate cyclase (AC) which catalyzed adenosine triphosphate (ATP) to cyclic 
AMP (cAMP) through a cyclisation reaction that removes two phosphate groups as 
pyrophosphate (PPi); a pyrophosphatase drives this synthesis by hydrolyzing the 
released pyrophosphate to phosphate. Cyclic AMP is unstable in the cell, because it is 
itself hydrolyzed by a specific phosphodiesterase to form 5'-AMP. The binding of cyclic 
AMP to the regulatory subunits of cAMP-depending protein kinase (PKA) induces a 
conformational change, thereby activating the kinase activity of the catalytic subunits. 
The release of the catalytic subunits requires the binding of more than two cAMP 
molecules to the regulatory subunits in the tetramer. This requirement greatly limits the 
response of the kinase to changes in cAMP concentration. Mammalian cells have at 
least two types of PKAs: type I is mainly in the cytosol, whereas type II is bound via its 
regulatory subunit and special anchoring proteins to the plasma membrane, nuclear 
membrane, mitochondrial outer membrane, and microtubules. In all cases, however, 
once the catalytic subunits are detached and active, they can migrate into the nucleus 
(where they can phosphorylate gene regulatory proteins), while the regulatory subunits 
remain in the cytoplasm. The three-dimensional structure of the protein kinase domain 
of the PKA catalytic subunit is able to phosphorylate the CREB gene regulatory protein. 
Once phosphorylated, CREB recruits the coactivator CBP, which stimulates the gene 
transcription for c-fos, c-jun, c-myc and vascular endothelial growth factor (VEGF), 
etc.. This signalling pathway controls different processes in cells, like hormone 
synthesis in endocrine brain cells for the production of proteins required for long-term 
memory in the brain.  
The alternative pathway which is predominantly activated by PACAP interacts with Gq. 
The activated receptor stimulates the plasma membrane bound enzyme phospholipase 
C- via a Gq protein. Depending on the isoform of the enzyme, it may be activated by 
the  subunit of Gq, by the  complex of another G protein, or by both. Two 
intracellular messenger molecules are produced when PI(4,5)P2 is hydrolyzed by the 
activated phospholipase C-. Inositol 1,4,5-triphosphate (IP3) diffuses through the 
cytosol and releases Ca
2+
 from the endoplasmic reticulum by binding to and opening 
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IP3-gated Ca
2+
-release channels in the endoplasmic reticulum membrane. The large 
electrochemical gradient for Ca
2+ 
across this membrane causes Ca
2+
 to escape into the 
cytosol. Diacylglycerol remains in the plasma membrane and, together with 
phosphatidylserine and Ca
2+
, helps to activate the enzyme protein kinase C, which is 
recruited from the cytosol to the cytosolic face of the plasma membrane [fig.6, (Alberts 
B 2002)].  
 
Figure 6. GPCR signalling cascade. The initial stage of GPCR activation occurs via agonist-induced 
conformational changes in the receptor to form an active agonist–receptor complex that is able to 
interact with heterotrimeric G-proteins and facilitate its activation via exchange of GDP for GTP at 
the subunit. (a). Following G-protein activation, the dissociated subunit and dimers modulate activity 
of effector proteins that control the level of intracellular signalling molecules. Levels of 
phosphatidylinositol biphosphate (PIP2) and inositol triphosphate (IP3, b) changes in the levels of the 
intracellular signalling molecules Ca2+ (c). G-protein subunit activation of adenylyl cyclase leads to 
cAMP increase (d). Finally, changes in the levels of these signalling molecules produce alterations in 
gene transcription or protein activity and result in the observed functional response of the cell; 
transcription factors such as CREB (cAMP response element binding protein) and reporter genes 
under the control of appropriate upstream elements (e and f). CRE, cAMP regulatory element, NFAT-
RE, Nuclear factor of activated T-cells response element and DAG, diacylglycerol. [from (Williams 
2004)] 
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1.2 VIP and Cancer 
VIP has important effects which include cell growth and differentiation of neuronal 
survival, early ontogeny and developmental functions. VIP can be stimulatory or 
inhibitory on cell growth (Muller et al. 1995) as well as normal tissues, to exert 
neuroprotective activity and requires glial cells secreting neuroprotective proteins 
(Gozes and Brenneman 2000). Also in cancer cells VIP plays a important role in 
stimulation and inhibition of cell growth of lung and breast cancer (Moody et al. 1998), 
but VIP behaves like a growth factor in the CNS as integrative regulator during 
development, neurogenesis and embryogenesis (Moody et al. 2003). VIP acts on 
pancreatic duct cells and mediates bicarbonate secretion (Jiang et al. 1997). The peptide 
also inhibits excessive growth stimulation of small cell lung cancer (SCLC) cells, this 
indicates an anti-proliferative effect of VIP (Maruno et al. 1998; Moody 1996). 
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PHYSICALY TISSUE EXPRESSION 
Organ/ Tissue 
Receptor 
Reference Organ/ Tissue 
Receptor 
Reference 
VPAC PAC1 VPAC PAC1 
Colon mucosa VPAC1  (Reubi et al. 1999) 
seminal vesicle smooth 
muscle 
VPAC2  (Reubi 2000) 
colorectal/gastric 
mucosa 
VPAC1  (Reubi 2000) smooth muscle VPAC  (Reubi et al. 1999) 
stomach VPAC2  (Adamou et al. 1995) smooth muscle VPAC2  (Schulz et al. 2004) 
 VPAC2  (Schulz et al. 2004) smooth muscle VPAC2  (Reubi 2003) 
stomach smooth 
muscle 
VPAC2  (Reubi 2000) skeletal muscle VPAC2  (Adamou et al. 1995) 
stomach mucosa VPAC1  (Reubi 2000) heart VPAC2  (Adamou et al. 1995) 
intestine VPAC1  (Ishihara et al. 1992) blood vessels VPAC1/2*  (Reubi 2000) 
PNS myentric plexus 
(colon wall) 
 PAC1 (Reubi 2000) blood vessels VPAC2  (Schulz et al. 2004) 
Lung acini VPAC1,2?  (Reubi 2000) monocytes VPAC1/2  (Kojima et al. 2005) 
Lung acini VPAC1  (Reubi et al. 2000) ateries/(veins) VPAC2  (Reubi 2003) 
Airway epithel, 
bronchus 
VPAC1  (Busto et al. 2003) vessels VPAC2  (Reubi et al. 1999) 
lung VPAC1  (Ishihara et al. 1992) liver VPAC1  (Ishihara et al. 1992) 
Uterus glands VPAC1,2? PAC1 (Reubi 2000) hepatocytes VPAC1  (Reubi et al. 2000) 
Uterus stroma VPAC1  (Reubi 2000) hepatocytes VPAC1  (Reubi 2000) 
Breast VPAC1  (Dagar et al. 2001) kidney VPAC2  (Adamou et al. 1995) 
breast lobulus/duct VPAC1  (Reubi 2000) kidney glomeruli VPAC1  (Reubi 2000) 
breast lobulus/duct VPAC1  (Reubi et al. 2000) Prostate glands VPAC1  (Reubi et al. 2000) 
Microglia VPAC1  (Delgado et al. 2003) Prostate glands VPAC1  (Reubi 2000) 
 VPAC1  (Delgado 2002) Prostate stroma VPAC2  (Reubi 2000) 
 VPAC1  (Kim et al. 2000) 
Prostate epithelial cell 
culture 
VPAC1/2  (Juarranz et al. 2001) 
Table 2. VPAC receptor expression pattern of physical tissue. *, indicates the dominant receptor; ?, receptor tested but not sure; blank, 
VPAC receptor subtypes are not analysed. 
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T cell VPAC1  (Delgado et al. 1996) Lymphnodes VPAC1  (Reubi 2000) 
neuron VPAC1/2*  (Gressens et al. 1993) Lymphnodes VPAC1  (Reubi et al. 2000) 
myenteric neurons VPAC1 PAC1 (Schulz et al. 2004) GALT VPAC1 PAC1 (Reubi 2000) 
neuroendocrinal cell VPAC2 PAC1 (Schulz et al. 2004) Spleen PALS VPAC1  (Reubi 2000) 
cerebal cortex VPAC1  (Ishihara et al. 1992) Thyroid follicle VPAC1  (Reubi 2000) 
hippocampus VPAC1  (Ishihara et al. 1992) Parotis gland VPAC1  (Reubi 2000) 
thalamus VPAC2  (Sheward et al. 1995) Adipose tissue VPAC2  (Adamou et al. 1995) 
Suprachiasmaticus 
nucleus (SCN) 
VPAC2  (Sheward et al. 1995) testis VPAC2  (Adamou et al. 1995) 
adreanal medulla VPAC1? PAC1 (Reubi 2000) Bladder/Ureter urothelium VPAC1  (Reubi 2000) 
adreanal medulla  PAC1 (Reubi et al. 2000)     
Pancreas VPAC2  (Adamou et al. 1995)     
Pancreas VPAC2  Jiang et al., 1997, CR     
Pancreas acini  PAC1? (Reubi 2000)     
Pancreas duct VPAC1  (Reubi et al. 2000)     
Pancreas duct VPAC1  (Reubi 2000)     
Mucosa VPAC1  (Schulz et al. 2004)     
Mucosa VPAC  (Reubi et al. 1999)     
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1.2.1 VPAC expression pattern of tumour cells 
Reubi et. al (2000) performed several in vitro receptor autoradiography studies with 
125
I-VIP or 
125
I-PACAP in tissue sections. The VPAC1 receptor is expressed in a wide 
variety of tissues including liver, breast, kidney, prostate, ureter, bladder, pancreatic 
ducts, gastrointestinal mucosa, lung, thyroid, adipose and lymphoid tissue, whereas the 
VPAC2 receptor is predominantly found in smooth muscles and blood vessels. The 
PAC1 receptor is distributed in adrenal medulla.  
VPAC1 receptors are also expressed in human tumours including breast, prostate, 
pancreas, lung, colon, stomach, liver and bladder carcinomas, lymphomas and 
meningeomas. Leiomyomas express preferentially VPAC2. Glial tumours, pituitary 
adenomas, neuroblastomas, paragangliomas, pheochromocytomas, endometrial 
carcinomas, preferentially express PAC1. Other researchers investigated the expression 
pattern of tumour tissue and cell lines as seen in table 3. 
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TUMOUR TISSUE 
Organ/ Tissue 
Receptor 
Reference Organ/ Tissue 
Receptor 
Reference 
VPAC1/2 PAC1 VPAC1/2 PAC1 
Colon Carcinoma HT-
29 
VPAC  (Bellan et al. 1992) 
Sup T1 cell 
lymphoblastom 
VPAC2  (Igarashi et al. 2002) 
 VPAC  (Ou et al. 2005) neuroblastoma VPAC  (Virgolini et al. 1994b) 
HT-29,SW430,DLD-1, 
Caco-2 
VPAC  (Lelievre et al. 1998) neuroblastoma VPAC  (Lilling et al. 1994) 
HCT-15 VPAC1  (Moody et al. 2001) neuroblastoma VPAC  (Wollman et al. 1993) 
HCT-15 VPAC  (Levy et al. 2002) neuroblastoma VPAC1/2  (Reubi 2003) 
gastroinestinal tact 
tumour 
VPAC  (Virgolini et al. 1996) 
neuroendrocrinial 
tumour 
VPAC1/2  
(Warner and O'Dorisio T 
2002) 
 VPAC  (Virgolini et al. 1994a) 
ACTH-prod. 
Hypophyseal adenoma 
VPAC  (Virgolini et al. 1994b) 
intestinal endocrine 
carcinoma 
VPAC  (Virgolini et al. 1996) medulloblastoma VPAC1/2  (Reubi 2003) 
 VPAC  (Ishihara et al. 1992) meningoma VPAC1 PAC1 (Schulz et al. 2004) 
 VPAC  (Adamou et al. 1995) Meningoma VPAC1  (Reubi 2000) 
 VPAC  (Virgolini et al. 1994b) meningoma VPAC1/2  (Reubi 2003) 
gastric carcinoma VPAC1  (Reubi 2003) Pituitary Adenoma VPAC1/2? PAC1 (Reubi 2000) 
 VPAC1  (Reubi 2000) Pituitary Adenoma VPAC1  (Schulz et al. 2004) 
Colon carcinoma VPAC1  (Reubi 2000) glioblastoma VPAC1/2 PAC1 (Schulz et al. 2004) 
   (Reubi et al. 2000) Glioma VPAC1/2? PAC1 (Reubi 2000) 
colorectal carcinoma  PAC1? (Schulz et al. 2004) CNS cancer VPAC1  (Moody et al. 2001) 
 VPAC1  (Reubi 2003) Pheochromocytomas VPAC1/2? PAC1 (Reubi 2000) 
gastric colorectal 
tumour 
VPAC1  (Reubi et al. 1999) Pheochromocytomas VPAC1 PAC1 (Reubi et al. 2000) 
gut cariniod, 
gastrinoma,  
VPAC1/2  (Reubi 2003) Paraganglia tumour VPAC1/2? PAC1 (Reubi 2000) 
Table 3. VPAC receptor expression pattern of tumour tissue. *, indicates the dominant receptor; ?, receptor tested but not sure; 
blank, VPAC receptor subtypes are not analysed. 
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insulinmoma VPAC  (Virgolini et al. 1994a) Paraganglia tumour VPAC1 PAC1 (Reubi 2000) 
 VPAC  (Virgolini et al. 1996) Pheochromocytomas VPAC  (Virgolini et al. 1996) 
 VPAC  (Virgolini et al. 1994b) Pheochromocytomas VPAC  (Virgolini et al. 1994b) 
 VPAC2?  (Schulz et al. 2004) 
ductal pancreas 
carcinoma 
VPAC1  (Reubi 2000) 
stomach carcinoma VPAC2? PAC1? (Schulz et al. 2004) 
Pancreatic 
Adenocarcinoma 
VPAC  (Estival et al. 1983) 
NSCLC VPAC1  (Moody et al. 2003) PANC-1 VPAC1/2  (Estival et al. 1983) 
 VPAC1  (Reubi 2000) 
Pancreatic 
adenocarcinoma (Capan-
1/2, Su.86.86, BxPC-
3,MDA Panc-3, AsPC-1, 
Hs766T, Panc-1) 
VPAC1  (Jiang et al. 1997) 
 VPAC1  (Reubi 2000) 
exocrine pancreatic 
tumour 
VPAC1  (Reubi 2003) 
 VPAC1  (Moody et al. 2001) pancreas cancer VPAC1  (Virgolini et al. 1994a) 
 VPAC1  (Reubi 2003) pancreas cancer VPAC1  (Schulz, et al. 2004) 
SCLC VPAC1/2  (Reubi 2003) Leiomyoma VPAC2  (Reubi 2003) 
SCLC VPAC  (Virgolini et al. 1994b) Leiomyoma VPAC2  (Reubi et al. 2000) 
SCLC (NCI-H345) VPAC2  (Moody et al. 2003) Leiomyoma VPAC2  (Reubi 2000) 
SCLC VPAC1  (Moody et al. 2003) leukemia VPAC1  (Moody et al. 2001) 
Lung cancer SCLC VPAC  (Maruno et al. 1998) liver carcinoma  PAC1? (Schulz et al. 2004) 
Lung carcinoma 
(SCLC, NSCLC) 
VPAC1/2  (Busto et al. 2003) liver carcinoma   
(Warner and O'Dorisio T 
2002) 
bronchi, pulmonary 
ateries carconoma 
VPAC1?,2  (Schmidt et al. 2001) liver metasatsis VPAC  (Virgolini et al. 1996) 
Lung epithelial 
carcinoma 
VPAC2  (Busto et al. 2003) hepatocellular carcinoma VPAC1  (Reubi et al. 2000) 
lung metastasis VPAC  (Virgolini et al. 1996)  VPAC1  (Reubi 2000) 
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lung cancer (NCI-
H1299) 
VPAC1  (Moody et al. 2004) hepatocellular carcinoma VPAC1  (Reubi 2003) 
lung carcinoma cell 
line (SW-900, Calu-1) 
VPAC  (Laburthe et al. 1981) 
Kidney carcinoma COS-
7 cell line 
VPAC1,2  (Virgolini et al. 1996) 
endometrial carcinoma VPAC1/2? PAC1 (Reubi 2000) kidney cancer VPAC1,2  
(Warner and O'Dorisio T 
2002) 
endometrial carcinoma VPAC1 PAC1 (Reubi et al. 2000) renal carcinoma VPAC1  (Reubi 2003) 
endometrial carcinoma VPAC1/2  (Reubi 2003) renal cancer VPAC1  (Moody et al. 2001) 
Ovarian cancer VPAC1  (Moody et al. 2001) Prostate carcinoma VPAC1  (Reubi et al. 2000) 
Ovarian carcinoma VPAC1  (Reubi 2003) Prostate carcinoma VPAC1  (Reubi 2000) 
Uterine 
adenocarcinoma 
VPAC1  (Ichikawa et al. 1996) prosate carcinoma VPAC1  (Reubi 2003) 
Breast cancer VPAC1  (Dagar et al. 2001) prostate cancer VPAC1 PAC1? (Schulz et al. 2004) 
breast cancer T47D VPAC1  (Igarashi et al. 2002) prostate cancer VPAC1  (Moody et al. 2001) 
breast cancer VPAC1*/2 PAC1 (Schulz et al. 2004) 
Non-Hodgekin 
lymphomas 
VPAC1  (Reubi 2000) 
breast cancer VPAC1  (Reubi et al. 2002) 
Non-Hodgekin 
lymphomas 
VPAC1  (Reubi et al. 2000) 
breast cancer (BT-20, 
MCF-7, MDA-MB-
231, SK BR-3, ZR-75-
1) 
VPAC  (Zia et al. 1996) lymphoma VPAC1/2  (Reubi 2003) 
breast cancer (MCF-7, 
T47D) 
VPAC1  (Moody et al. 2000) thyroid carcinoma  PAC1? (Schulz et al. 2004) 
ductal/ lobular breast 
cancer 
VPAC1  (Reubi 2000) thyroid carcinoma VPAC  (Virgolini et al. 1994b) 
ductal/ lobular breast 
cancer 
VPAC1  (Reubi et al. 2000) thyroid carcinoma VPAC  
(Warner and O'Dorisio T 
2002) 
breast carcinoma VPAC1  (Reubi 2003) carcinoid cancer VPAC2?  (Schulz et al. 2004) 
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ductal breast cancer VPAC1/2  (Virgolini et al. 1994b) carcinoid carcinoma VPAC  (Virgolini et al. 1994b) 
esophageal cracinoma VPAC1  (Reubi 2003)  VPAC  (Virgolini et al. 1996) 
urothelial carcinoma 
(bladder) 
VPAC1  (Reubi 2000) 
urinary bladder 
carcinoma 
VPAC1  (Reubi 2003) 
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1.2.1.1 VPAC1-specific ligand 
The most important amino acids for VPAC1 affinity are His
1
, Asp
3
, Phe
6
, Arg
12,14
 and 
Leu
23
. Furthermore Asn
24
 is a very important amino acid at this position for human 
VPAC1 high affinity (Ito et al. 2001). Substitution of Ala at positions 1, 3, 6, 12, 14 and 
23 of VIP reduces binding affinity to human VPAC1 receptors over 50-fold. Also a 
substitution of Ala at positions 5, 7, 10, 15, 16, 20, 22 and 26 reduces binding affinity 5-
50 times. Most amino acids for VPAC1 receptor binding are identical in PACAP-27, 
nine amino acids which are different are Ala
2,8,9,11,19,24,25,27, 28
 to determine a high 
affinity for VPAC1 and enhanced metabolic activity. Nicole et. al (2000) and his group 
developed a VIP analogue Ala
(11,22,28)
-VIP (>1000-fold) highly selective for VPAC1. 
Because Virgolini and her group showed that 
123
I-VIP and 
123
I-OCT (somatostatin 
analogues octreotide) targets VPAC expressing tumours (Vanneste et al. 2004; Virgolini 
et al. 1994a; 1996; 1994b), and because upon systemic administration not only tumour 
targeting but also vasorelaxation via VPAC2 occurred. The advantage of a VPAC1 
specific analogue could be to circumvent VPAC2 mediated vasorelaxation and 
specifically target VPAC1 expressing cancer cells.  
1.2.2 VPAC receptors as cell entry point for drug delivery 
Peptide receptors as molecular targets for cancer diagnosis and therapy were previously 
known. Reubi and his group (2000) summarized the significance of peptides and their 
receptors in cancer. In cancer overexpressed G-protein coupled receptors can internalise 
into the cell together with their specifically bound ligands. Ligands may function as 
pharmacophor (e.g. radiotracer), these internalisation may accumulate radiotracer in the 
cell as the target. The strategy can be used for peptides linked to cytotoxic drugs or 
radioactive isotopes. Small and hydrophilic peptides penetrate the tissue well, this 
permits rapid access to the tumour site after systemic application. Typically peptides 
will not cross the blood-brain-barrier and do not enter the brain in a significant amount.  
An 8-20 amino acid long peptide provide an adequate attachment site for a chelator 
molecule like dietyhlenetriaminopentaacetic acid (DTPA) or 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), which accept certain types of 
metallic radioisotopes (Reubi 2003). 
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VPAC receptors as entry point for drugs were previously shown by Moody et. al 
(2001). They investigated the VPAC receptor antagonist VIPhyb or (SN)VIPhyb, with 
or without conjugated chemotherapeutic drugs like taxol, to inhibit growth of breast 
cancer cells.  
Ellipticine is a topoisomerase II inhibitor, it causes double strand breaks in the DNA. 
Also topoisomerase I inhibitors cause single strand breaks in DNA, and are used as 
treatment for lung cancer patients. Moody developed VIP-ellipticine conjugates, VIP-
ALALA-ellipticine and VIP-LALA-ellipticine, which are coupled to the C-terminus of 
VIP and are cytotoxic for lung cancer cells. VIP-ellipticine conjugates function as 
VPAC1 agonist and after internalisation it elevates cAMP. VIP conjugates targeted to 
VPAC1 can increase the selectivity of drug delivery, however we have to expect that 
also normal cells which express the receptor are treated. The advantage of peptide 
chemotherapeutic agents is that the peptide acts as a prodrug, which means that the 
inactive prodrug is delivered and recognizes the VPAC as the target. Because of the 
high density of receptors at the cell surface, appreciable amounts of the prodrug are 
internalised into the cells and elicit its function (Moody et al. 2004).  
Another approach was performed by Ou et. al (2005), they investigated radioiodinated 
antisense oligonuclide mediated by the VPAC receptors. A 15-mer phosphorothioate 
antisense oligonuclide (ASON) is complimentary to the start region of c-myc oncogene 
mRNA, which was radioiodinated to enhance anti-tumour activity. VIP covalently 
bound to polylysine (VIP-
131
I-ASON) was used as a carrier to deliver the 
oligonucleotide to the VPAC positive tumour cells. VIP-polylysine carrier greatly 
increased HT-29 tumour uptake of ASON. Treatment with VIP-
131
I-ASON complexes 
results in tumour growth delay in human colon cancer in an animal model. 
1.2.2.1 VIP-Hematoporphyrin for PDT 
Photodynamic therapy (PDT) is a therapeutic modality for treatment of cancer diseases 
and non-oncological disorders first described in the early 1970s. This approach is based 
on systemic administration and selective accumulation of a photo-sensitiser in tumour 
tissue. Typical photo-sensitisers belong to following chemical classes: phthalocyanine, 
porphyrin, porphyrin-oligomer, chlorine, porphycene, chlorophyll a derivates, 
phenantroperylenequinone. All molecule classes have different targets in the cell. 
Typically targets are mitochondria, ER, Golgi apparatus, lysosomes, endosomes and 
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plasma membrane. The light absorption spectrum depends on the photo-sensitiser, 
usually it is between 600-800nm. After irradiation the photo-sensitiser transforms from 
its ground singlet state into an excited singlet state. It can decay back to the ground state 
by emitting fluorescence. A fraction of the excited singlet state is transformed via 
intersystem crossing into a relatively long-lived excited triplet state (micro-
nanoseconds). This triplet state can either be derived from free radicals or radical ions 
by hydrogen atom extraction or electron transfer to biological substrates, soluble 
molecules or oxygen. These radicals can interact with ground state oxygen to produce 
hydrogen peroxide, hydroxyl radials and superoxide anion radicals (type I reaction, 
fig.7). As alternative pathway the excited triplet state can be derived from non-radical 
but highly reactive singlet oxygen (
1
O2, type II reaction). The ratio between the two 
pathways depends on the chemical properties of the photo-sensitiser and the nature of 
the substrate molecule. Singlet oxygen (
1
O2) has a prevalent role in the molecular 
process initiated by PDT.  
The photodamage and cytotoxicity after PDT treatment depends on multiple factors 
such as photosensitising agent, the localisation at the time of irradiation, total 
administered dose, total light exposure, light fluency rate, the time between 
administration and the photo-sensitiser irradiation and the type of tumour with its level 
of oxygenation. PDT in vivo has been shown to reduce the number of clonogenic 
tumour cells through direct ROS-mediated photodamage (Henderson et al. 1985). PDT 
has a much lower potential to cause DNA damage compared to X-rays. Typically the 
photo-sensitisers do not reach the nucleus, because of the short life-time of singlet 
oxygen (t1/2<0,04µs, radius of action <0,02µm). Photoactive components localizing to 
the mitochondria or ER promote apoptosis upon a certain threshold of oxidative stress, 
whereas the photo-sensitiser targets either the plasma membrane or lysosomes by 
delaying or blocking the apoptotic program predisposing the cell to necrosis. Autophagy 
may be induced by PDT to repair and survive photoinjury to key organelles and turns 
into cell death signals if the repair fails. Three major morphologies of programmed cell 
death appear after photosensitisation: apoptosis, necrosis and autophagy. Type I 
programmed cell death (PCD) is characterized by changes involving nuclear 
condensation and general cellular shrinking. Type II PCD is distinguished by a 
lysosomal–dependent digestion of the cell and the presence of autophagy vacuoles 
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(autophagosomes) while type III PCD is marked by cellular swelling and a rapid loss of 
cell membrane integrity. These processes are defined as apoptosis, autophagy cell death 
and necrosis. All pathways are signalling through different death signal molecules, the 
pathways are interchangeable, therefore specific inhibition of one death signal is not 
sufficient to block PDT-mediated cell death (Buytaert et al. 2007). 
 
 
Figure 7. The action mechanism of photosensitising agents in PDT. A photo sensitiser in its 
singlet ground state (PTS) is excited to higher energy levels (PTS*) upon irradiation and absorption of 
a photon of the appropriate wavelength. Deactivation occurs either through the emission of 
fluorescence or via intersystem crossing leading to formation of the excited triplet state (3PTS). 
Subsequently, energy can be lost in the presence of biological substrates and molecular oxygen (3O2), 
via Type I and Type II reactions leading to the formation of free radicals and ROS (O2
•−, HO
•
, H2O2, 
and 1O2). These cytotoxic species cause cellular photodamage which can activate a repair mechanism 
or lead to cell death when the damage is beyond repair capacity. [from (Buytaert et al. 2007)] 
 
Photodynamic therapy offers the advantage of an effective and selective method of 
destroying diseased tissues without damaging surrounding healthy tissues. One of the 
aspects of anti-tumour effectiveness of PDT is related to the distribution of 
photosensitizing drugs. We were interested wheter or not we can link a classical PDT 
substance. Hematoporphyrin to VIP and use VIP-conjugate as pharmacophore for 
specific cell targeting.  
Hematoporphyrin is a macrocyclic tetrapyrrolic ring system with highly reactive 
hydroxyl side groups termed porphyrin. Yang et. al (2007) described a PDT assay with 
a semiconductor laser at 630nm with the energy density of 2, 5, 10, and 20 J/cm. After 
further culture for 24h, the survival rate of LoVo and CoLo205 cells were analyzed by 
MTT assay, and the cellular fluorescence intensity of hematoporphyrin derivate 
luminescene was measured. 
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The hematpoporphyrin derivate Photofrin
®
/photosan, also called porfimer natrium, is a 
porphyrin oligomer with a molecular mass of about 50 kDa. The molecule is excited 
between 600-700nm. Photofrin
®
 was the first approved photodynamic therapy agent to 
combat cancer. The intercellular distribution of Photofrin
®
 was observed after 4 houres 
incubation in malignent MCF-7 and A549 cells. The most intensive signal was found 
around the nuclear envelope (Saczko et al. 2007).  
Photosan is highly sensitve to light, patients treated with porfimer natrium are extra 
sensitve to light for at least 30 days after treatment. Light includes sunlight, bright 
indoor lights, and vehicle headlights.  
1.2.2.2 VIP-DOTA-Gd  
Radio-labelled VIP (
123
I-VIP or 
123
I-OCT) was successfully used in the detection of 
gastrointestinal and breast tumours (Vanneste et al. 2004; Virgolini et al. 1994a; 1996; 
1994b), and therapy (Krenning et al. 2004; Virgolini et al. 1998). Peptides can be 
labelled with various trivalent radiometals for imaging or targeting radionuclide therapy 
applications (Sosabowski and Mather 2006). 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid (DOTA) is a macrocyclic chelator, almost capable of strongly 
encapsulating metals used for photon emission tomography (PET). Radioisotopes like 
111
In, 
86
Y, 
90
Y, 
67
Ga, 
68
Ga and 
64
Cu or for 
99
mTc and 
188
Re require a chelator like 
DOTA. VIP conjugation to DOTA with trivalent metallic isotopes forms a stable 
complex. DOTA is a chelator to quench cytotoxic effects of the trivalent metals 
(Heppeler et al. 2000). 
Gadolinium (Gd) is a non isotopic trivalent metal which is widely used to enhance the 
contrast of images in magnet resonance imaging (MRI). Unpaired electrons of 
gadolinium generate electron spin that interfere with the nuclear spin of hydrogen which 
conditions the paramagnetic effect of gadolinium. The chelates function as extracellular 
space markers that enhance tissue contrast. The common oxidation state of Gd is 3+ in 
which the three outer electrons are lost. There are no electrons or orbitals available for 
covalent binding; therefore free Gd
3+
 is highly toxic. The ionic radius of Gd
3+
 (107,8 
pm) is close to that of Ca
2+
 (114 pm) and therefore unchelated Gd inhibits those 
physiological processes which are depending upon Ca
2+
 influx. To reduce the toxicity 
for medical applications Gd is chelated. Gd chelates do not diffuse through plasma 
membranes and therefore is not able to penetrate the blood-brain barrier (BBB). 
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Macrocyclic chelates such as Gadoteratemeglumine (DOTA-Gd) and Gadoteridol (Gd-
HP-DO3A) are more stable than linear molecules like Gadodiamide (Gd-DTPA-BMA) 
and Gadopentetatedimeglumine (Gd-DPTA). The chemical instability of the chelate can 
lead to exchanges with other metal ions like Cu
2+,
 Zn
2+
 and Ca
2+
. Transmetallation 
between contrast agents and body cations has biological consequences such as 
accumulation of Gd
3+
 in bones, interaction with metalloenzymes, increased zincuria, 
interaction with scintigraphic procedures and hence superious hypocalcaemia. 
Released free Gd
3+
 of the macrocyclic chelate DOTA-Gd and Gd-HP-DO3A is less than 
1%, whereas it is much higher for the linear chelates Gd-DTPA-BMA and Gd-DPTA 
(35%). Half–life time of macrocyclic chelates (Gd-DOTA T1/2 >1 month, Gd-HP-DO3A 
T1/2=3h) differs clearly from linear chelates [(Gd-DTPA T1/2=10min, Gd-DTPA-BMA 
T1/2~30s; (Idee et al. 2006)]. 
VIP-DOTA as chelator of metal ions has good potential to improve the tumour targeting 
with diagnostic or therapeutic radionuclides. We produced VIP-DOTA-Gd, where 
DOTA is linked to VIP. We were interested whether or not the construct has potential in 
tumour cell targeting. Chelate binding of Gd in DOTA does not largely change the 
molecular size appearance of the VIP-conjugate.  
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2 Objectives and aims 
Two issues arise with the use of VPAC receptors as anti-cancer drug targets. We aimed 
to investigate the potential of non radioactive labelled VIP tumour targeting. 
We expect that VIP-DOTA can internalise Gd at similar rates than radioisotopes. VIP-
DOTA internalisation and cytoplasmic accumulation could improve the background 
signal ratio in clinical imaging applications. The sensitivity and/or specificity of 
diagnostic and therapeutic procedures could be enhanced.  
The second issue in discussion is whether or not VPAC1 receptor can serve as more 
specific target for delivery of anti-cancer drugs into the cell. We envisioned a specific 
VPAC1-drug delivery system, with a selective VPAC1 analogue which targets VPAC1 
positive tumour cells. The advantage of targeting VPAC1 is to circumvent side effects 
due to the physiological properties of VIP, i.e. vasodilation and relaxation via VPAC2. 
Another advantage may be the overexpression of VPAC1 receptors in tumour cells 
compared to healty tissue.  
2.1 Find tumour cells with VPAC receptors 
We investigated the expression pattern of 14 tumour cell lines and one endothelial cell 
line for their VPAC1, VPAC2 and PAC1 expression pattern by immunohistochemistry 
(ICC) staining with specific monoclonal and polyclonal antibodies to VPAC1, VPAC2 
and PAC1. Also western blot (WB) was used for the detection of VPAC receptors with 
these antibodies. 
2.2 Select peptide analogues 
We were interested in the potential of VIP and a selective VPAC1 agonist to be a carrier 
for conjugates (drugs), envisioning their applicability in cancer diagnostics. 
- The conjugates Cy3 and Fluo linked to VIP (VIP-Cy3, VIP-Fluo) were tested for 
their potential of internalisation via VPAC receptors into the cell.  
- DOTA and DOTA-Gd conjugated to VIP (VIP-DOTA, VIP-DOTA-Gd) were 
analysed for their potential in MRI diagnostics and the cytotoxicty of Gd in cell 
culture.  
- VIP linked to hematoporphyrin (VIP-PDT) was studied for its potential in 
photodynamic therapy (PDT). 
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- The specific VPAC1 agonist (Ala
11,22,28
)-VIP was used to investigate the 
selective VPAC1 mediated entry into the cell. The peptide was conjugated to 
FITC which served the visualisation of intracellular conjugates via CLSM. 
- Because of the short half-life time of VIP we produced nanosized liposomes and 
proticles as peptide carriers, designed for VIP delivery. These nanoparticles can 
protect the peptides from proteolytic degradation. I tested if liposomes and 
proticles cause a sustained biological response, indicating a protection and 
release of VIP.  
2.3 Test Peptide constructs for internalisation  
When envisioning VIP peptide analogues as carriers for cancer cell targeting, the most 
important step is the internalisation of peptide conjugates into the cell. We analyzed 
fluorescent VIP conjugates, like VIP-Cy3, VIP-Fluo and (Ala
11.22.28
)-VIP-FITC with 
confocal laser scanning microscopy (CLSM) and fluorescent correlation spectroscopy 
(FCS) for their internalisation behaviour. 
In addition to the direct visualisation of internalised fluorochromes, we used indirect 
methods, i.e. ELISA, to visualise the internalisation of peptide conjugates into the cell. 
Because VIP is internalised to elicit specific biological responses, we can use these 
responses to show internalisation of non-fluorescing peptide conjugates (i.e. VIP-PDT, 
VIP-DOTA-Gd). The measuring of the second messenger cAMP by ELISA reveals the 
internalisation of VIP and VIP conjugates.  
2.4 Test Peptide constructs for other effects (proliferation, cytotoxicity) 
Aiming at the medical use of peptide conjugates, we were interested in further important 
aspects like proliferative or cytotoxic properties of the substances. Therefore we 
investigated all peptide constructs for their proliferation modification and cytotoxicity 
by MTT assays in cell culture.  
The potential of VIP-PDT was analysed in cells, by tests for their reactive oxygen 
species (ROS) with and without light radiation. Furthermore the PDT conjugate was 
tested for the potential to induce apoptosis or proliferation in cell culture after treatment 
with light radiation. 
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3 Material and Methods 
3.1  Cell culture 
Cell lines were cultured with different medium supplements at 37°C with 5% CO2 in the 
atmosphere in polyethylene 25/75cm
2
 Cell Culture Flasks (Corning, Lowell, USA). The 
medium was changed every second day, therfore cell were washed once with PBS. The 
aherently growing cells were split at about 90% confluency in subcultivation ratio 
depending on each cell line. Before splitting, the cells were washed with PBS and 
incubated with 1x Trypsin-EDTA (PAA, Pasching, Austria) for 2-5min at 37°C with 
5%CO2 in the atmosphere. Afterwards cells were suspended in 5ml medium and 
centrifuged at 1000rpm for 5min (Rotanta 46 RC, Hettrich Zentrifugen, Tuttlingen, 
Germany). The pellet was resuspended in 5ml medium and divided depending on their 
subcultivation ratio and cultured at 37°C 5%CO2. 
Before supplementation of medium, the fetal bovine serum (PAA) was once heat 
inactivated at 60°C for 15min and stored at -20°C. 
 
Phosphate buffered saline (PBS): 
A stock solution of 10x PBS was prepared. All chemicals were purchased by Merck 
(Darmstadt, Germany).  
 
Table 4. 10x Phosphate buffered saline (PBS). 
 
chemical substances concentration [M] concentration [g/l] 
Na2HPO4*2H2O 92,3 mM 14,4g 
KH2PO4 14,6 mM 2g 
KCl 26,8 mM 2g 
NaCl 1,4M 80g 
 
Substances from table 4 were dissolved in l000ml bidest. water to obtain 10x PBS. PBS 
was adjusted to pH 7,4 and sterile filtrated with 0,22µM filters (Corning, Lowell, USA). 
3.1.1 Cell lines 
The cell lines used in this project were obtained from the American Type Culture 
Collection (ATCC, LGC Promochem, Wesel Germany) and the tissue culture facility of 
the Institute of Cancer Research Vienna (KIM-1 Medical University, Vienna Austria; 
table 5). 
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Organ 
Tumour cell 
line 
Growth properties Medium 
Reference or 
ATCC No. 
Human prostate carcinoma LNCaP 
adherent, single cells and 
loosely attached clusters 
RPMI 1640 CRL-1740 
Human prostata carcinoma PC-3 adherent RPMI 1640 CRL-1435 
Human pancreas 
adenocarcinoma 
Capan-1 adherent RPMI 1640 HTB-79 
Human pancreas duct 
epithelioid carcinoma 
PANC-1 adherent DMEM CRL-1469 
Lung carcinoma A427 adherent MNP HTB-53 
Human liver hepatocellular 
carcinoma 
Hep3B adherent RPMI 1640 HB-8064 
Human thyriod 
adenocarcinoma 
SW1736 adherent RPMI 1640 Inst. Cancer Research 
Human glioblastoma MGC adherent MEME Inst. Cancer Research 
Human colorectal carcinoma HCT-15 adherent RPMI 1640 CCL-225 
Human colorectal carcinoma HT-29 adherent RPMI 1640 HTB-38 
Human colorectal carcinoma CaCo-2 adherent RPMI 1640 HTB-37 
Human colorectal carcinoma HCT-116 adherent MEME CCL-247 
Human mammary gland, 
epithelial adenocarcinoma 
MCF-7 adherent 
DMEM without 
phenolred modified 
HTB-22 
Human microvascular 
endothelial cells 
HMEC-1 adherent DMEM modified Inst. Cancer Research 
Table 5. Used cell lines 
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LNCaP is a human prostate carcinoma cell line derived from a left supraclavicular 
lymph node (ATCC Number CRL-1740) of a 50 year old Caucasian male. The 
epithelial adherent cell line consists of single cells or loosely attached clusters. The cells 
were cultured with the medium RPMI 1640 at 37°C with 5% CO2 in the atmosphere, 
and subcultivated 1:10. 
 
PC3 is a human prostate adenocarcinoma derived from bone, tumour state grad IV 
(ATCC Number CRL-1435) of a 62 year old Caucasian male. These cells form 
epithelial adherent clusters. The medium for this cell line was RPMI 1640. The cells 
were cultured at 37°C, with 5%CO2 in the atmosphere and subcultivated 1:10.  
 
Capan-1 is a human pancreas adenocarinoma derived from liver (ATCC Number HTB-
79) of 40 year old Caucasian male. The cells are epithelial and adherent. The medium 
for this cell line was RPMI 1640. The cell line was cultured at 37°C, with 5% CO2 in 
the atmosphere and subcultivated 1:5.  
 
PANC-1 is a human pancreas duct epithelioid carcinoma cell line (ATCC Number 
CRL-1469) from a 56 year old Caucasian male. An epithelial adherent cell line cultured 
with RPMI 1640. Cells grew at 37°C with 5% CO2 in the atmosphere. The 
subcultivation ratio was 1:5. 
 
A427 is a human lung carcinoma (ATCC Number HTB-53) from a 52 year old 
Caucasian male. The epithelial cell line grows adherent. The medium for this cell line 
was MNP. The cells were cultured at 37°C with 5% CO2 in the atmosphere and 
subcultivated 1:5.  
 
Hep3B is a human liver hepatocellular carcinoma (ATCC Number HB-8064) from an 8 
year black juvenile. The epithelial cell line grows adherent. The cell line was cultured 
with RPMI 1640. The cells grew at 37°C with 5%CO2 in the atmosphere and a 
subcultivation ratio of 1:2. 
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SW1736 is a human thyroid adenocarcinoma cell line cultured at the tissue culture 
facility of the Institute of Cancer Research, Vienna, Austria, from a biopsy. This 
adherent cell line was cultured with RPMI 1640. The cells grew at 37°C with 5%CO2 in 
the atmosphere and a subcultivation ratio of 1:10. SW1736 cells were grown on 
collagen (Sigma Aldrich, St.Louis, MO) layer coated flasks (85µl Collagen/1616µl PBS 
for 25cm
2
). 
 
MGC is a human glioblastoma cell line. The cell line was initiated at the tissue culture 
facility of the Institute of Cancer Research, Vienna, Austria from a biopsy. This 
adherent cell line was cultured with MEME supplemented at 37°C with 5%CO2 in the 
atmosphere and subcultivated 1:5.  
 
HCT-15 is a human colorectal adenocarcinoma Duke´s type C (ATCC Number CCL-
225) from a male. The cell line is epithelial and adherent. It was cultured with RPMI 
1640 at 37°C with 5% CO2 in the atmosphere and subcultivated1:10.  
 
HT-29 is a human colorectal adenocarcinoma (ATCC Number HTB-38) derived from a 
44 year old female Caucasian. Cells were isolated from a primary tumour in 1964 by J. 
Fogh. The cell line is epithelial and adherent. It was cultured with RPMI 1640 
complemented with a final concentration of 10% FBS at 37°C with 5%CO2 in the 
atmosphere, and subcultivated 1:10. 
 
CaCo-2 is a human colorectal adenocarcinoma (ATCC Number HTB-37) derived from 
72 year old Caucasian male. The cell line is epithelial and adherent. It was cultured with 
RPMI 1640 at 37°C with 5%CO2 in the atmosphere. CaCo-2 cells were subcultivated 
1:5. 
 
HCT-116 is a human colorectal adenocarcinoma (ATCC Number CCL-247) derived 
from adult male. The cell line is adherent and was cultured with DMEM modified 
medium (see chapter 3.1.2.2) at 37°C with 5%CO2 in the atmosphere, and subcultivated 
1:10. 
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MCF-7 is a human breast mammary gland epithelial adenocarcinoma (ATCC Number 
HTB-22) derived from pleural effusion of a 69 year old female Caucasian. The cell line 
is adherent and cultured with DMEM modified medium without phenol red (see chapter 
3.1.2.2) and supplemented with 10% FBS. The cells grew at 37°C with 5%CO2 in the 
atmosphere, and were subcultivated 1:10. 
 
HMEC-1 is a human microvascular endothelial cell line (Ades et al. 1992) derived from 
the tissue culture facilities of the Institute of Cancer Research, Vienna, Austria from a 
biopsy. The cells were grown on collagen (Sigma Aldrich, St.Louis, MO) layer coated 
flasks (85µl Collagen/1616µl PBS for 25cm
2
) at 37°C with 5%CO2 in the atmosphere. 
The adherent cell line was cultured with DMEM modified medium (see chapter 3.1.2.2) 
and subcultivated 1:4. 
3.1.2 Cell Culture Medium 
3.1.2.1 RPMI 1640 
RPMI 1640 (Sigma Aldrich, St.Louis, MO) was complemented with 10% fetal bovine 
serum (FBS, PAA) 2g/l NaHCO3 (VWR, Vienna, Austria) and 1% Penicillin-
Streptomycin (PAA). After addition the solution was sterile filtered 0,22µm filter 
(Corning) and stored at 4°C for max. 2 weeks. 
RPMI 1640 without phenol red (PAA) was used for MTT assays. 
3.1.2.2 DMEM 
DMEM (Sigma Aldrich) was complemented with 10% FBS (PAA), 3,7g/l NaHCO3 
(VWR) and 1% Penicillin-Streptomycin (PAA). After addition the solution was sterile 
filtered 0,22µm filter (Corning) and stored at 4°C for max. 2 weeks. 
 
Medium for MCF-7 cell line: 
DMEM without phenol red (Invitrogen, Carlsbad, USA) was complemented with 10% 
FBS (PAA) 3,7g/l NaHCO3 (VWR) and a total concentration of 4,5g/l glucose 
monohydrate (VWR). After addition the solution was sterile filtered 0,22µm filter 
(Corning). The sterile medium was supplemented with 57,2µl/l of 3,5µM insulin stock 
(Sigma Aldrich), 2mM L-Glutamine (Sigma) and 1% Penicillin-Streptomycin (PAA) 
and stored at 4°C up to 2 weeks. 
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Medium for HMEC-1 cell line: 
DMEM (Sigma Aldrich) was supplemented with 10% FBS (PAA) 3,7g/l NaHCO3 
(VWR). After addition the solution was sterile filtered 0,22µm filter (Corning). The 
sterile medium was supplemented with 10µg/ml endothelial growth factor (EGF, Sigma 
Aldrich) and 24ng/ml hydrocortisone (Sigma Aldrich) and stored at 4°C for one week. 
3.1.2.3 MEME 
MEME (Sigma Aldrich) was supplemented with 10% FBS (PAA), 2,2g/l NaHCO3 
(VWR) and 1% Penicillin-Streptomycin (PAA). After addition the solution was sterile 
filtered 0,22µm filter (Corning) and stored at 4°C up to 2 weeks. 
3.1.2.4 MNP 
MEME (Sigma Aldrich) was complemented with 10% FBS (PAA), 2,2g/l NaHCO3 
(VWR), 1% Penicillin-Streptomycin (PAA), 2µl/ml pyruvate (Sigma Aldrich) and 1% 
non-essential amino acids (NEAA, PAA). After addition the solution was sterile filtered 
0,22µm filter (Corning) and stored at 4°C for max. 2 weeks. 
3.2 Peptides and other Substances 
Vasoactive intestinal peptide (VIP), VIP-DOTA with and without gadolinium (VIP-
DOTA-Gd), pituitary adenlyate cyclase-activating peptide (PACAP), VIP-
hematoporphyrin (VIP-PDT), photosan, VIP-Cy3 and VIP-Fluo were synthesized using 
FMOC solid-phase peptide synthesis (FMOC-SPPS) and finally purified by RP-HPLC 
(piCHEM, Graz, Austria). (Ala
11,22,28
)-VIP and (Ala
11,22,28
)-VIP-FITC were produced by 
Bachem (Bubendorf, Switzerland).  
The liposome batch L08I was synthesised by Ruth Prassel (Institute of Biophysics and 
Nanosystems Research, Academy of Sciences, Graz, Austria). VIP-loaded proticles 
batch #G (PG) were produced and purified by Andreas Zimmer (Institute of 
Pharmacological Sciences, University Graz, Austria). 
All conjugates were covalently linked to the C-terminus except scrambled VIP, where 
Cy3 is linked to N-terminus (table.6). Chemical structures of VIP-conjugates are shown 
in fig.8.  
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Table 6. Peptides and substances used. 
 
Peptide 
Sequence N-C terminus 
(one letter aa code) 
Molecular 
mass [Da] 
conjugate 
Produced 
by 
VIP HSDAVFTDNYTRLRKQMAVK-NH2 3325,9 - piCHEM 
(Ala
11,22,28
)-
VIP 
HSDAVFTDNYARLRKQ- 
M(O)-Dip-VKKALNSILA-NH2 
3160,7 - Bachem 
VIP-DOTA 
Ac-HSDAVFTDNYTRLRKQM(O) 
AVKKYLNSILNK(DOTA)-NH2 
3898,4 DOTA piCHEM 
VIP-
DOTA-Gd 
Ac-HSDAVFTDNYTRLRKQM(O) 
AVKKYLNSILNK(DOTA[Gd])-NH2 
3994,6 DOTA-Gd piCHEM 
VIP-PDT 
HSDAVFTDNYTRLRKQMAVK 
KYLNSILNK(Haem)-NH2 
4075,0 hematoporphyrin piCHEM 
PACAP 
HSDGIFTDSYSRYRKQMAVK 
KYLAAVLGKRKQRVKNK-NH2 
4531,5 - piCHEM 
Photofrin
® 
hematoporphyrin oligomer  ca.10.000 - piCHEM 
VIP-Cy3 
HSDAVFTDNYTRLRKQ 
MAVK-K-Cy3 
3921,7 Cy3 piCHEM 
VIP-Fluo 
HSDAVFTDNYTRLRKQ 
MAVK-K-Fluo 
3812,3 Flourescein piCHEM 
Ala
(11,22,28)
-
VIP-FITC 
HSDAVFTDNYARLRKQ-M(O)-Dip-
VKKALNSILA-K-FITC-NH2 
3678,26 FITC Bachem 
Cy3-Scr-
VIP 
Cy3-AhxYIKKMNRVLAQDN 
SDATYSVLNTKHLRF-NH 
3906,7 Cy3 piCHEM 
Et-Cy3-OH Ethyl-Cy3-OH 629,8 Cy3 piCHEM 
Liposome 
batch L08I 
VIP in Lyso-PG:DSPE 
[PEG200]=11:7,5:1 
100nm 
filter 
- 
Ruth 
Prassl 
Proticle  
batch #G 
VIP-loaded proticles 
(Oligonuctleotide:VIP:protamin=1:2:0,6) 
100µg/ml - 
Andreas 
Zimmer 
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Figure 8. Chemical structure of VIP conjugates used in this study. Cy3 and Fluorescein are 
fluorescing molecules. DOTA, DOTA chelated to gadolinium (Gd) has an application in MRI 
diagnostic. All conjugates are linked to the C-terminus of VIP with lysine as linker. 
3.3 Western Blot analysis (WB) 
Western blot analysis was performed to determine the VPAC1 and VPAC2 expression of 
the cells. The concentration of protein lysate of all cell lines were analysed to separate 
on a polyacrylamide gel for SDS-PAGE. Separated proteins were blotted onto 
nitrocellulose membrane. An immunodetection was done with specific antibodies and 
were visualised with chemiluminescence on an X-ray films. 
 
Total protein content: 
- RIPA II Buffer: 50mM TRIS-Cl (Merck), pH 7,4, 500mM NaCl (Sigma 
Aldrich), 1% Nonidet NP40 (Sigma Aldrich), 0,1% SDS (Roth, Karlsruhe, 
Germany), 0,05% Natriumazid NaN3 (Merck). 
- 1mM Natriumorthovanadate NaVO4 in PBS 
All preparations were done on ice. All cells lines were cultured in 25cm
2
 flask for 2 day 
at 37°C with 5%CO2 in the atmosphere. The cells were scraped off with a cell scraper 
(Corning) in 3ml fresh medium including 1mM NaVO4 (Sigma Aldrich). The flak was 
washed with PBS, NaVO4 to remove all cells. After centrifugation at 1500rpm for5min, 
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cells were washed with 3ml PBS, NaVO4. After a centrifugation at 1500rpm for 5min, 
the pellet was lysed with 100µl RIPA II buffer, 1x Complete Protease inhibitor (Roche 
Diagonstics, Basel, Switzerland) and NaVO4. Cell lysate was sonicated (Sonoplus 
Bandelin, Berlin, Germany) 3 times 3s and centrifuged at 1500rpm for 5min. The total 
protein lysate was stored at -20°C.  
 
Determination of Protein Concentration: 
The protein concentration was determined with Bradford assay. A bovine serum 
albumin (BSA, Pierce, Rockford, USA) standard curve (range 0-8mg/ml) was used to 
calculate the unknown protein concentration. 1µl RIPA II buffer, 0-8µl BSA, 150µl 
Coomassie Protein Assay Reagent (Pierce) complemented with bidest. water to reach 
160µl in total. 1µl protein lysate, 9µl bidest. water and 150µl Coomassie Protein Assay 
Reagent (Pierce) were used for determination of protein concentration. Standards and 
samples absorbance were measured at 595nm with Synergy HT Microplate Reader 
(BIO-TEK, Vermont, USA). 
 
SDS-PAGE: 
- 10x Electrophoresis buffer, all chemicals were purchased by Merck: 14,4% 
(w/v) glycine, 3% (w/v) TRIS, 1% (w/v) SDS. 1x electrophoresis buffer was 
diluted 1:10 with dest. water. 
- Resolving gel buffer: 1,5M TRIS/HCl pH 8,8 
- Stacking gel buffer: 0,5M TRIS/HCl pH 6,8 
- 40% Acrylamide/Bisacrylamide 37,5:1 (2,6% C) (Bio-Rad, Hercules, Canada) 
- 10% (w/v) SDS (Sigma Aldrich) 
- 10% /w/v) APS (Sigma Aldrich) 
- TEMED (Sigma Aldrich) 
- 6x SDS-PAGE reducing buffer: 7ml 1M TRIS (Merck) pH 6,8; 2ml Glycerine 
(Merck), 1ml Mercaptoethanole (Sigma Aldrich), 1g SDS (Merck); 0,1mg 
bromphenole blue (Sigma Aldrich). Aliquotes were stored at -20°C. 
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Table 7. Recipe for a 12% polyacrylamide (PAA) gel. 
 
Amount for 2 gels Resolving gel 12% Stacking gel 5% 
40% Acryl/Bisacrylamide 3 ml 0,5 ml 
Resolving Buffer pH 8,8 2,5 ml -------- 
Stacking Buffer pH 6,8 ------- 1,0 ml 
bidest. Water 4,5 ml 2,5 ml 
degas 
10% SDS 100µl 100µl 
10% APS 100µl 100µl 
TEMED 4,0µl 8,0µl 
Amount 10,2 ml 4,2 ml 
 
After overlaying the separation gel (tab.7) with 96 % ethanol, the gel was polymerised 
during 30 minutes. The ethanol was then removed and the stacking gel was polymerised 
during 30 minutes in the presence of a sample comb 0,75mm (Hoefer SE 260, 
Amersham, San Francisco, USA). 
For denaturing the samples, they were mixed in 1x SDS-PAGE reducing sample buffer, 
incubated for 5 minutes at 95°C and shortly centrifuged. 20µg/lane of proteins and 
5µl/lane of the Page Ruler Prestained Protein Ladder (Fermantas, Ontario, Canada) 
were loaded onto the gel. The electrophoresis chamber (Hoefer SE 260) was then filled 
with 1x electrophoresis buffer before separating the proteins at 130V/100mA 1-1,5 
hours at room temperature. Once the proteins were separated, the gels were used for 
western blot. 
 
Blotting: 
- 10x blot buffer: 14,4% (w/v) glycine (144g/l), 3% (w/v) TRIS (30g/l), 0,2% 
(w/v) SDS (2g/l). All chemicals were purchased by Merck. 1x Blot buffer 
consisted of 20% (v/v) MeOH and was cooled to 4°C before use. 
After electrophoresis the gel was equilibrated in 1x blot buffer. The nitrocellulose 
membrane (Bio-Rad) was also pre-soaked in the 1x blot buffer. The sandwich of blot, 
gel, filter paper and fibre pads was constructed in the blotting cassette according to the 
supplier’s instructions (Hoefer TE 22). The electro blotting was performed at 
25V/60mA over night at 4°C. 
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Ponceau staining: 
A reversible staining of the proteins on the membrane was performed using 0.5% 
Ponceau Red S (Sigma Aldrich) in 1% acetic acid (Sigma Aldrich) for 5 minutes. The 
membrane was then carefully washed with water to reveal the protein bands. Before 
immunodetection, the ponceau staining was removed during the blocking step. 
 
Immunodetection with antibodies: 
- TPBS buffer (Blocking solution): PBS, 3% BSA (Sigma), 0,5% Tween20 
(Merck) 
- Washing buffer: PBS, 0,5% Tween20 (Merck) 
- primary Ab: monoclonal anti-VPAC1 (1mg/ml) (Abcam, Cambridge, UK), 
monoclonal anti-VPAC2 mouse (1mg/ml) (Abcam), polyclonal rabbit anti-actin 
(1mg/ml) (Sigma Aldrich) 
- secondary Ab: rabbit polyclonal peroxidase conjugated anti-mouse (Calbiochem 
Merck), goat polyclonal peroxidase conjugated anti-rabbit (Calbiochem Merck) 
- Super Signal West Pico Chemiluminescence Substrate (Pierce)  
Nitrocellulose membrane was blocked with blocking buffer for 1h. After blocking both 
primary antibodies, anti-VPAC1 and anti-VPAC2 were diluted 1:10.000 and anti-actin 
1:5000 in blocking buffer and incubated 1h at RT. The membranes were washed 5 times 
each 5min with washing buffer. Secondary antibody anti-mouse was diluted 1:10.000 
and anti-rabbit 1:7500 in blocking buffer and incubated 1h at RT. The membranes were 
washed 5 times each 5min with washing buffer. The membrane was incubated with 
Chemiluminescence Substrate mixed 1:1 for 5min and exposed on CL-Xposure film 
(Pierce) for some minutes.  
3.4  Immunocytochemistry (ICC) 
An immunocytochemistry staining allows the detection of antigens with specific 
antibodies. After fixation of cells, a blocking step with FBS and afterwards incubations 
with primary and secondary antibody conjugated to biotin were performed. Biotin signal 
was multiplied with streptavidin-peroxidise complex. The enzyme peroxidase converted 
the substrate DAB into a brown colour precipitation. Schematic drawing of ICC (fig.9) 
shows the detection of antigen with primary and secondary antibodies. Marker indicates 
several different visualisation systems. 
Material and Methods 45 
 
Figure 9. Scheme of immunocytochemistry (ICC) staining. The primary antibody recognizes the 
antigen. The secondary antibody covalently linked to a marker molecule, e.g. enzyme, binds to the 
primary ab. The marker molecule is able to convert a substrate to a visible product. [from (Alberts B 
2002)] 
 
ICC Procedure: 
10
5 
cells/well were grown in 4-well Lab-Tek Chamber Slides (Nunc, Roskilde, 
Denmark) over night at 37°C with 5%CO2 in the atmosphere. The cells were washed 
twice 5min with PBS and fixated with 2% paraformaldehyd (PFA, Sigma) for 30min at 
4°C. Cells were washed twice each 5min and air dried for 10min. 30min blocking step 
with 3%BSA/0,5%Tween20/PBS was performed at RT. Incubation of primary 
antibodies polyclonal rabbit anti-VPAC1 (1:200, 1mg/ml, Abcam), polyclonal rabbit 
anti-VPAC2 (1:1000, 1mg/ml, Abcam) and polyclonal rabbit anti-PAC1 (1:1000, 
1mg/ml, Abcam) was done for 1h. As a negative control one well was incubated with 
PBS without primary antibody. Following three washing steps with PBS were 
performed and the secondary antibody goat polyclonal anti-rabbit-Ig-biotin (1:500, 
Dako Cytomation, Glostrup, Denmark) diluted in blocking solution was incubated for 
30min. The negative control was treated with secondary antibody under the same 
conditions. After two washes with 0,3% H2O2 in PBS for 10min, the cells were washed 
with PBS for 5min. The cells were incubated with Streptavidin Peroxidase Ready to Use 
(Lab Vision, Fremont, USA) for 30min. Additional three washing steps with PBS each 
5min were performed. As substrate for peroxidase Liquid DAB+Substrate Chromogen 
System (Dako Cytomation) was used and it was incubated for 20-40min (brown 
precipitates), followed by three additional washing steps. 
 
Nuclea staining with Mayer´s Hematoxylin: 
Mayer´s Hematoxylin Solution 0,1% (Sigma) was diluted 1:3 and cells were incubated 
for 10min. The slide was washed with bidest. water and incubated with tap water for 
10min (blue staining of cell nuclei). 
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Mounting: 
The slides were incubated with 96% ethanol (Sigma) for 10 min. Slides were further 
dehydrated with 100% ethanol for 10min. Two incubation steps with xylol (Sigma) 
were done for 10min each. After dehydration the object slides were mounted in Eukitt 
(O.Kindler, Freiburg, Germany) and hardened over night. Microscopic analysis was 
performed with a 60x objective Eclipse 80i microscope (Nikon, Kanawaga, Japan). 
3.5 Vitality test  
Trypane blue is an acidic dye which cannot penetrate intact living cell membranes. It 
was used to visualise dead cells. Not coloured cells indicated the survival and vitality of 
cells. Blue colour in the cells indicate dead cells. 
The medium of the cells was aspirated and a staining with 0,4% trypane blue (Sigma 
Aldrich) diluted 1:20 in PBS was performed for 2min. The solution was aspirated and 
cells were covered with PBS. Micrographs were taken with an Eclipse TS 100 
microscope (Nikon). If cells were cultured after staining, the PBS was aspirated and 
culture medium was added. 
3.6  Proliferation assay (MTT) 
A non-radioactive cell proliferation and cytotoxcity assay [MTT test with 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid; EZU4 Kit, Biomedica, Vienna, 
Austria] was used for studying of peptide analogues behaviour at cells growth 
conditions. Few cells (10
3
-10
5
) were grown on 96-well microtiter plates with a defined 
concentration of peptide analogue and incubated for 72h at 37°C with 5%CO2 in the 
atmosphere. Tetrazolium salts (yellow) were used for cell viability; therefore living cells 
were capable to reduce slightly coloured tretrazolium salt into intensive coloured 
formazan derivate (deep red). This reduction process requires functional 
dehydrogenases in mitochondria of living cells, which are inactivated within a few 
minutes after cell death. This method was an excellent tool to discriminate living from 
death cells. 
 
Procedure:  
10
5
 cells/well were grown in medium in a 96-well microtiter plate (Falcon Becton 
Dickson Labware, Franklin Lakes, USA). Following peptides and analogues were tested 
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for their proliferation or toxicity: VIP, (Ala
11,22,28
)-VIP, VIP-DOTA, VIP-DOTA-Gd, 
PACAP. The analogues were analysed in following concentration: 10µM, 10nM and 
10pM (table 8). Peptides analogues were diluted in medium and 100µl cell suspension 
and 100µl peptide dilution of each were mixed and loaded in the microtiter plate. Also a 
negative control was performed with 100µl cell suspension and 100µ medium. The cells 
were incubated for 72h at 37°C with 5%CO2 in the atmosphere. After incubation the 
medium was aspirated and 200µl RPMI 1640 without phenol red (PAA) was added to 
each wells. 20µl of premixed dye-solution (2,5ml solution mixed with one bottle of dye) 
EZU4 Kit (Biomedica) was used to visualise viable cells. The plate was incubated 1-4h, 
depending on cell line, at 37°C 5%CO2 to convert dye substrate into a deep red 
formazan derivate product. The colour reaction was measured at 450nm and 620nm as 
reference by Synergy HT Microplate Reader (BIO-TEK). For calculation, the reference 
absorptions (620nm) of each four peptide dilutions and the negative control were 
subtracted and averaged. The standard deviation for the same values was calculated. 
The average of the negative control was supposed to 100%, and other data were 
calculated from this 100%. All calculated data were illustrated in a table, averages and 
standard deviations are given in the diagram. 
 
Table 8. MTT loading scheme for 96-well plates. 
 
 
 
 
 
 
 
 
 
 
3.7 Enzyme Linked Immuno Sorbent Assay (ELISA) 
Enzyme linked immuno sorbent assay (ELISA) is a method to detect specific antigens 
after antibody treatment. The so called “sandwich ELISA” is explained in fig.10. 
Coated microtiter plate with sera and antigen is recognized by monoclonal primary 
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antibody. The polyclonal secondary antibody is conjugated to an enzyme which 
converts a soluble substrate into a precipitate, it detects the primary antibody. A distinct 
wavelength can be measured by photometry and quantified via a standard curve.  
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Sandwich ELISA assembly. Unspecific binding sites are blocked with proteins and 
antigen. Antigen coated surface is detected by primary antibody. Enzyme linked secondary antibody 
recognizes the primary ab and converts a substrate to a coloured product. [from (Nelson D L 2004)] 
 
The second messenger cAMP is used to detect VIP internalisation and the indirect 
detection of the VIP signalling pathway. Following chemical substances are influencing 
VIP signalling pathway (fig.11): 
Forskolin is known to activate adenylate cyclase (AC), an enzyme responsible for 
synthesis of cAMP. It results in an increased amount of available cAMP leading to 
increased lipolysis and oxidation of fatty acids resulting in increased thermogenesis. 
Forskolin does not influence or interact with the VIP signalling pathway. 
IBMX, 1-methyl-3-(2-methylpropyl)-7H-purine-2,6-dione, is a potent cyclic nucleotide 
phosphodiesterase inhibitor. Due to this action, the compound increases cAMP and 
cGMP in tissue and thereby activates cyclic nucleotide-regulated protein kinases. The 
phosphodiesterase inhibitor IBMX prevents breakdown of cAMP.  
SQ22,536; [9-(tetrahydro-2-furanyl)-9H-purin-6-amine], is an adenlyate cyclase 
inhibitor.  
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Figure 11. VIP signal transduction pathway and the influence of Forskolin, IBMX and 
SQ22,536. Red arrows indicate activation and red dots inhibition of proteins. Forskolin actives the 
adenlyate cyclase directly (VIP independent). SQ22,536 inhibits the adenlyate cyclase. IBMX 
prevents the degradation of cAMP to 5´AMP by blocking cyclic nuclide phosphodiesterase.  
VIP vasoactive intestinal peptide, VPAC1/2 VIP receptor subtypes, PAC1 PACAP-preferring receptor 
subtype, Gs stimulatory G-protein activates AC, Gq stimulatory G-protein activates PLC-β, PLC-β 
Phospholiase C, IP3 Inositol-3-phosphate, DAG Diacylglycerol, PKC Ca
2+-depending protein kinase, 
ATP Adenosintriphosphate, cAMP cyclic adenosinemonophosphate.  
3.7.1 ELISA setup 
10
5
 cells/well of HMEC-1, HT-29 and Capan-1 were grown in medium in a 96-well 
microtiter plate (Falcon Becton Dickson Labware) at 37°C with 5%CO2 in the 
atmosphere over night. The cells were incubated in starvation medium (medium 
containing only 3% BSA) for 3h at 37°C with 5%CO2 in the atmosphere.  
Following peptide and substance dilutions were used a total concentration/100μl well 
starvation medium of: 
- 10nM of VIP, (Ala11,22,28)-VIP, VIP-DOTA-Gd and VIP-PDT 
- 500µM 3-isobutyl-1-methyl-xanthine (IBMX, Sigma) 
- 20µM Forskolin 20µM (Sigma) 
- 100µM SQ22,536 (Sigma) 
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Table 9. ELISA loading scheme of 96-well plate. 
 
 1 2 3 4 5 6 
A Medium VIP VIP VIP IMBX IMBX 
  1nM 10nM 100nM 1nM VIP 10nM VIP 
B IBMX + SQ SQ SQ Forskolin Forskolin 
 100nM VIP 1nM VIP 10nM VIP 100nM VIP  IBMX 
C Medium VIP VIP VIP IMBX IMBX 
  1nM 10nM 100nM 1nM VIP 10nM VIP 
D IBMX SQ SQ SQ Forskolin Forskolin 
 100nM VIP 1nM VIP 10nM VIP 100nM VIP  IBMX 
 
5µl of 1µM VIP-conjugates, 25µl of 10mM IBMX stock, 5µl of 1:20 diluted 20mM 
forskolin stock and 5µl of 20mM SQ22,536 stock were used in the assay. After 
starvation, peptides and substances were mixed (table 9) and incubated for 20min at 
37°C with 5%CO2 in the atmosphere. Medium was aspirated and cells were lysed using 
Amersham cAMP Biotrak Enzyme immunoassay (EIA) System (GE Healthcare, 
Uppsala, Sweden) with 200µl lysis buffer 1B. After 10min shaking, the supernatant was 
directly used in EIA Kit or stored at -20°C. The complete cell lysis was tested with the 
vitality test (see chapter 3.5). 
 
ELISA procedure:  
EIA cAMP standards were mixed as shown in table 10. Standards were used within 1h. 
 
Table 10. cAMP EIA standard loading scheme. 
 
 
 
 
 
 
 
 
 
Following amounts were loaded to the microtiter plate (see fig.12): 
- 100µl lysis reagent 1B and 100µl lysis reagent 2B were loaded in NSB well.  
- 100µl lysis reagent 1B was loaded in Std 0 well. 
cAMP 
[fmol] 
µl stock 
32 pmol 
µl dilution 
µl Lyses 
reagent 1B 
1600 500 - 500 
800 - 500 500 
400 - 500 500 
200 - 500 500 
100 - 500 500 
50 - 500 500 
25 - 500 500 
12,5 - 500 500 
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- 100µl of each standard (0-3200pM) and 100µl sample. 
 
Figure 12. EIA loading scheme of 96-well 
microtiter plate. B blank, NSB non specific 
binding, 0-3200 fmol standards, S sample 
 
Samples were run in duplicates. All 
reagents were warmed up to RT and the 
plate was put on ice. 100µl antisera 
were loaded in all wells except NSB und 
B, and incubated 2h at 4°C. 50µl cAMP-
peroxidase conjugate was added to all wells except B and incubated 1h at 4°C. The 
plate was washed 4 times with 200µl wash buffer. 150µl enzyme substrate was 
transferred to all wells and incubated 1h at RT with shaking. The blue colour was 
measured at 630nm (as reference) with Synergy HT Microplate Reader (BIO-TEK). 
100µl 1M sulfuric acid (Sigma) was added to stop the reaction. The yellow colour was 
measured at 450nm within 30min with Synergy HT Microplate Reader (BIO-TEK). 
The absorbance data were calculated with a standard calibration curve of cAMP. The 
averages of the duplicates were built and the standard deviation was calculated. All 
averages and standard deviations were illustrated in a diagram. 
3.7.2 Time course experiment 
The cell assay was performed with PASMC (pulmonary artery smooth muscle cells) 
10
5
cells/well in DMEM medium. Cells were cultured in 24-well plates (Nunc) for 2-3 
days at 37°C with 5%CO2 in the atmosphere. The cells were incubated in starvation 
medium (medium containing only 3% BSA) for 3h at 37°C with 5%CO2 in the 
atmosphere. 
Following substances were diluted in starvation medium with a total concentration of 
(table 11): 
- 10nM VIP 
- 10nM and 100nM liposomes #L08I 
- 10nM and 100nM proticles #G 
- 500µM 3-isobutyl-1-methyl-xanthine (IBMX) (Sigma) 
- 20µM Forskolin 20µM (Sigma) 
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Table 11. ELISA loading scheme for lipsome assay in 96-well plate. 
 
 1 2 3 4 5 6 
A Medium VIP Liposome Liposome Proticle Proticle 
5min  10nM 10nM 100nM 10nM 100nM 
B IBMX VIP Liposome Liposome Proticle Proticle 
10min  10nM 10nM 100nM 10nM 100nM 
C Forskolin VIP Liposome Liposome Proticle Proticle 
20min  10nM 10nM 100nM 10nM 100nM 
D IBMX + VIP Liposome Liposome Proticle Proticle 
60min Forskolin 10nM 10nM 100nM 10nM 100nM 
 
 
Lane A was incubated for 5min, B for 10min, C for 20min, D for 60min, IBMX, 
Forskolin and both together each 20min. Cells were washed with PBS and lysated with 
150µl 0,1M HCl (Merck) for 10min with shaking. Lysis was repeated twice (each 
150µl) and supernatant was stored at -20°C or used directly for cAMP direct EIA Kit 
(Assay Design, Ann Arbor, USA) . 
Also PANC-1 cells passage 4 (P4) were used for time course experiment with proticles 
#G. The same assay like for liposomes was performed for proticles, but with the cell 
assay described in chapter 3.7.1. 10
5
 cells/well of PANC-1 P4 were cultured in 96-well 
plates (Falcon Becton Dickson Labware). The agonists were incubated for 5/10/ 20/ 30/ 
45/60min. 1µM and 300nM proticles #G and 10nM and 100nM of VIP were used in the 
assay. Controls were done with forskolin and IBMX. The cAMP level was measured 
with a ELISA assay (see 3.7.1). 
 
ELISA procedure: 
Acetylated assay was used for the cAMP detection. The cAMP standards were mixed as 
followed (table 12). Standards should be used within 30min. 
 
Table 12. Standard preparation for cAMP assay, Assay Design. 
 
cAMP 
Standard 
c [pmol/ml] 
Stock 
(2000pM/ml) 
0,1M HCl Addition of 
1 20 10μl 990μl - 
2 5 - 750μl 250μl of Std 1 
3 1,25 - 750μl 250μl of Std 2 
4 0,312 - 750μl 250μl of Std 3 
5 0,078 - 750μl 250μl of Std 4 
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10µl acetylating reagent (0,5ml acetic anhydride, 1ml triethylamine) was added to 
200µl standards and samples. 50µl acetylating reagent was transferred to NSB and B0. 
All standards, samples and controls were run in duplicates (table 13) and measured at 
405nm with a Microplate Reader Asys, Expert Plus (Eugendorf, Austria). 
 
Table 13. 96-well plate pipette scheme for cAMP detection assay, Assay Design. 
 
 
Wells 
Blank 
A1, B1 
TA 
C1, D1 
NSB 
E1, F1 
Std 0 (B0) 
G1, H1 
Std 1-5 
A2, B2 
Samples 
C3-D3 
Neutralisation 
Regent 
- - 50 μl 50 μl 50 μl 50 μl 
0,1M HCl - - 150 μl 100 μl - - 
Std or sample - - - - 100 μl 100 μl 
Blue Conjugate - - 50 μl 50 μl 50 μl 50 μl 
Antibody - - - 50 μl 50 μl 50 μl 
Incubation 2h RT, shaking 
3x wash each 200μl wash solution (1:20) 
Blue Conjugate - 5 μl - - - - 
Substrat pNpp 200 μl 200 μl 200 μl 200 μl 200 μl 200 μl 
Incubation 2h RT 
Stop Solution 50 μl 50 μl 50 μl 50 μl 50 μl 50 μl 
 
The concentrations of the duplicates were calculated with a standard calibration curve of 
cAMP. The average and the standard deviation of the duplicates was calculated and 
illustrated in a diagram. 
3.8  Photodynamic therapy assay (PDT) 
Photodynamic therapy (PDT) is a method to induce cell growth in healthy cells or 
induce cell death/apoptosis in tumour cells. PDT is based on a hematoporphyrin ring 
which produces radicals after irradiation exposure at about 650nm with a laser. 
Hematoporphyrin is light sensitive and also decays at day light. Free radicals produce 
oxidative stress and cells go in apoptosis. One method to quantify reacting oxygen 
species (ROS) uses dichlorofluorescein (DCFDA). DCFDA detects cellular peroxides, 
accumulates in the cytosol and is cytotoxic in high concentration. An optimal 
concentration is between 1-10µM. To avoid contaminations with endogenous esterase, 
serum free medium should be used for the assay. DCFDA´s strong fluorescence is 
visualised at ex488/em525nm (Halliwell and Whiteman 2004).  
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Figure 13. Scheme of redox reaction in PDT. The conversion of DCFDA (2´7´-dichlorofluorescein 
diacetate) to a fluorescent product.  
It is hydrolyzed by cellular esterases to dichlorofluorescin (2´7´-dichlorodihydrofluorescein), whose 
oxidation by several ROS yields florescent DCF (2´7´-dichlorofluorescein) via an intermediate radial, 
DCF•-. Peroxidases can also convert it into a phenoxyl radical that can interact with antioxidants such 
as ascorbate (AH-), reducing the phenoxyl radical and oxidizing ascorbate, or with GSH. GS• 
resulting from the latter reaction can lead to O2
•-generation. The phenoxyl radical can also be recycled 
by NADH (not shown), producing NAD• radical, which reacts rapidly with O2 to produce O2
•-: NAD• 
+ O2  NAD
+ + O2
 •-[from Halliwell and Whiteman, 2004)]. 
 
H2O2 or O2
•-
cannot oxidize DCFDA, neither can peroxyl, alcoxyl,
 
NO2
•-
, carbonate, 
OH
•-
and peroxynitirte. Also the fluorescence of the medium should be measured. 
Horseradish peroxidase (HRP) or other heme proteins can also oxidize DCFDA in 
presents of H2O2. This method is a general assay for oxidative stress but not particular 
for any ROS (fig.13).  
3.8.1 Reactive oxygen species (ROS) 
Cell assay: 
200µl of HCT-15, PC-3, Hep3B, HT-29, HMEC-1 and SW1736 (10
5 
cells/well) were 
grown on 96-well microtiter plate over night at 37°C with 5%CO2 in the atmosphere in 
medium containing serum. Two plates were cultured to compare the oxidative stress of 
radiated and non-radiated cells. Four different cell lines were analysed at one plate (tab. 
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14). H2O2, photosan (PS) and VIP-PDT calibrated an internal standard with following 
concentrations (200µl/well) in duplicates:  
H2O2 was diluted 1mM–100pM from 3% stock solution, photosan 10µM-10pM from 
1mg/ml stock solution and VIP-PDT 10µM-10pM from 1mM stock solution (table 14). 
Dilution steps of 10 times each were done. Also a negative control of each cell line was 
performed in duplicates without a treatment with chemicals.  
 
Table 14. Reactive oxygen species (ROS) assay loading scheme for 96-well plate. 
 
 
 
 
 
 
 
 
 
 
 
All dilutions were prepared in RPMI 1640 without phenol red or other supplements, and 
PBS to compare the autofluorescence and influence of RPMI on DCFDA. 10µM 
DCFDA (Dichlorofluorescein diacetate, stock 1mM) were transferred to each well and 
incubated for 30min at 37°C with 5%CO2 in the atmosphere. One plate was irradiated 
with 150W 50-60Hz Infratherm Comfort PIL-2200 (Bosch, Stuttgart, Germany) in 
20cm distance from plate for 30min at 37°C. The other plate was not radiated but 
performed with the same conditions. Fluorescence was measured with Synergy HT 
Microplate Reader (BIO-TEK) at 530nm. 
The fluorescence of the values was averaged and the standard deviation was calculated. 
The averages of the radiated and the non-radiated data were given in a diagram. 
3.8.2 PDT experiment 
10
5
cells/well of CaCo-2, Capan-1, HT-29 and HCT-15 cells were grown in medium on 
a 96-well microtiter plate (Falcon Becton Dickson Labware) at 37°C with 5%CO2 in the 
atmosphere over night. VIP-PDT and Photosan (store in dark!) were added in following 
 
1 2 3 4 5 6 
H2O2 PS VIP-PDT 
cell 
control 
cell 
+PS 
cell 
+VIP-PDT 
A 1mM 10µM 10µM 0 1µM 5µM 
B 1mM 10µM 10µM 0 1µM 5µM 
C 100µM 5µM 5µM 0 100nM 2µM 
D 100µM 5µM 5µM 0 100nM 2µM 
E 10µM 1µM 1µM 0 1µM 5µM 
F 10µM 1µM 1µM 0 1µM 5µM 
G 1µM 100nM 100nM 0 100nM 2µM 
H 1µM 100nM 100nM 0 100nM 2µM 
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concentration: 0M (control cells), 1µM, 100nM, 10nM, 1nM, and 10pM in RPMI 
without phenol red supplemented with FCS and 1x Complete protease inhibitor (Roche 
Diagnostics). Peptide dilutions were incubated at 37°C with 5%CO2 in the atmosphere 
for 30min. The light radiation was done with an Infratherm Comfort PIL-2200 (Bosch) 
150W/50-60Hz in 20cm distance from plate, for 30min in the incubator. Treated cells 
were incubated for 5-24h at 37°C with 5%CO2 in the atmosphere. To compare treated 
cells also a non-treated cell assay was performed with same conditions but without 
radiation. 
After incubation the medium was aspirated and 200µl RPMI without phenol red (PAA) 
was added to the wells. 20µl of premixed dye-solution mix (2,5ml solution mixed with 
1 bottle of dye) EZU4 Kit (Biomedica) was used to visualise viable cells. The plate was 
incubated 1-3h, depending on cell line, at 37°C with 5%CO2 in the atmosphere to 
convert dye substrate into a deep red formazan derivate product. The colour reaction 
was measured at 450nm and 620nm as reference by Synergy HT Microplate Reader 
(BIO-TEK). 
The fluorescence values were averaged and the standard deviation was calculated. The 
survival rate of control cells was calculated and suggested to 100%. The averages of 
radiated and non-radiated data were given a diagram. 
3.9  Fluorescent correlation microscopy (FCS) 
FCS is a spectroscopic technique for study molecular interactions in solution. FCS 
monitors the random motion of fluorescently labelled molecules inside a defined 
volume element irradiated by a focused laser beam (fig. 14). These fluctuations provide 
information on the rate of diffusion or diffusion time of a particle and this, in turn, is 
directly dependent on the particle's mass. As a consequence, any increase in the mass of 
a molecule, e.g. as a result of an interaction with a second molecule, is readily detected 
as an increase in the particle's diffusion time. Not least due to its simple underlying 
principle, FCS is an ideal approach for the study of thermodynamic and kinetic features 
of molecular interactions in solution (Schwille P 2004). 
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Figure 14. Schematic drawing of FCS setup. The exciting 
radiation provided by a laser beam is directed into a 
microscope objective via a dichroic mirror and focused on the 
sample. Water immersion objectives with a high numerical 
aperture (ideally > 0.9) are used. The fluorescence light from 
the sample is collected by the same objective and passed 
through the dichroic mirror and the emission filter. The pinhole 
in the image plane (field aperture) blocks any fluorescence 
light not originating from the focal region, thus providing axial 
resolution. Afterwards, the light is focused onto the detector, 
preferably an avalanche photodiode or a photomultiplier. [from 
(Schwille P 2004)] 
 
FCS was introduced in the early 1970s has become a powerful tool for researchers in 
life science. Examples of successful FCS applications include studies on molecular 
diffusion, DNA hybridisation reaction and ultrasensitive pathogen detection. In the last 
years the first FCS application on living cells has been published. Rigler and co-workers 
used rhodamine-labelled ligands to demonstrate specific binding sites for C-peptide on 
human fibroblasts. Schwille et. al (2004) investigated ligand diffusion and specific 
binding on model membrane, as well as a model receptor system. They obtained typical 
diffusion constants for ligands freely diffusing in solution, ligands diffusing in the cell 
membrane, ligands bound to cell membrane receptor and a type of ligand diffusion in 
the cell which they termed “anomalous subdiffusion”; one possible explanation for the 
latter being binding to intracellular membranes. 
Due to this very high sensitivity and the small measuring volume, FCS is a promising 
tool investigating low concentrations and confounding factors, e.g. an additional 
intracellular receptor complicate its detection. 
 
FSC setup: 
Ne/He laser 543nm: The measurements were performed with a Confocor (Carl Zeiss-
Evotec, Jena, Germany) equipped with an Ne/He-Laser 543nm attenuated with an 
appropriate density filter, a C-Apochromat 63x/1.2W Korr objective, a dichroic mirror 
and bandpass filters. The pinhole size was set to 45μm, resulting in a confocal volume 
element of 0.35m in the xy (lateral) and 2.4μm in the z (axial) dimension as determined 
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by calibrating using Rhodamine B (Sigma Aldrich). Intensity fluctuations were 
recovered by an avanche photodiode (SPCM-CD 3017) and autocorrelated with a 
hardware correlator (ALV 5000, ALV, Langen, Germany) 
To calibrate the FCS setup a 1:1000 dilution of Rhodamin B was used and 10 
measurements were performed. From the calibration data the structure parameter was 
calculated and used for all following measurements.  
 
Ar laser 488nm: The measurements were performed with a Confocor (Carl Zeiss-
Evotec, Jena, Germany) equipped with an Argon-Laser 5488nm attenuated with an 
appropriate density filter, a C-Apochromat 63x/1.2W Korr objective, a dichroic mirror 
and bandpass filters. The pinhole size was set to 45μm, resulting in a confocal volume 
element of 0.35m in the xy (lateral) and 2.4μm in the z (axial) dimension as determined 
by calibrating using Rhodamine 6G (Sigma Aldrich). Intensity fluctuations were 
recovered by an avanche photodiode (SPCM-CD 3017) and autocorrelated with a 
hardware correlator (ALV 5000, ALV, Langen, Germany). 
To calibrate the FCS a 1:100 dilution of Rhodamin 6G was used and 10 measurements 
were performed. From the calibration data the structure parameter was calculated and 
used for all following measurements.  
 
 
Procedure: 
PANC-1 cells passage 8 (P8) were used for this study. The cells were grown at 
37°C/5%CO2/95% rel. humidity in 75cm
2
 cell culture flasks in RPMI 1640 medium. 
After one passage, 5x10
4
 cells were cultured in a LabTek chambered coverglass (Nagle 
Nuc, Naperville, IL). 
The incubated living cells were taken out of the incubator and the first well was filled 
with 10µM hepes buffer in PBS, while the other wells remained in medium. The FCS 
measurements were performed during the first 2h, afterwards a new cell covered Labtek 
was incubated. 
All experiments were performed with 200μl of 1:1000 diluted peptides, VIP-Cy3 and 
VIP-Fluo in PBS. The negative control, Et-Cy3-OH, was diluted 1:10
5 
and Cy3-Scr-VIP 
1:1000 in PBS. Labelled proticles #G were diluted 1:100 in PBS. 
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3.9.1 Freely diffusion in solution 
The diluted peptides were transferred to a well and the focus was placed above the 
glass. The measurement duration of the intensity fluctuations took 30 seconds with 3s 
delay between each measurement. 10 measurements were performed.  
3.9.2 Membrane binding 
Measurements were performed by first placing the focus at a cell-free solution volume 
in order to obtain count rate and autocorrelation function for the ligand diffusing freely 
in the buffer. A typical measurement series on a cell started several μm above the cell 
(where count rate and correlation curve were the same as in the pre-measurement lateral 
of the cell); the focus was then moved in 1μm steps from the top to the bottom of the 
cell and a 30s measurement was taken at every position. At the end of the scan the 
unaltered position of the cell was controlled by visual re-evaluation and a second 
recording of the typical intensity fluctuations at the cell membrane position. 
3.9.3 Time course 
A method to measure the intensity in the cytoplasm during time is a time course. The 
focus is placed in the cytoplasm of the cell; this means it is focused on equatorial plate. 
The focus is fixed and will not be moved anymore. Afterwards intensity fluctuations of 
peptide were measured during a time periode. Each 30s a measurement of 5s was done 
over a period of 30 minutes. To calculate the different amounts of intensity in the 
cytoplasm, a diagram with count rate on y (intensity [kHz]) and time [min] on x was 
performed.  
3.10  Confocal Laser Scanning Microscopy (CLSM) 
Confocal laser scanning microscopy (CLSM) is a very good tool to focus distinct 
regions in a specimen and to illuminate with fluorescence. Fig. 15 shows a simplified 
diagram which the basic arrangement of optical components is similar to that of the 
standard fluorescence microscope, except that a laser is used to illuminate a small 
pinhole whose image is focused at a single point in the specimen (A). Emitted 
fluorescence from this focal point in the specimen is focused at a second (confocal) 
pinhole (B). Emitted light from elsewhere in the specimen is not focused here and 
therefore does not contribute to the final image (C). By scanning the beam of light 
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across the specimen, a very sharp two-dimensional image of the exact plane of focus is 
built up that is not significantly degraded by light from other regions of the specimen.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Scheme of a Confocal Laser Scanning Microscope (CLSM). A laser beam passes a small 
pinhole and activates the fluorescence in the sample. The emitted fluorescence passes a confocal pinhole, to 
achieve a z-resolution, and is detected by the detector. After scanning the beam through the specimen a two 
dimensional image is reconstructed. [from (Alberts B 2002)] 
 
Procedure: 
Internalisation studies allow the detection of fluorescent labelled peptides in living cells. 
10
4
cells/well of
 
LNCaP, Capan-1, PANC-1 passage P14 and P40, A427, Hep3B, 
SW1736, HT-29, CaCo-2, HCT-116 were grown in medium on coverslips (G. 
MENZEL, Braunschweig, Germany) over night at 37°C with 5%CO2 in the atmosphere. 
The cells were carefully washed twice with PBS. Unspecific binding was blocked with 
10% FBS in PBS for 30min. They were incubated for 30min with 1µM VIP-Cy3 or 
60min with 3µM (Ala
11,22,28
)-VIP-FITC in PBS. Only HT-29 cells were incubated 
15min with (Ala
11,22,28
)-VIP-FITC because of cell apoptosis. Nuclear double staining 
was performed with 1µM TO-PRO
®
-3 iodide (Molecular Probes, Leiden, Netherlands). 
After incubation the cells were washed twice with PBS and mounted with Citifluor 
(Gröple, Vienna, Austria) and directly analysed with CLSM. Controls were performed 
with 1µM unlabelled VIP, 3µM (Ala
11,22,28
)-VIP and 1µM TOPRO
®
-3 and incubated for 
30min at 37°C with 5%CO2 in the atmosphere.  
The fluorescence signal of Cy3 (ex/em: 550/570), fluorescein (494/518) and TOPRO
®
-3 
(642/660) were determined with a 63x objective and zoomed by Confocal Laser 
Scanning Microscope (Leica DM Irbe, Wetzlar, Germany).  
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4 Results 
4.1  VPAC receptor expression by cell line 
14 tumour cell lines and one endothelial cell line were analyzed for their receptor 
expression pattern for VPAC receptors. VPAC1, VPAC2 and PAC1 receptors were 
detected with monoclonal and polyclonal specific antibodies for these receptors by 
immunocytochemistry (ICC) stainings and western blots (WB).  
WB analysis was not consulted for determination of VPAC receptors expression pattern, 
therefore immunocytochemistry staining was performed. 
Immunodetections with monoclonal antibodies were performed by ICC stainings. Many 
tryouts with antibody dilutions did not reveal better signals and the negative control 
gave often a positive signal. So we decided to stain with polyclonal antibodies. After 
analysis with polyclonal antibodies the positive control was negative and the signal 
intensity was increased. ICC stainings from all cell lines were done twice.  
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Fig.16 shows immunocytochemistry (ICC) stainings with different antibody dilution at different cell lines. PC-3 was used for VPAC1 
optimation, because PC-3 cells express VPAC1, which was known previous. HCT-116 cells were detected with VPAC2 ab and LNCaP for 
PAC1. 
Figure 16. ICC staining with primary antibody 
dilutions, A-D) PC-3 cells, E-F) HCT-116 cells 
and I-L) LNCaP cells. Nuclei are stained very 
light blue with Mayer´s Hematoxylin. 
Polyclonal rabbit anti-VPAC1 antibody of PC-3 
cells were stained with DAB as a substrate. A) 
negative control without primary ab, B) 1:200 
dilution, C) 1:100 dilution and D) 1:50 dilution of 
ab. All dilutions show specific signals above 
negative controls. 
Polyclonal rabbit anti-VPAC2 antibody of HCT-
116 cells were stained with DAB as a substrate. E) 
negative control without primary ab, F) 1:3000 
dilution of ab, G) 1:2000 dilution and H) 1:1000 
dilution of ab. Dilution of 1:1000 gives a specific 
signal. 
Polyclonal rabbit anti-PAC1 antibody of LNCaP 
cells were stained with DAB as a substrate. I) 
negative control without primary ab, J) 1:3000 
dilution of ab, K) 1:2000 dilution and L) 1:1000 
dilution of ab. Dilution of 1:1000 gives a specific 
signal. 
 
 
 
In the case of VPAC1 antibody, antibody dilutions did not show an effect of specify signal between 1:50-1:200 dilution (fig.16A-D). 
Further ICCs were done with 1:200 dilution of polyclonal anti-VAPC1 antibody. VPAC2 and PAC1 indicates a better signal with 1:1000 
dilution than 1:2000 and 1:3000 (fig.16E-L), 1:1000 dilution was performed in all other ICC experiments. 
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Immunocytochemistry of 14 tumour cell lines and one endothelial cell line: 
Fig.17 shows ICC of LNCaP cells. Unspecific signal is viewed in the negative control, also VPAC1 staining is unspecific diffuse because 
only nuclei are visualised. VPAC2 staining indicated a positive brown signal in the cytoplasm. Some nuclei are stained dark brown, which 
might be a real signal of receptor in the nucleus or a staining/fixing artefact. PAC1 staining shows a weak punctual brown staining in the 
cytoplasm; also some nuclei are stained dark brown. 
 
 
Figure 17. ICC staining of prostate carcinoma LNCaP cells. A) Negative control without prim. ab, B) VPAC1 staining, C) VPAC2 staining and D) PAC1 staining with 
DAB as a substrate. Cell nuclei are counter stained with diluted Mayer´s Hematoxylin. VPAC1 staining reveals an unspecific diffuse signal. VPAC2 and PAC1 show a 
brown staining which indicates a specific receptor expression. 
 
Fig.18 indicates an ICC staining of PC-3 cells with DAB as a substrate. Negative control gives a diffuse weak signal, all three receptor 
types, VPAC1, VPAC2 and PAC1, show a brown signal in the cytoplasm. Also nuclei are stained stronger than cytoplasm.  
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Figure 18. ICC staining of prostate carcinoma PC-3 cells. A) Negative control without prim. ab, B) VPAC1 staining, C) VPAC2 staining and D) PAC1 staining with 
DAB as a substrate. Nuclei are stained light blue with Mayer´s Hematoxylin. VPAC1, VPAC2 and PAC1 show a brown staining which indicates a specific receptor 
expression. 
 
Fig.19 shows ICC staining of Capan-1 cells. The negative control and VPAC1 receptor displays no specific signal. VPAC2 shows a 
heterogeneous pattern of DAB staining in the cytoplasm. Some cells are stained strong and other neighbouring cells very weak. Anti-
VPAC2 also penetrates the nucleus and gives a signal. PAC1 receptor is weaker stained than VPAC2 but also indicates a positive signal in 
the cytoplasm. 
 
 
Figure 19. ICC staining of pancreas carcinoma Capan-1 cells. A) Negative control without prim. ab, B) VPAC1 staining, C) VPAC2 staining and D) PAC1 staining 
with DAB as a substrate. Nuclei are stained light blue with Mayer´s Hematoxylin. No specific VPAC1 signal is visualised. VPAC2 staining shows a heterogeneous 
distribution of receptor in the same population. Specific staining is also revealed when staining PAC1receptor. 
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Fig.20 shows two ICC staining of PANC-1 cells in different passages. A-D) demonstrates PANC-1 cells in passage 6 (P6). Negative 
control gives a very weak diffuse signal whereas VPAC1 receptor indicates a strong brown signal in the cytoplasm. Note that some cells 
show a clear blue staining of nuclei with Mayer´s Hematoxylin and other a dark brown staining of DAB. This data might indicate that the 
brown staining of the nucleus is a fixing or staining artefact. VPAC2 and PAC1 receptors show a punctual and specific distribution in the 
cytoplasm and reveals a blue nuclei signal. E-H) visualises PANC-1 cells in passage 20 (P20). Negative control and VPAC1 staining 
indicates no signal of DAB substrate. VPAC2 and PAC1 receptors show a weak staining but compared to PANC-1/P6 cells display a much 
weaker expression of VPAC2 and PAC1 receptors and no expression of VPAC1 receptor.  
 
 
Figure 20. ICC staining of pancreas carcinoma PANC-1 cells. Nuclei are stained light blue with Mayer´s Hematoxylin. A-D) PANC-1 cells in passage 6 (low passage 
number). E-H) PANC-1 cells in passage 20 (high passage number). A, E) Negative control without prim. Ab; B, F) VPAC1 staining; C, G) VPAC2 staining and H, D) 
PAC1 staining with DAB as a substrate. Low passage (P6) shows specific brown staining of VPAC1, VPAC2 and PAC1 receptor. Whereas high passage (P20) reveals only 
specific signals of VPAC2 and PAC1 staining. VPAC1 receptor expression might be downregulated. Note the different VPAC expression pattern in different passages of 
cell culture. 
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Fig.21 shows the ICC staining of lung carcinoma A427 cells. VPAC1 demonstrates a very weak signal but a punctual localisation in the 
cytoplasm which indicates an expression of VPAC1 receptor. A strong brown staining of VPAC2 and PAC1 receptors staining is shown in 
the cytoplasm compared to the negative control. Note the brown staining of nuclei in case of VPAC2 and PAC1. Fig.22 shows ICC 
stainings of Hep3B liver carcinoma. Also specific signals of VPAC1, VPAC2 and PAC1 receptors can be seen in this staining. 
 
Figure 21. ICC staining of lung carcinoma A427 cells. A) Negative control without prim. ab, B) VPAC1 staining, C) VPAC2 staining and D) PAC1 staining with DAB 
as a substrate. Nuclei are stained light blue with Mayer´s Hematoxylin. All three receptor staining showed a specific signal, which indicates a VPAC receptor expression. 
 
 
Figure 22. ICC staining of liver carcinoma Hep3B cells. A) Negative control without prim. ab, B) VPAC1 staining, C) VPAC2 staining and D) PAC1 staining with 
DAB as a substrate. Nuclei are stained light blue with Mayer´s Hematoxylin. VPAC1, VPAC2 and PAC1 reveal a specific signal which demonstrates a VPAC receptor 
expression. 
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Fig.23 demonstrates an ICC staining of SW1736 cells. VPAC1 receptors don´t show a signal like the negative control. VPAC2 and PAC1 
display a very heterogeneous expression signal in adjacent areas. SW1736 have a large nucleus which is mostly stained brown, it´s difficult 
to determine between nuclei and cytoplasm. Cells which are stained weak show a light blue nuclei, those who are stained strong have also a 
dark brown nucleus staining.  
 
Figure 23. ICC staining of thyroid carcinoma SW1736 cells. A) Negative control without prim. ab, B) VPAC1 staining, C) VPAC2 staining and D) PAC1 staining with 
DAB as a substrate. Nuclei are stained light blue with Mayer´s Hematoxylin.VPAC1 does not show a specific signal which indicates no receptor expression. VPAC2 and 
PAC1 indicate a heterogeneous receptor expression in the cytoplasm within the same population. 
 
Fig.24 exhibit ICC staining of glioblastoma MGC cells. VPAC1 receptor has a very weak punctual staining in the cytoplasm compared to 
negative control. VPAC2 shows a strong brown staining in the nucleus and a brighter signal in the cytoplasm whereas brown nuclei can be 
seen. Also PAC1 indicates a certain localisation in the cytoplasm furthermore blue staining of nuclei. 
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Figure 24. ICC staining of glioblastoma MGC cells. A) Negative control without prim. ab, B) VPAC1 staining, C) VPAC2 staining and D) PAC1 staining with DAB as 
a substrate. Nuclei are stained light blue with Mayer´s Hematoxylin. VPAC1and PAC1 reveal a very weak staining, while VPAC2 is clearly labelled. All three receptor 
types are expressed in glioblastoma cells at different rates. 
 
Immunocytochemistry staining of HCT-15 cells (fig.25) show a weak diffuse signal in the case of negative control. VPAC1 demonstrates a 
positive signal, punctual distributed in the cytoplasm and a stronger signal in the nuclei. A non-specific signal in the cytoplasm is shown 
when staining VPAC2 and PAC1 receptor.  
 
Figure 25. ICC staining of colon carcinoma HCT-15 cells. A) Negative control without prim. ab, B) VPAC1 staining, C) VPAC2 staining and D) PAC1 staining with 
DAB as a substrate. Nuclei are stained light blue with Mayer´s Hematoxylin. Note the specific signal of VPAC1, which indicates receptor expression. Whereas VPAC2 
and PAC1 reveal unspecific signals, these indicates no expression of VPAC2 and PAC1 receptor.  
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Fig.26 shows ICC staining of HT-29 cells. The negative control shows a weak signal but VPAC1 indicates a stronger staining in the 
cytoplasm and of the nuclei. VPAC2 and PAC1 have a heterogeneous signal distribution at adjacent regions. A weak staining of cytoplasm 
is coupled with a weak staining in the nuclei. Stronger staining occurs in both cytoplasm and nuclei.  
 
 
Figure 26. ICC staining of colon carcinoma HT-29 cells. A) Negative control without prim. ab, B) VPAC1 staining, C) VPAC2 staining and D) PAC1 staining with 
DAB as a substrate. Nuclei are stained light blue with Mayer´s Hematoxylin. Note the specific signal of VPAC1 and VPAC2 and the heterogeneous distribution of PAC1 
receptor in the same cell culture population. 
 
Fig.27 shows ICC staining of CaCo-2 cells. VPAC1 and PAC1 receptors are stained in the cytoplasm as well in the nuclei, whereas VPAC2 
indicates no signal in the cytoplasm like the control, nuclei are stained blue. 
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Figure 27. ICC staining of colon carcinoma CaCo-2 cells. A) Negative control without prim. ab, B) VPAC1 staining, C) VPAC2 staining and D) PAC1 staining with 
DAB as a substrate. Nuclei are stained light blue with Mayer´s Hematoxylin. VPAC1 and PAC1 receptor show a specific staining which indicate an expression of these 
receptors. No specific signal is visible in the case of VPAC2 which demonstrates no VPAC2 receptor expression. 
 
Fig.28 and fig.29 display ICC stainings of colon carcinoma HCT-116 cells and breast carcinoma MCF-7 cells. Both cell lines express the 
same receptor signal. VPAC1 is punctual and stronger stained than the negative control. Some nuclei show a brown signal, others a blue 
signal. VPAC2 and PAC1 have a strong brown staining of DAB substrate with dark brown stained nuclei. The receptor signals are 
distributed among the whole cytoplasm. 
 
Figure 28. ICC staining of colon carcinoma HCT-116 cells. A) Negative control without prim. ab, B) VPAC1 staining, C) VPAC2 staining and D) PAC1 staining with 
DAB as a substrate. Nuclei are stained light blue with Mayer´s Hematoxylin. All three types of VPAC receptors reveal a specific signal. VPAC1 is weaker expressed than 
VPAC2 and PAC1.  
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Figure 29. ICC staining of breast carcinoma MCF-7 cells. A) Negative control without prim. ab, B) VPAC1 staining, C) VPAC2 staining and D) PAC1 staining with 
DAB as a substrate. Nuclei are stained light blue with Mayer´s Hematoxylin. All three types of VPAC receptors reveal a specific signal. VPAC1 is weaker expressed than 
VPAC2 and PAC1. 
 
The microvascular endothelial cells HMEC-1 (fig.30) show an unspecific signal of VPAC1 receptor. A very determined distribution of 
VPAC2 receptor with a strong brown signal in the cytoplasm and also in the nuclei is visible. Interestingly PAC1 receptor reveals a non-
specific staining like the negative control. The brown dots at the apical or lateral side of the cells might be a specific signal of PAC1 at the 
membrane or a staining artefact. 
 
Figure 30. ICC of microvascular endothelial cells HMEC-1. A) Negative control without prim. ab, B) VPAC1 staining, C) VPAC2 staining and D) PAC1 staining with 
DAB as a substrate. Nuclei are stained light blue with Mayer´s Hematoxylin. No specific signal of VPAC1 can be seen, which indicates no expression of VPAC1. Note the 
distribution of VPAC2 and. PAC1 signal at the membranes. This might indicate a receptor accumulation at the membranes or it simply might be an artefact. 
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Summary of VPAC receptors (VPAC1, VPAC2 and PAC1) expression pattern with ICC (table 15): 
 
Table 15. VPAC receptor expression pattern of human cell lines. + expression, -no expression of receptor subtype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Organ Tumour cell line VPAC1 VPAC2 PAC1 
Human prostata carcinoma LNCaP - + + 
Human prostata carcinoma PC-3 + + + 
Human pancreas adenocarcinoma Capan-1 - + + 
Human pancreas duct epithelioid carcinoma PANC-1 P6 + + + 
Human pancreas duct epithelioid carcinoma PANC-1 P20 - + + 
Lung carcinoma A427 + + + 
Human liver hepatocellular carcinoma Hep3B + + + 
Human thyriod adenocarcinoma SW1736 - + + 
Human glioblastoma MGC - + + 
Human colorectal carcinoma HCT-15 + - - 
Human colorectal carcinoma HT-29 + + + 
Human colorectal carcinoma CaCo-2 + - + 
Human colorectal carcinoma HCT-116 - + + 
Human mammary gland, 
breast epithelial adenocarcinoma 
MCF-7 + + + 
Human microvascular endothelial cell HMEC-1 
 
- + - 
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4.2  Proliferation assays (MTT) 
Proliferation studies of all 15 cell lines were performed to test toxicity or proliferative 
properties of VIP-conjugates. Two experiments with 8 to 12 values of each peptide 
analogue were averaged and standard deviation was calculated.  
 
Prostate Carcinoma LNCaP data: 
Table 16. MTT assay of LNCaP cell line. 
 
peptide analogues 
1 2 
average 
n=8 
std. deviation 
n=2 
average  
n=4 
average 
n=4 
VIP 10µM 103,13 110,21 106,67 5,01 
VIP 10nM 93,65 103,43 98,54 6,92 
VIP 10pM 108,44 95,89 102,17 8,87 
(Ala
11,22,28
)-VIP 10µM 101,36 108,49 104,93 5,04 
(Ala
11,22,28
)-VIP 10nM 97,46 105,38 101,42 5,60 
(Ala
11,22,28
)-VIP 10pM 101,63 90,83 96,23 7,64 
VIP-DOTA 10µM 99,67 96,36 98,02 2,34 
VIP-DOTA 10nM 103,26 99,94 101,60 2,35 
VIP-DOTA 10pM 101,12 105,81 103,47 3,32 
VIP-DOTA-Gd 10µM 117,17 109,95 113,56 5,11 
VIP-DOTA-Gd 10nM 118,28 110,06 114,17 5,81 
VIP-DOTA-Gd 10pM 109,69 115,36 112,53 4,01 
PACAP 10µM 91,94 102,50 97,22 7,47 
PACAP 10nM 92,72 100,23 96,48 5,31 
PACAP 10pM 94,02 100,44 97,23 4,54 
RPMI 1640 3,55 4,09 3,82 0,38 
 
The MTT assays of LNCaP cells show a dose-effect of peptide conjugates. The peptide 
concentrations don´t indicate a significant difference of proliferation or toxicity of cells 
because the cell growth is rested at about 100%. No increase or decrease of cell number 
is observed after treatment with peptides. RPMI 1640 is used as a control of absorption 
of the medium (fig.31, table 16). 
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Figure 31. MTT assay of LNCaP cells. No significant proliferation or toxicity of LNCaP cells 
treated with VIP conjugates can be seen. 
 
Prostate carcinoma PC-3 cells data: 
Table 17. MTT assay of PC-3 cells. 
 
peptide analogues 
1 2 
average 
n=8 
std. deviation 
n=2 
average  
n=4 
average 
n=4 
VIP 10µM 116,44 137,08 126,76 14,59 
VIP 10nM 117,97 131,25 124,61 9,39 
VIP 10pM 111,33 129,44 120,39 12,81 
(Ala
11,22,28
)-VIP 10µM 115,02 132,41 123,72 12,30 
(Ala
11,22,28
)-VIP 10nM 121,26 128,57 124,92 5,17 
(Ala
11,22,28
)-VIP 10pM 122,63 114,74 118,69 5,58 
VIP-DOTA 10µM 117,57 133,04 125,31 10,94 
VIP-DOTA 10nM 110,46 139,33 124,90 20,41 
VIP-DOTA 10pM 109,00 142,19 125,60 23,47 
VIP-DOTA-Gd 10µM 94,33 123,17 108,75 20,39 
VIP-DOTA-Gd 10nM 95,54 108,01 101,78 8,82 
VIP-DOTA-Gd 10pM 98,61 113,46 106,04 10,50 
PACAP 10µM 111,37 128,46 119,92 12,08 
PACAP 10nM 112,94 134,43 123,69 15,20 
PACAP 10pM 108,35 142,07 125,21 23,84 
RPMI 1640 4,66 6,11 5,39 1,03 
 
The MTT assays of PC-3 cells reveal an increased cell number of about 20% after 
incubation with investigated peptides, except VIP-DOTA-Gd. VIP-DOTA-Gd shows no 
proliferation at different concentrations (fig.32, table 17). 
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Figure 32. MTT assay of PC-3 cells. All conjugates except VIP-DOTA-Gd show a significant 
increase of cell number of about 20% cell, indicating increased cell growth by all conjugates except 
VIP-DOTA-Gd. None of the conjugates reveal any toxicity.  
 
Pancreas carcinoma Capan-1 cells data: 
Table 18. MTT assay of Capan-1 cells. 
 
peptide analogues 
1 2 
average 
n=8 
std. deviation 
n=2 average n=4 
average 
n=4 
VIP 10µM 103,51 98,61 101,06 3,465 
VIP 10nM 105,86 94,42 100,14 8,089 
VIP 10pM 107,90 97,48 102,69 7,368 
(Ala
11,22,28
)-VIP 10µM 108,59 102,88 105,74 4,038 
(Ala
11,22,28
)-VIP 10nM 99,55 99,74 99,65 0,134 
(Ala
11,22,28
)-VIP 10pM 106,60 96,19 101,40 7,361 
VIP-DOTA 10µM 101,75 102,85 102,30 0,778 
VIP-DOTA 10nM 108,34 104,92 106,63 2,418 
VIP-DOTA 10pM 107,42 103,94 105,68 2,461 
VIP-DOTA-Gd 10µM 97,79 105,04 101,42 5,127 
VIP-DOTA-Gd 10nM 102,36 112,72 107,54 7,326 
VIP-DOTA-Gd 10pM 90,48 103,54 97,01 9,235 
PACAP 10µM 103,15 99,75 101,45 2,404 
PACAP 10nM 106,19 104,65 105,42 1,089 
PACAP 10pM 104,95 98,95 101,95 4,243 
RPMI 1640 3,52 4,11 3,82 0,417 
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The diagram of Capan-1 cell shows MTT assays, indicating no proliferative or toxicity 
properties of peptides. All peptide conjugates reveal no significant increase in cell 
number cell, the cell growth is rested at about 100% (fig.33, tab.18). 
 
Figure 33. MTT assay of Capan-1 cells. None of the VIP conjugates demonstrate a proliferative or 
toxic effect. 
 
Pancreas carcinoma PANC-1/P8 cells data: 
Table 19. MTT assay of PANC-1 cells passage 8. 
 
peptide analogues 
1 2 
average 
n=8 
std. deviation 
n=2 
average  
n=4 
average 
n=4 
VIP 10µM 125,11 130,78 127,95 4,01 
VIP 10nM 129,40 152,78 141,09 16,53 
VIP 10pM 131,77 138,95 135,36 5,08 
(Ala
11,22,28
)-VIP 10µM 132,59 114,26 123,43 12,96 
(Ala
11,22,28
)-VIP 10nM 130,54 128,14 129,34 1,70 
(Ala
11,22,28
)-VIP 10pM 130,61 114,43 122,52 11,44 
VIP-DOTA 10µM 131,35 149,09 140,22 12,54 
VIP-DOTA 10nM 125,60 168,56 147,08 30,38 
VIP-DOTA 10pM 120,08 154,05 137,07 24,02 
VIP-DOTA-Gd 10µM 135,22 133,07 134,15 1,52 
VIP-DOTA-Gd 10nM 125,11 170,77 147,94 32,29 
VIP-DOTA-Gd 10pM 126,57 139,44 133,01 9,10 
PACAP 10µM 133,30 128,21 130,76 3,60 
PACAP 10nM 132,46 139,54 136,00 5,01 
PACAP 10pM 127,33 121,67 124,50 4,00 
RPMI 1640 5,73 5,06 5,40 0,47 
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PANC-1/P8 cells exhibit an increased cell number after incubation with peptide 
conjugates at about 20-40%. VIP, (Ala
11,22,28
)-VIP and PACAP show the same 
proliferation properties like the conjugates VIP-DOTA and VIP-DOTA-Gd (fig34, 
tab.19).  
 
Figure 34. MTT assay of PANC-1 cells, passage 8. At passage 8 PANC-1 cells show a significant 
increased number of cells of about 40%, indicating a proliferation with all peptide conjugates. None 
of the conjugates are toxic.  
 
Lung carcinoma A427 cells data: 
Table 20. MTT assay of A427 cells. 
 
peptide analogues 
1 2 
average 
n=8 
std. deviation 
n=2 
average  
n=4 
average 
n=4 
VIP 10µM 67,20 74,70 70,95 5,30 
VIP 10nM 132,87 119,32 126,10 9,58 
VIP 10pM 128,03 120,22 124,13 5,52 
(Ala
11,22,28
)-VIP 10µM 131,67 115,91 123,79 11,14 
(Ala
11,22,28
)-VIP 10nM 133,50 112,18 122,84 15,08 
(Ala
11,22,28
)-VIP 10pM 123,18 107,43 115,31 11,14 
VIP-DOTA 10µM 134,83 125,43 130,13 6,65 
VIP-DOTA 10nM 130,69 120,41 125,55 7,27 
VIP-DOTA 10pM 128,94 117,07 123,01 8,39 
VIP-DOTA-Gd 10µM 111,59 114,82 113,21 2,28 
VIP-DOTA-Gd 10nM 125,66 124,70 125,18 0,68 
VIP-DOTA-Gd 10pM 121,07 118,53 119,80 1,80 
PACAP 10µM 141,63 130,18 135,91 8,10 
PACAP 10nM 122,41 101,96 112,19 14,46 
PACAP 10pM 123,25 101,96 112,61 15,05 
RPMI 1640 27,46 25,72 26,59 1,23 
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MTT assays of A427 cells indicated an increased cell number increase after treatment 
with peptides at about 20%. The incubation with 10µM VIP displays a cell viability of 
about 70%. (fig.35, tab.20). Also the negative control has a higher absorption than in the 
others MTT assays, because A427 cell metabolise formazan derivate more slowly and 
the other cell lines. A427 cells need more time to develop red dye product. After 3h 
incubation of the dye, the absorption rate is not as high as in quick metabolising cells. 
 
Figure 35. MTT assay of A427 cells. Note the significant lower cell number after incubation with 
10µM VIP indicating either a proliferation inhibition or a toxic effect of this concentration on this cell 
line. The incubation with all other VIP conjugates result in an increase of viable cells of about 20%.  
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Liver carcinoma Hep3B cells data: 
Table 21. MTT assay of Hep3B cells. 
 
peptide analogues 
1 2 
average 
n=8 
std. deviation 
n=2 
average 
 n=4 
average 
n=4 
VIP 10µM 105,78 106,60 106,19 0,58 
VIP 10nM 101,54 108,18 104,86 4,70 
VIP 10pM 108,00 110,46 109,23 1,74 
(Ala
11,22,28
)-VIP 10µM 104,93 113,05 108,99 5,74 
(Ala
11,22,28
)-VIP 10nM 102,42 110,62 106,52 5,80 
(Ala
11,22,28
)-VIP 10pM 98,09 97,34 97,72 0,53 
VIP-DOTA 10µM 96,60 106,40 101,50 6,93 
VIP-DOTA 10nM 100,82 102,80 101,81 1,40 
VIP-DOTA 10pM 101,29 95,99 98,64 3,75 
VIP-DOTA-Gd 10µM 98,21 97,11 97,66 0,78 
VIP-DOTA-Gd 10nM 99,49 97,41 98,45 1,47 
VIP-DOTA-Gd 10pM 93,20 96,03 94,62 2,00 
PACAP 10µM 93,50 109,68 101,59 11,44 
PACAP 10nM 100,43 104,37 102,40 2,79 
PACAP 10pM 96,12 96,24 96,18 0,08 
RPMI 1640 3,97 4,52 4,25 0,39 
 
The MTT assays of Hep3B cells indicate no proliferative or toxicity effect of cells after 
incubation with peptide conjugates. No significant increase in cell number after 
treatment with peptides is seen at about 100% (fig.36, tab.21). 
 
Figure 36. MTT assay of Hep3B cells. No proliferation or toxicity can be seen when cells incubated 
with VIP conjugates. 
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Thyroid carcinoma SW1736 cells data: 
Table 22. MTT assay of SW1736 cells. 
 
peptide analogues 
1 2 3 
average 
n=12 
std. deviation 
n=3 
average 
n=4 
average 
n=4 
average 
n=4 
VIP 10µM 99,81 99,44 106,43 101,89 3,93 
VIP 10nM 92,23 90,30 97,49 93,34 3,72 
VIP 10pM 91,54 89,21 111,40 97,38 12,19 
(Ala
11,22,28
)-VIP 10µM 99,76 96,62 106,21 100,86 4,89 
(Ala
11,22,28
)-VIP 10nM 92,88 97,29 100,06 96,74 3,62 
(Ala
11,22,28
)-VIP 10pM 94,56 95,48 105,16 98,40 5,87 
VIP-DOTA 10µM 92,25 97,01 106,31 98,52 7,15 
VIP-DOTA 10nM 88,73 94,67 106,86 96,75 9,24 
VIP-DOTA 10pM 86,68 95,65 110,11 97,48 11,82 
VIP-DOTA-Gd 10µM 97,45 101,97 88,22 95,88 7,01 
VIP-DOTA-Gd 10nM 94,43 88,08 110,15 97,55 11,36 
VIP-DOTA-Gd 10pM 91,26 92,47 118,19 100,64 15,21 
PACAP 10µM 97,45 103,06 101,17 100,56 2,85 
PACAP 10nM 89,01 95,53 102,53 95,69 6,76 
PACAP 10pM 84,71 99,43 101,48 95,21 9,15 
RPMI 1640 5,90 5,37 4,99 5,42 0,46 
 
The MTT assays of SW1736 cells reveal no significant proliferative or toxicity of cells 
after treatment with peptide conjugates (fig.37, tab.22). The cell viability results in 
about 100%. 
 
Figure 37. MTT assay of SW1736 cells. No significant proliferation or toxicity can be visualised 
after treatment with VIP conjugates.  
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Glioblastoma MGC cells data: 
Table 23. MTT assay of glioblastoma MGC cells. 
 
peptide analogues 
1 2 
average 
n=8 
std. deviation 
n=2 
average 
n=4 
average 
n=4 
VIP 10µM 120,54 137,34 128,94 11,88 
VIP 10nM 124,47 115,38 119,93 6,43 
VIP 10pM 111,71 99,02 105,37 8,97 
(Ala
11,22,28
)-VIP 10µM 114,22 97,54 105,88 11,79 
(Ala
11,22,28
)-VIP 10nM 116,02 97,24 106,63 13,28 
(Ala
11,22,28
)-VIP 10pM 103,18 94,71 98,95 5,99 
VIP-DOTA 10µM 106,30 99,12 102,71 5,08 
VIP-DOTA 10nM 111,18 97,39 104,29 9,75 
VIP-DOTA 10pM 85,27 101,32 93,30 11,35 
VIP-DOTA-Gd 10µM 96,73 92,24 94,49 3,17 
VIP-DOTA-Gd 10nM 130,02 96,65 113,34 23,60 
VIP-DOTA-Gd 10pM 105,01 104,58 104,80 0,30 
PACAP 10µM 100,26 98,91 99,59 0,95 
PACAP 10nM 99,96 105,71 102,84 4,07 
PACAP 10pM 101,42 100,24 100,83 0,83 
RPMI 1640 5,98 5,43 5,71 0,39 
 
The MTT assays of MGC cells show a dose-effect of VIP. (Ala
11,22,28
)-VIP and VIP-
conjugates like DOTA and DOTA-Gd do not reveal a significant proliferative or 
toxicity of the cells (fig.38, tab.23).  
 
Figure 38. MTT assay of MGC cells. Note the dose-effect of VIP, high concentration of VIP 
indicates an cell increase to 130%. All conjugates did not show a proliferation or toxicity of treated 
cells. 
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Colon carcinoma HCT-15 cells data: 
Table 24. MTT assay of HCT-15 cells. 
 
peptide analogues 
1 2 
average 
n=8 
std. deviation 
n=2 
average 
n=4 
average 
n=4 
VIP 10µM 96,29 95,00 95,65 0,91 
VIP 10nM 101,13 99,89 100,51 0,88 
VIP 10pM 103,18 101,59 102,39 1,12 
(Ala
11,22,28
)-VIP 10µM 102,42 95,20 98,81 5,11 
(Ala
11,22,28
)-VIP 10nM 108,01 102,52 105,27 3,88 
(Ala
11,22,28
)-VIP 10pM 101,46 97,08 99,27 3,10 
VIP-DOTA 10µM 103,55 96,75 100,15 4,81 
VIP-DOTA 10nM 94,04 97,94 95,99 2,76 
VIP-DOTA 10pM 102,39 94,45 98,42 5,61 
VIP-DOTA-Gd 10µM 101,20 93,90 97,55 5,16 
VIP-DOTA-Gd 10nM 101,38 95,92 98,65 3,86 
VIP-DOTA-Gd 10pM 104,05 92,94 98,50 7,86 
PACAP 10µM 108,09 101,41 104,75 4,72 
PACAP 10nM 98,15 103,40 100,78 3,71 
PACAP 10pM 95,56 104,90 100,23 6,60 
RPMI 1640 4,14 3,21 3,68 0,66 
 
The MTT assays of HCT-15 cells indicate no proliferative or a toxicity property of the 
peptide conjugates. The cell growth after treatment with peptides is about 100% (fig.39, 
tab.24). 
 
Figure 39. MTT assay of HCT-15. The assay indicates no proliferative or toxic properties of the VIP 
conjugates. 
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Colon carcinoma HT-29 cells data: 
Table 25. MTT assay of HT-29 cells. 
 
peptide analogues 
1 2 
average 
n=8 
std. deviation 
n=2 
average 
n=4 
average 
n=4 
VIP 10µM 113,30 108,65 110,98 3,29 
VIP 10nM 108,00 111,25 109,63 2,30 
VIP 10pM 115,03 106,83 110,93 5,80 
(Ala
11,22,28
)-VIP 10µM 97,12 108,06 102,59 7,74 
(Ala
11,22,28
)-VIP 10nM 96,30 107,22 101,76 7,72 
(Ala
11,22,28
)-VIP 10pM 86,74 99,44 93,09 8,98 
VIP-DOTA 10µM 93,90 104,89 99,40 7,77 
VIP-DOTA 10nM 95,92 106,21 101,07 7,28 
VIP-DOTA 10pM 92,94 110,55 101,75 12,45 
VIP-DOTA-Gd 10µM 94,23 110,15 102,19 11,26 
VIP-DOTA-Gd 10nM 100,61 109,49 105,05 6,28 
VIP-DOTA-Gd 10pM 99,02 100,03 99,53 0,71 
PACAP 10µM 95,25 96,20 95,73 0,67 
PACAP 10nM 96,46 95,81 96,14 0,46 
PACAP 10pM 92,70 100,79 96,75 5,72 
RPMI 1640 5,95 3,35 4,65 1,84 
 
HT-29 cells show a cell number increase of about 10% after incubation with VIP. The 
other conjugates like DOTA, DOTA-Gd and VPAC1-specific analogue do not reveal a 
significant increase of cell number (fig.40, tab.25).  
 
Figure 40. MTT assay with HT-29 cells. Incubation with VIP resulted in a slight proliferation. All 
other VIP conjugates do not significantly increase the viably cells. None of the substances display 
cytotoxicity. 
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Colon carcinoma CaCo-2 cells data: 
Table 26. MTT assay of CaCo-2 cells. 
 
peptide analogues 
1 2 3 
average 
n=12 
std. deviation 
n=3 
average 
n=4 
average 
n=4 
average 
n=4 
VIP 10µM 88,60 100,27 101,66 96,84 7,17 
VIP 10nM 87,89 100,88 98,70 95,82 6,96 
VIP 10pM 92,43 102,19 96,67 97,10 4,89 
(Ala
11,22,28
)-VIP 10µM 92,12 90,72 99,65 94,16 4,80 
(Ala
11,22,28
)-VIP 10nM 96,62 93,18 91,87 93,89 2,45 
(Ala
11,22,28
)-VIP 10pM 93,59 92,50 89,92 92,00 1,88 
VIP-DOTA 10µM 84,45 83,13 97,31 88,30 7,83 
VIP-DOTA 10nM 86,14 102,92 94,54 94,53 8,39 
VIP-DOTA 10pM 86,14 96,88 101,36 94,79 7,82 
VIP-DOTA-Gd 10µM 82,01 94,37 93,87 90,08 7,00 
VIP-DOTA-Gd 10nM 85,90 101,59 95,02 94,17 7,88 
VIP-DOTA-Gd 10pM 89,19 84,93 104,79 92,97 10,46 
PACAP 10µM 106,01 104,51 107,14 105,89 1,32 
PACAP 10nM 104,53 96,90 101,22 100,88 3,83 
PACAP 10pM 106,06 102,11 102,49 103,55 2,18 
RPMI 1640 0,78 6,48 4,05 3,77 2,86 
 
CaCo-2 cells exhibit a slightly reduction of cell number after incubation with peptide 
conjugates at about 95%. But no significant toxicity of VIP-conjugates is detected 
(fig.41, tab.26). 
 
Figure 41. MTT assay with CaCo-2 cells. Incubation with VIP conjugates show a slightly reduction 
of viable cells, no significant toxicity of the substances is detected. 
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Colon carcinoma HCT-116 cells data: 
Table 27. MTT assay of HCT-116 cells. 
 
peptide analogues 
1 2 
average 
n=8 
std. deviation 
n=2 
average 
n=4 
average 
n=4 
VIP 10µM 93,09 96,40 94,75 2,341 
VIP 10nM 98,41 99,58 99,00 0,827 
VIP 10pM 96,63 93,49 95,06 2,220 
(Ala
11,22,28
)-VIP 10µM 91,22 93,43 92,33 1,563 
(Ala
11,22,28
)-VIP 10nM 77,10 82,03 79,57 3,486 
(Ala
11,22,28
)-VIP 10pM 96,70 94,29 95,50 1,704 
VIP-DOTA 10µM 100,54 96,36 98,45 2,956 
VIP-DOTA 10nM 101,46 100,32 100,89 0,806 
VIP-DOTA 10pM 106,59 103,46 105,03 2,213 
VIP-DOTA-Gd 10µM 100,99 98,08 99,54 2,058 
VIP-DOTA-Gd 10nM 106,03 99,11 102,57 4,893 
VIP-DOTA-Gd 10pM 100,73 98,45 99,59 1,612 
PACAP 10µM 101,50 95,01 98,26 4,589 
PACAP 10nM 102,25 93,19 97,72 6,406 
PACAP 10pM 105,75 102,10 103,93 2,581 
RPMI 1640 3,99 3,80 3,90 0,134 
 
The MTT assays of HCT-116 cells reveal a cytotoxicity of about 20% after incubation 
with 10nM VPAC1-specific agonist. All other concentrations do not show a significant 
reduction in cell number (fig.42, tab.27). 
 
Figure 42. MTT assay HCT-116 cells. VIP conjugates do not show significant proliferation or 
toxicity. Note the reduction of viable cells when treating cells with 10nM (Ala11,22,28)-VIP. 
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Breast carcinomaMCF-7 cells data: 
Table 28. MTT assay of MCF-7 cells. 
 
peptide analogues 
1 2 
average 
n=8 
std. deviation 
n=2 
average 
n=4 
average 
n=4 
VIP 10µM 96,29 105,53 100,91 6,53 
VIP 10nM 101,19 94,32 97,76 4,86 
VIP 10pM 104,74 92,85 98,80 8,41 
(Ala
11,22,28
)-VIP 10µM 98,21 104,74 101,48 4,62 
(Ala
11,22,28
)-VIP 10nM 103,32 99,78 101,55 2,50 
(Ala
11,22,28
)-VIP 10pM 102,68 97,00 99,84 4,02 
VIP-DOTA 10µM 98,28 97,20 97,74 0,76 
VIP-DOTA 10nM 100,11 99,36 99,74 0,53 
VIP-DOTA 10pM 97,36 99,36 98,36 1,41 
VIP-DOTA-Gd 10µM 103,18 104,77 103,98 1,12 
VIP-DOTA-Gd 10nM 104,58 106,01 105,30 1,01 
VIP-DOTA-Gd 10pM 104,35 104,29 104,32 0,04 
PACAP 10µM 103,22 102,47 102,85 0,53 
PACAP 10nM 102,20 98,21 100,21 2,82 
PACAP 10pM 81,10 101,69 91,40 14,56 
RPMI 1640 4,04 3,38 3,71 0,47 
 
The MTT assays with MCF-7 cells indicate no increase in cell number after incubation 
with peptide conjugates. No significant increase in cell number is observed (fig.43, 
tab.28). 
 
Figure 43. MTT assay of MCF-7 cells. No proliferation or toxicity of peptide conjugates is 
visualised after treatment of cells. 
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Microvascular endothelial cells Hmec-1 cells data: 
Table 29. MTT assay of HMEC-1 cells. 
 
peptide analogues 
1 2 
average 
n=8 
std. deviation 
n=2 
average 
n=4 
average 
n=4 
VIP 10µM 97,19 111,71 104,45 10,27 
VIP 10nM 131,90 127,33 129,62 3,23 
VIP 10pM 133,34 142,79 138,07 6,68 
(Ala
11,22,28
)-VIP 10µM 117,16 106,97 112,07 7,21 
(Ala
11,22,28
)-VIP 10nM 134,48 134,10 134,29 0,27 
(Ala
11,22,28
)-VIP 10pM 130,00 135,06 132,53 3,58 
VIP-DOTA 10µM 119,56 124,63 122,10 3,59 
VIP-DOTA 10nM 118,42 113,96 116,19 3,15 
VIP-DOTA 10pM 130,18 141,50 135,84 8,00 
VIP-DOTA-Gd 10µM 119,80 136,59 128,20 11,87 
VIP-DOTA-Gd 10nM 120,03 131,73 125,88 8,27 
VIP-DOTA-Gd 10pM 127,88 139,07 133,48 7,91 
PACAP 10µM 104,19 108,83 106,51 3,28 
PACAP 10nM 109,26 81,77 95,52 19,44 
PACAP 10pM 109,86 94,97 102,42 10,53 
RPMI 1640 5,51 7,61 6,56 1,48 
 
The MTT assays of HMEC-1 cells display a dose-effect after incubation with peptide 
conjugates. Increasing concentration of peptides increased cell number of about 40%. 
The VPAC1-specific agonist (Ala
11,22,28
)-VIP shows more proliferation of cells than 
PACAP (fig.44, tab.29).  
 
Figure 44. MTT assay of HMEC-1 cells. Note the increased cell number at about 40% of VIP 
conjugates. (Ala11,22,28)-VIP shows more cell growth stimulation than PACAP. 
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4.3 Indirect internalisation by functionality test 
The cAMP level of three representative cell lines HMEC-1, HT-29 and MCF-7 were 
measured with cAMP ELISA. The cells were incubated with VIP, (Ala
11,22,28
)
-
VIP 
receptor 1 specific agonist and VIP-DOTA-Gd. The cAMP level of cells without 
treatment was measured as a negative control. Fig.45 indicates the cAMP level of 
microvascular endothelial cells HMEC-1 cells (black), where the highest amount of 
cAMP is seen after incubation with VIP. Released cAMP after incubation with the 
VPAC1-specific agonist is lower than with VIP. VIP-DOTA-Gd is also internalised and 
released cAMP in the same amount like VIP. Treatment with IBMX reveals higher 
cAMP level than without IBMX, and lower cAMP level with SQ22,536.  
HT-29 cells show the highest cAMP level with VIP, lower with (Ala
11,22,28
)
-
VIP and the 
lowest with VIP-DOTA-Gd (light gray). Peptides additionally treated with IBMX reveal 
10 times higher cAMP level. The treatment with SQ22,536 causes two times less cAMP 
level than without. The peptide internalisation of Capan-1 cells (dark gray) and cAMP 
release behave like in HT-29 cells. But Capan-1 cells show low cAMP level after 
treatment with VIP conjugates, and high cAMP value when additionally treated with 
IBMX.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45. ELISA of VIP conjugates of three cell lines, colon carcinoma HT-29 (light gray) and 
pancreas carcinoma Capan-1 (dark gray) and endothelial cells HMEC-1 (black). The cAMP level 
was measured. Treated HMEC-1 cells show no increased cAMP indicating that this cell line may uses 
another signalling pathway like PLC and Ca
2+
. HT-29 cells treated with VIP display the highest cAMP 
increase compared to the other VIP-conjugates. This indicates an internalisation of (Ala
11,22,28
)-VIP and 
VIP-DOTA into the cell which triggers cAMP as second messenger. Capan-1 cells show a cAMP 
increase after treatment with conjugates and IBMX, indicating that Capan-1 cells may have an increased 
metabolism rate. 
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Pulmonary smooth muscle cells PASMC (fig.46) are observed for VIP internalisation 
via liposomes and proticles. An increase in cAMP level is measured with ELISA. A 
time depending release of cAMP is seen between liposomes and VIP. Note that 10min 
incubation with VIP indicates the highest cAMP level, and the incubation with 
liposomes L08I displays a delayed cAMP release up to 20min. After 60min no 
increased cAMP is measured. Proticles #G do not show a lagged release of cAMP level 
because cAMP is lower than cell treated with VIP.  
 
Figure 46. cAMP ELISA of pulmonary smooth muscle cells. PASMC treated with VIP, liposomes 
L08I and proticles #G in a time course assay 5-60min. VIP treatment displays the highest cAMP 
increase after 10min incubation. Liposomes 08I show a delayed release effect of cAMP at 20min time 
point. Proticles #G don´t reveal an increased cAMP at any time point. 
 
Pancreas duct carcinoma PANC-1 P4 cells are used to observe proticles #G 
internalisation behaviour on carcinoma cells. Fig.47 shows the cAMP level after 
incubation of VIP and proticles #G at different time points. VIP indicates a time 
depending increase of cAMP. Proticles #G clearly reveals a delayed release of cAMP 
compared to free VIP. The highest cAMP release after incubation with proticles #G is 
reached after 20min. After 30min VIP is not able to induce cAMP, whereas proticles #G 
do. After 45min and 60min no cAMP respond is observed, neither VIP nor proticles #G 
induce cAMP.  
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Figure 47. cAMP ELISA of pancreas duct carcinoma PANC-1 P4 treated with VIP and 
proticles #G in a time course assay (5-60min). VIP induces an increased cAMP release with 
increasing time. Proticles #G show a delayed increase of cAMP after 30min. After 45min neither VIP 
nor proticles #G indicate increased cAMP levels, indicating a degradation of cAMP.  
4.4  Visualisation by Fluorescence Correlation Spectroscopy  
Direct internalisation of VIP and conjugates were measured with Fluorescence 
correlation spectroscopy. The diffusion time of peptides in buffer is shown in table 30. 
The size and chemical properties depend on the diffusion time. The bigger the 
molecular weight the larger the diffusion time. 
Table 30. Fluorescent peptide conjugates and their diffusion times measured in PBS. 
 
 
 
 
 
 
 
Fig.48 shows an intensity scan measured with FCS. Fluorescent signal intensity of a 
PANC-1 P8 cell is measured in the cytoplasm and at the membrane. VIP-Cy3 shows a 
high absorption peak on the glass and a second small peak indicating the cell 
membrane. In buffer solution the intensity goes towards zero, the peptide is enriched in 
the cell and on the membrane (fig.48).  
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Peptide Conc. [µM] Diffusion time (µs) 
VIP-Cy3 0,255 112,5 ± 12,5 
VIP-Fluo 0,262 75,3 ± 3,3 
Cy3-Scr-VIP 0,256 164,0 ± 43,1 
Et-Cy3-OH 0,256 59,8 ± 5,7 
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Figure 48. FCS intensity scan of VIP-Cy3 of a 
single PANC-1 P8 cell. a) cytoplasm, b) plasma 
membrane and c) buffer solution. The highest peak 
indicates Cy3 glass absorption. The second small 
peak demonstrates the plasma membrane. Compared 
to buffer solution, the most Cy3 signal is visible in 
the cytoplasm, indicating internalisation of VIP-Cy3 
into the cell. 
 
Ligand-receptor specifies was tested with Cy3-Src-VIP, which is a VIP sequence in 
random assembly and covalently linked Cy3 at the N terminus. This peptide should not 
bind to VPAC receptors because of unfolded interaction site.  
 
 
 
Figure 49. FCS intensity scan of Cy3-Scr-VIP 
of a PANC-1 P8 cell. a) cytoplasm, b) plasma 
membrane and c) buffer solution. The first peak 
at 5,260mm indicates Cy3 glass absorption. The 
second peak reflects the plasma membrane. 
Compared to buffer solution, the most Cy3 signal 
is visible on the membrane, indicating no 
internalisation of Cy3-Scr-VIP into the cell. 
 
The intensity scan of Cy3-Scr-VIP shows has a very high absorption at the cell 
membrane (fig.49), more than the glass peak. The time course experiment over 20 
minutes reveals a low intensity signal at about 2-3 kHz (fig.52A2) which corresponds 
with the autofluorescence of PANC-1 cells (fig.52B2). The intensity signal of the 
autofluorescence is about 2 kHz.  
To demonstrate that Cy3 hydrophilic interacts with the membrane, experiments with 
Cy3 dye were performed. Et-Cy3-OH was used for these analyses. As expected the 
intensity scan visualises a large membrane peak and lower absorption at the glass 
(fig.50). Also high intensity signals in the buffer solution and low absorption in the 
cytoplasm are observed.  
 
 
Figure 50. FCS intensity scan of Et-Cy3-OH of a 
PANC-1 P8 cell. a) cytoplasm, b) plasma membrane 
and c) buffer solution. The first peak at 5,300mm 
indicates Cy3 glass absorption. The second peak 
demonstrates the plasma membrane. Compared to 
cytoplasm, the most Cy3 signal is visible in the 
buffer solution, indicating no internalisation of Et-
Cy3-OH into the cell. 
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The time course experiment of Et-Cy3-OH shows the same characteristics like the 
autofluorescence with PBS. The value of intensity is about 5 kHz. Free diffusion time in 
solution averages 59,8µs ± 5,7µs. Cy3 is internalised by the cell; it sticks on the 
membrane by hydrophilic interactions. 
These experiments show that VIP-analogues have a specific VIP receptor interaction 
and is not triggered by Cy3, because Cy3-Scr-VIP and Et-Cy3-OH indicate no signal in 
the cytoplasm.  
The interaction of Cy3 dye with the membrane personates difficulties to calculate the 
percentage of free/bound receptor, because Cy3 hydrophilic interacts with the 
membrane without specific peptide-receptor interaction. So VIP was labelled with a 
fluorescent dye fluorescein, VIP-Fluo, and tested. Fluorescein is not as hydrophilic as 
Cy3 and does not stick on the membrane. Also glass absorption was seen but not as high 
as with Cy3 (fig.49). In fig.51 no membrane peak of fluorescein is seen, only an 
enrichment of peptide in buffer solution is visible. 
 
 
Figure 51. FCS intensity scan of VIP-Fluo of a 
PANC-1 P8 cell. a) cytoplasm, b) plasma membrane 
and c) buffer solution. The first peak at 5,300mm 
indicates fluorescein glass absorption. No membrane 
absorption is visible. The plateau displays the buffer 
solution. Also in the cytoplasm the intensity of 
fluorescein is measured, indicating the internalisation 
of VIP-Fluo into the cell. 
 
The correlation curve of VIP-Fluo indicates two short components, like the diffusion 
time of VIP-Fluo in free solution, and one longer component at about 1,5ms. The 
difference to Cy3 labelled peptides results in the none-hydrophilic interaction of the 
dyes with the membrane. Fluorescein does not stick to inner membranes and therefore a 
good correlation is calculated (data not shown). 
Time course experiments with both VIP-Cy3 and VIP-Fluo indicate that the fluorescent 
signal reaches its steady state level after about 5 minutes. Cy3-Scr-VIP does not enter 
the cell, indicating the importance of the specific ligand receptor reaction for 
internalisation. No increased fluorescent signal is reached when measuring the 
autofluorescence. As a conclusion, specific interaction of VIP-conjugates with VPAC 
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receptors and a following internalisation of the conjugates into the cytoplasm occur 
(fig.52). 
 
Figure 52. Fluorescence correlation spectroscopy with VIP-conjugates; time course of 
internalisation in PANC-1 P8 cells of Cy3 (A) VIP-Cy3 (A, line 1) and Cy3-Scr-VIP (A, line 2) and 
Fluorescein (B) VIP-Fluo (B, line 1) and background due to autofluorescence (B, line 2). With both, 
VIP-Cy3 and VIP-Fluorescein, the internalisation reaches its steady state level (100%) after about 5 
minutes. ScrVIP-Cy3 does not enter the cell, indicating the importance of the specific ligand receptor 
reaction for the internalisation. The autofluorescence measurement produced no signal. 
 
The intensity scan of VIP-Cy3 labelled proticles #G shows a glass absorption peak of 
Cy3 and two smaller membrane peaks (fig.53). The fluorescent signal is visible in the 
cytoplasm, but no signal is seen in the buffer solution. The correlation curve of labelled 
proticles #G indicate three compnents, one short like free diffusion of VIP-Cy3, and two 
long components >3000ms (data not shown). 
 
 
Figure 53. FCS intensity scan of VIP-Cy3 labelled 
proticles #G of a PANC-1 P8 cell. a) cytoplasm, b) 
plasma membrane and c) buffer solution. The first 
peak at 5,280mm indicates Cy3 glass absorption and 
two membrane peaks are visible. Also in the 
cytoplasm intensity of Cy3 is measured, indicating 
internalisation of VIP-Cy3 labelled proticles #G into 
the cell.  
 
The time course experiment with VIP-Cy3 labelled proticles #G over 30min, reveals a 
steady state of VIP-Cy3 after about 5min (fig.54). Whereas Cy3 labelled proticles #G 
continuously increase in the cytoplasm. A steady state is not reached after 30min. Cy3 
signal of VIP-Cy3 and labelled proticles #G reach the same intensity after 30min. 
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Figure 54. Fluorescence correlation spectroscopy with VIP-Cy3 labelled proticles and VIP-Cy3; 
time course of internalisation in PANC-1 P8 cells of VIP-Cy3 (red dots) and VIP-Cy3 labelled 
proticle #G (black line). VIP-Cy3 reaches its steady state level after about 5 minutes. VIP-Cy3 
labelled proticles #G showed continuous increase of intensity signal. Steady state is not reached after 
30min, this indicates the delayed VIP-Cy3 release from proticles.  
4.5 Visualisation by Confocal Laser Scanning Microscopy 
In addition to FCS we used Confocal Laser Scanning Microscopy (CLSM) for direct 
visualisation of VIP conjugates internalisation in living cells. Some cell lines were 
tested with VIP-Cy3 (red) and (Ala
11,22,28
)-VIP-FITC (green). Cell nuclei were stained 
with TOPRO-3
® 
(blue).  
We observed a relatively high background-signal ratio after incubation with (Ala
11,22,28
)-
VIP-FITC, whereas incubation with VIP-Cy3 delivered a very good signal to noise 
ratio. TOPRO-3
®
 occasionally stained the cytoplasm or the cell membrane which may 
be an artefact of the experimental system. When testing the autofluorescence for 
peptides or cells, (negative controls with unlabelled VIP, (Ala
11,22,28
)-VIP and TOPRO-
3
®
) we did not observe specific signal.  
 
Fig.55 shows LNCaP prostate carcinoma cells after incubation with fluorescent labelled 
peptides. VIP-Cy3 internalises into the cytoplasm, in addition to the marked membrane 
signal. (Ala
11,22,28
)-VIP-FITC produces a marked membrane signal, without 
internalisation into the cytoplasm.  
Similar signal distributions for the respective peptides are found in the pancreas 
adenocarcinoma cell line Capan-1 cells (fig.56).  
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Figure 55. LNCaP cells after incubation with fluorescence-labelled peptides. Cell nuclei are 
counterstained with TOPRO-3® (blue). A) Control with unlabelled VIP and (Ala11,22,28)-VIP. B) 
Staining with VIP-Cy3 (red) and C) staining with (Ala11,22,28)-VIP-FITC (green). Note that VIP-Cy3 
reveals a membrane signal and a cytoplasmic signal. VPAC1-specific agonist shows preferentially a 
membrane signal, indicating that this cell line has no functional VPAC1 receptors. 
 
 
Figure 56. Capan-1 cells after incubation with fluorescence-labelled peptides. Cell nuclei are 
counterstained with TOPRO-3® (blue). A) Control with unlabelled VIP and (Ala11,22,28)-VIP. B) 
Staining with VIP-Cy3 (red) and C) staining with (Ala11,22,28)-VIP-FITC (green). Note that VIP-Cy3 
reveals a membrane signal and a cytoplasmic signal. VPAC1-specific agonist shows only a membrane 
signal, indicating that this cell line has no functional VPAC1 receptors. 
 
Interestingly pancreas duct carcinoma PANC-1 cells in different passages P14 (fig.57A-
C) and P40 (fig.57D-F) show differences in internalisation behaviour. Both cell ages 
indicate VIP-Cy3 signal in the cytoplasm. PANC-1 P14 cells also show a (Ala
11,22,28
)-
VIP-FITC signal in the cytoplasm, but PANC-1 cells in P40 reveal much weaker 
(Ala
11,22,28
)-VIP-FTIC internalisation into the cytoplasm than in P14.  
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Figure 57. PANC-1 cells, P14 (A-C) and P40 (D-F), after incubation with fluorescence-labelled 
peptides. Cell nuclei are counterstained with TOPRO-3® (blue). A,D) Control with unlabelled VIP 
and (Ala11,22,28)-VIP. B,E) Staining with VIP-Cy3 (red) and C,F) staining with (Ala11,22,28)-VIP-FITC 
(green). Note that VIP-Cy3 reveals a cytoplasmic signal in both cell ages. VPAC1-specific agonist 
(Ala11,22,28)-VIP-FITC show cytoplasmic signal in PANC-1 P14 cells, whereas PANC-1 P40 cells 
show a much weaker signal of VPAC1-specific agonist, indicating that P40 cell line looses their 
functional VPAC1 receptors. 
 
Lung carcinoma A427 cells (fig.58) and hepatocellular carcinoma Hep3B (fig.59) 
exhibit a strong VIP-Cy3 internalisation into the cytoplasm and a weaker staining with 
(Ala
11,22,28
)-VIP-FITC but also in the cytoplasm.  
 
Figure 58. A427 cells after incubation with fluorescence-labelled peptides. Cell nuclei are 
counterstained with TOPRO-3® (blue). A) Control with unlabelled VIP and (Ala11,22,28)-VIP. B) 
Staining with VIP-Cy3 (red) and C) staining with (Ala11,22,28)-VIP-FITC (green). Note that VIP-Cy3 
reveals a cytoplasmic signal. VPAC1-specific agonist (Ala
11,22,28)-VIP-FITC shows a much weaker 
cytoplasmic signal, indicating that this cell line has less functional VPAC1 receptors. 
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Figure 59. Hep3B cells after incubation with fluorescence-labelled peptides. Cell nuclei are 
counterstained with TOPRO-3® (blue). A) Control with unlabelled VIP and (Ala11,22,28)-VIP. B) 
Staining with VIP-Cy3 (red) and C) staining with (Ala11,22,28)-VIP-FITC (green). Note that VIP-Cy3 
reveals a cytoplasmic signal. VPAC1-specific agonist (Ala
11,22,28)-VIP-FITC displays a much weaker 
cytoplasmic signal, indicating that this cell line has less functional VPAC1 receptors. 
 
SW1736 cells (thyroid adenocarcinoma) reveal an internalisation of VIP-Cy3 and also 
display a membrane signal. We observe a green signal on the membrane after 
incubation with (Ala
11,22,28
)-VIP-FITC, but no signs of internalisation after 1h (Fig.60). 
 
Figure 60. SW1736 cells after incubation with fluorescence-labelled peptides. Cell nuclei are 
counterstained with TOPRO-3® (blue). A) Control with unlabelled VIP and (Ala11,22,28)-VIP. B) 
Staining with VIP-Cy3 (red) and C) staining with (Ala11,22,28)-VIP-FITC (green). Note that VIP-Cy3 
reveals a membrane signal and a cytoplasmic signal. VPAC1-specific agonist exhibits only a 
membrane signal, indicating that this cell line has no functional VPAC1 receptors. 
 
Colorectal carcinoma HT-29 cells (fig.61) display a VIP-Cy3 and (Ala
11,22,28
)-VIP-FITC 
internalisation into the cytoplasm. Incubation with (Ala
11,22,28
)-VIP-FITC at following 
time points, 15/ 30/ 45min and 1h, were tried for HT-29 cells. After 30min until 1h, HT-
29 cells reveal internalisation signals but show apoptosis. 15min incubation with 
(Ala
11,22,28
)-VIP-FITC indicate a marked membrane-and internalisation signal (fig.61).  
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Figure 61. HT-29 cells after incubation with fluorescence-labelled peptides. Cell nuclei are 
counterstained with TOPRO-3® (blue). A) Control with unlabelled VIP and (Ala11,22,28)-VIP. B) 
Staining with VIP-Cy3 (red) and C) staining with (Ala11,22,28)-VIP-FITC (green). Note that both 
peptides and fluorochromes reveal a membrane signal and a cytoplasmic signal indicating that this 
cell line has functional VPAC1 receptors which internalise the peptide.  
 
CaCo-2 cells show a VIP-Cy3 signal into the cytoplasm, also (Ala
11,22,28
)-VIP-FITC is 
seen in the cytoplasm (fig.62). Fig.63 HCT-116 cells exhibit a strong uptake with VIP-
Cy3 into the cytoplasm but a weak internalisation of (Ala
11,22,28
)-VIP-FITC. 
 
Figure 62. CaCo-2 cells after incubation with fluorescence-labelled peptides. Cell nuclei are 
counterstained with TOPRO-3® (blue). A) Control with unlabelled VIP and (Ala11,22,28)-VIP. B) 
Staining with VIP-Cy3 (red) and C) staining with (Ala11,22,28)-VIP-FITC (green). Note that both 
peptides and fluorochromes reveal a membrane signal and a cytoplasmic signal indicating that this 
cell line has functional VPAC1 receptors which internalise the peptide. 
 
 
Figure 63. HCT-116 cells after incubation with fluorescence-labelled peptides. Cell nuclei are 
counterstained with TOPRO-3® (blue). A) Control with unlabelled VIP and (Ala11,22,28)-VIP. B) 
Staining with VIP-Cy3 (red) and C) staining with (Ala11,22,28)-VIP-FITC (green). Note that both 
peptides and fluorochromes reveal a cytoplasmic signal. (Ala11,22,28)-VIP-FITC is internalised weaker 
than VIP-Cy3, indicating that this cell line has less functional VPAC1 receptors which internalise the 
peptide.  
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4.6 VIP as carrier for hematoporphyrin (Photodynamic Therapy)  
Photodynamic therapy experiments were done to check the potency of VIP-PDT as a 
pharmacophore. First the oxidative stress level was tested with DCFDA after incubation 
with H2O2 (fig.64) and photosan (fig.65). The readout was fluorescing intensity which 
correlates with the amout of free oxygen reactive species (ROS). These components are 
known as standard substances to induce oxidative stress. We were interested in the 
question whether or not VIP-PDT can increase the celluar oxidative stress level, and 
investigated incubations with and without light radiation. For control purposes some 
experiments are performed without cells in PBS (data not shown) and RPMI 1640. The 
fluoescence in PBS lies between 100-200, which is about three times higher in RPMI 
1640 (Fig 64). Fig.64 displays increasing flurescence with increasing concentration of 
H2O2. Radiated assays show a about 1,5 times increased fluorescence signal.  
 
Figure 64. Reactive oxygen species released from H2O2 in RPMI measured with DCFDA. 
Radiated and non-radiated assays is compared (n=8). Note the increase in fluorescent signal after light 
radiation, 1,5 times more than non-radiated, indicating an increase of ROS after light radiation. 
 
Fig.65 reveals increasing fluorescence with increasing concentration of photosan. 
Assays treated with radiation shows four times higher fluorescence. The highest 
fluorescence was observed after incubation with 1µM photosan. 
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Figure 65. Reactive oxygen species released from photosan in RPMI measured with DCFDA. 
Radiated and non-radiated assay is compared in the diagram (n=8). Note that 1µM photosan shows 
the highest fluorescent signal in both assays. Radiated assay shows more signals, indicating an 
increase of ROS after radiation 
 
Fig.66 shows fluorescence with decreasing concentration of VIP-PDT. Overall the 
fluorescence release is half as compared with photosan on an equimolar basis, there is 
little difference between radiated and non-radiated assays. The most effective 
fluorescence release is with incubation of 1µM VIP-PDT. 
 
Figure 66. Reactive oxygen species released from VIP-PDT measured with DCFDA. Radiated 
and non-radiated assay is compared in the diagram (n=4). No difference between radiated or non-
radiated assay is visible. 1µM VIP-PDT shows the highest fluorescent signal. Compared to fig. 70, 
VIP-PDT is not able to release similar amounts of ROS, indicating that VIP-PDT has not the potential 
of ROS induction than photosan.  
 
The same assay was performed with cells treated with VIP-PDT and photosan. The cell 
lines PC-3, Hep3B, SW1736, HCT-15, HT-29 and HMEC-1 were analysed for their 
oxidative stress level and if VIP-PDT or photosan induces ROS in the cell. PC-3 cells 
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don´t show an increased oxidative stress level compared to the control cells (fig.67). 
Also without radiation cells produce more fluorescence than radiated once. 
 
Figure 67. ROS of PC-3 cells measured with DCFDA. VIP-PDT and photosan with different 
concentrations are tested in radiated and non-radiated assays (n=2). Both peptides are not able to 
induce ROS level; radiation could not reveal significant increase of ROS, indicating that cells defend 
against small amounts of ROS. 
 
All analysed cell lines show the same trend as PC-3 cells, where no difference between 
light radiated and non-radiated assays are observed. This effect might be a defence 
mechanism of the cell against small amounts of reactive oxygen species (fig.68-72). 
 
Figure 68. ROS of Hep3B cells measured with DCFDA. VIP-PDT and photosan with different 
concentrations are tested in radiated and non-radiated assays (n=2). Both peptides are not able to 
induce ROS level; radiation can not reveal significant increase of ROS, indicating that cells defend 
against small amounts of ROS. 
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Figure 69. ROS of SW1736 cells measured with DCFDA. VIP-PDT and photosan with different 
concentrations are tested in radiated and non-radiated assays (n=2). Both peptides are not able to 
induce ROS level; radiation can not reveal significant increase of ROS, indicating that cells defend 
against small amounts of ROS. 
 
 
Figure 70. ROS of HCT-15 cells measured with DCFDA. VIP-PDT and photosan with different 
concentrations are tested in radiated and non-radiated assays (n=2). Both peptides are not able to 
induce ROS level; radiation can not reveal significant increase of ROS, indicating that cells defend 
against small amounts of ROS. 
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Figure 71. ROS of HT-29 cells measured with DCFDA. VIP-PDT and photosan with different 
concentrations are tested in radiated and non-radiated assays (n=2). Both peptides are not able to 
induce ROS level; radiation can not reveal significant increase of ROS, indicating that cells defend 
against small amounts of ROS. 
 
 
Figure 72. ROS of HMEC-1 cells measured with DCFDA. VIP-PDT and photosan with different 
concentrations are tested in radiated and non-radiated assays (n=2). Both peptides are not able to 
induce ROS level; radiation can not reveal significant increase of ROS, indicating that cells defend 
against small amounts of ROS. 
 
Photodynamic therapy experiments were performed with VIP-PDT and photosan at 
different concentrations. The concentrations of substances were chosen from the ROS 
experiment, where 1µM of VIP-PDT and 1µM of photosan showed the most released 
ROS.  
CaCo-2 cells were incubated with VIP-PDT and PS treated with or without radiation. 
Survival of cells was measured 5h after treatment. Fig 73. reveals an increased cell 
number after incubation with VIP-PDT or photosan. Non-radiated cells show no 
significant difference in cell growth stimulation, the cell viability is about 100% 
compared to control cells. 
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Figure 73. Measurement of survival rate of CaCo-2 cells after incubation with VIP-PDT and 
photosan. Assays were performed without radiation and cell survival was measured 5h after 
treatment (n=4). Both peptides show no reduction or proliferation in cell growth, indicating that 
without radiation peptides do not influence cell growth. 
 
Fig.74 shows CaCo-2 cells treated with radiation; a significant decrease in cell survival 
is seen after treatment with photosan. All concentrations of photosan show the similar 
effect, 70-80% cell survival of CaCo-2. Whereas cells incubated with VIP-PDT reveal 
no reduction of cell growth at all concentrations (100%).  
 
Figure 74. Measurement of survival rate of CaCo-2 cells after 5h with radiation of incubated 
peptides (VIP-PDT and photosan). Assays were performed with radiation and cell survival was 
measured 5h after treatment (n=4). Photosan shows reduction of cell growth of about 20-30%. VIP-
PDT do not reveals a reduction of growth, indicating that only radiation of photosan influence cell 
growth. 
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The survival rate of radiated Capan-1 cells after 24h incubation is measured and shows 
the same trend like CaCo-2 cells. Photosan indicated a significant decrease of viable 
cells at about 80%, but VIP-PDT has no effect on cell growth behaviour after light 
radiation (fig.75). 
 
 
Figure 75. Measurement of survival rate of Capan-1 after 24 hours, cells after incubation (VIP-
PDT and photosan) and radiation. Assays were performed with radiation and cell survival was 
measured 24h after treatment (n=4). Photosan shows reduction of cell growth of about 20%. VIP-PDT 
do not reveals a reduction of growth, indicating that only radiation of photosan reduces the viable 
cells. 
 
The same experiment was done with HT-29 cells. Non-radiated cells after 5h incubation 
show no significant difference of cell viability. VIP-PDT and PS incubated cells reveal 
no significant increase of growth (100%; fig.76). Fig.77 exhibits a reduction of 1µM 
photosan radiated cells of about 10-20%. Other concentrations of photosan indicate no 
growth defects. VIP-PDT has no effect on cell growth behaviour after radiation. 
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Figure 76. Measurement of survival rate of HT-29 cells after 5h incubation with VIP-PDT and 
photosan. Assays were performed without radiation (n=4). Both peptides show no reduction or 
proliferation in cell growth, indicating that without radiation peptides do not influence cell numbers. 
 
 
Figure 77. Measurement of survival rate of HT-29 cells after after 5 hours, cells after incubation 
(VIP-PDT and photosan) and radiation. (n=4). 1µM Photosan shows a reduction of cell growth of 
about 10-20%. Other concentrations of PS or VIP-PDT do not reveal a reduction of growth, 
indicating that only radiation of 1µM photosan influence cell growth. 
 
Further HT-29 cell survival is measured 24h after cells treated with light radiation 
(fig.78), because HT-29 do not show similar effect of photosan 5h after treatment like 
CaCo-2 and Capan-1. Interestingly 24h incubation of radiated photosan reveals the 
same result like 5h after treatment. 1µM photosan decreases the cell number to 50%, all 
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other concentrations show an increase of cell growth at about 120%. Cells incubated 
with VIP-PDT indicate a significant cell survival of about 300%. 
 
Figure 78. Measurement of survival rate of HT-29 after 24 hours, cells after incubation (VIP-PDT 
and photosan) and radiation (n=4). 1µM Photosan shows reduction of cell growth of about 50%, all 
other concentrations increase cell growth of about 20%. VIP-PDT reveals an increase of growth of 
300%, indicating that only radiation of 1µM photosan reduces cell growth. 
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5 Discussion 
We investigated several aspects of VIP as possible carrier for diagnostic or therapeutic 
moieties, and revealed some interesting new concepts with potential as anti tumour 
drug. More specifically the following concepts were investigated:  
 
- VIP-DOTA-Gd revealed some good potential for MRI diagnostics. 
- (Ala11,22,28)-VIP indicated a good potential to selectively target VPAC1 
expressing tumour cells, which is a promising approach to circumvent hypotonic 
reactions after systemic application. 
- VIP-PDT did not release measurable amounts of reactive oxygen species inside 
the cell, it did not reveal any cytotoxic effect after treatment with red light 
radiation, whereas photofrin
®
/photosan with red light radiation raised reactive 
oxygen species (ROS), which resulted in an cyotoxic effect.  
- None of the peptide conjugates or analogue displayed a cytotoxic effect,  
- some cell lines were proliferation stimulated by VIP conjugates 
- To reveal the potential of VPAC receptors for anti-cancer drug delivery we 
observed different VIP analogues and conjugates, by FCS, confocal microscopy 
and ELISA. 
5.1 Cell receptor expression 
Immunocytochemistry (ICC) stainings of VPAC receptors were performed. We 
observed unspecific reactions with some of the antibodies; therefore we used a variety 
of monoclonal and polyclonal antibodies for the ICC staining. The anti-VPAC1 
antibodies did not reveal the same signal densities suggesting a lower sensitivity as 
compared to the anti-VPAC2 and anti-PAC1 immunoglobulines. Interestingly many cell 
lines showed very strong nuclear staining with VPAC antibodies which positively 
correlated with the receptor expression (fig. 17C, 18B, 19C, 20B, 21CD, 22CD, 29CD). 
It may be an artefact or it may indicate that cells with high receptor expression show 
receptors within the cell nucleus.  
The expression pattern of all cell lines were also performed with Western Blot analysis 
(n=20). Monoclonal and polyclonal antibodies against VPAC receptors were 
investigated in WB. Immunodetection with VPAC polyclonal antibodies exhibited a 
non-specific binding on the blot (data not shown). Also immunodetection with 
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monoclonal antibody were not as specific as expected also by chancing the 
nitrocellulose membrane to PVDF membrane, it did not show a better signal. Different 
buffers with 0,5x TPBS and TTBS were tried but no specification of signal can be 
visualised. A gently band of protein lysates detected with anti-VPAC1 was seen between 
45-55kDa and a stronger band at 55kDa between several unspecific bands. VPAC1 
receptor has a molecular weight of 49kDa. A brighter band at 55kDa was made by 
secondary antibody, which was tested previous (data not shown). The anti-VPAC2 blots 
displayed many bands, amongst other a band at 55kDa which is the weight of VPAC2. 
A control blot was detected for actin, where strong specific band could be seen. The 
WB data was not taken to determine VPAC expression pattern of the cell lines, because 
of additional unspecific binding of antibodies. Previously experiments performed by DI 
Dr. Chantal Rodgarkia-Dara indicated the same problems with non-specific binding of 
these antibodies (personal communication). 
In summary the results with ICC and WB indicate that the available immunoglobulines 
for the receptor expression are prone to produce artefacts next to specific binding.  
5.1.1 Cell specificity of receptor expression 
However based on negative controls we observed specific staining (signal density 
beyond negative control) which was indicative for a differential receptor expression of 
the investigated cell lines.  
We observed the expression of VPAC1, VPAC2 and PAC1 in 14 human tumour cell 
lines and one human microvascular endothelial cell line (HMEC-1). Many of these cell 
lines had a preference for VPAC1 receptor expression (for example: PC-3 fig.18; 
PANC-1 P6 fig.20; A427 fig. 21; Hep3B fig.22; MGC fig.24; HCT-15 fig.25; HT-29 
fig.26; CaCo-2 fig.27; HCT-116 fig.28 and MCF-7 fig.29). Others had a preference for 
VPAC2 receptor expression (LNCaP fig.17; Capan-1 fig.19; SW1736 fig.23 and 
HMEC-1 fig.30). All cell lines except of HMEC-1 and HCT-15 showed also PAC1 
expression.  
  
Interestingly our data are in agreement with (Reubi 2003) and (Moody et al. 2003), 
which described dominantly overexpressed VPAC1 receptor in cancer cells compared to 
healthy tissue. Other colleagues characterized healthy-and tumour tissue and cell lines 
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for their VPAC expression pattern (table 2 and 3), which are in agreement with our 
studies.  
5.1.2 Variability of receptor expression  
We observed that the receptor expression varied within the culture, cells with high 
expression were found near cells with low expression, For example the PAC1 receptor 
expression in SW1736 (fig.23C,D) and in HT-29 (fig.26CD) is heterogeneous. The 
same situation was observed for VPAC2, heterogenic expression was observed in the 
same culture of SW1736 (fig.23CD). These results indicate that within the same cell 
population the receptor expression of individual cells can vary from high to low.  
We have seen that in PANC-1 cells the receptor expression is variable and depends on 
culture age. PANC-1 cells in passage about 1-15 express VPAC1, VPAC2 and PAC1 
receptors, whereas PANC-1 cells in passage about 20 loose VPAC1 receptor completely 
and downregulate the expression of VPAC2 and PAC1 receptor (fig.20). This might 
indicate a technical artefact and differences in sensitivity of signal, or a gradual receptor 
downregulation under experimental in vitro conditions.  
Based on my work I conclude the receptor expression in culture is variable to each 
individual cell and possibly depends on the age of the culture.  
5.2 Internalisation behaviour of VIP-conjugates 
Fluorescence correlation spectroscopy (FCS) and Confocal Laser Scanning Microscopy 
(CLSM) was used to observe the direct internalisation of VIP-conjugates in living cells 
via the specific VIP signalling pathway.  
5.2.1 Indirect visualisation of internalisation by cAMP measurement 
Indirect visualisation of internalisation was shown with cAMP ELISA of HT-29, 
Capan-1 and HMEC-1 cells. Fig.45 clearly displayed the one signalling pathway of HT-
29 and Capan-1 tumour cell lines. cAMP was released after stimulation with VIP, 
(Ala
11,22,28
)-VIP and VIP-DOTA-Gd. VIP revealed the highest cAMP release compared 
with the other conjugates, because VIP-conjugates increase in molecular size, differ in 
chemical properties and may have other interaction behaviour. All these causes 
contributed to less cAMP release. Capan-1 cells showed less cAMP response compared 
to HT-29 cells, this might be explained by individual degradation velocities of cAMP of 
each cell line. Also the functionality of the peptide conjugates and biological activity of 
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VIP-conjugates are proven by cAMP signalling response. My data also indicate that 
VPAC receptor recycling is not interfering and disabled with conjugates. HMEC-1 cells 
did not exhibit a cAMP signalling when stimulation with VIP and conjugates, this could 
have several reasons. Endothelial cells are cultured on collagen basis, either cells were 
not grown or lysated properly, the most important reason might be that endothelial-and 
smooth muscle cells dominantly expressing VPAC2 receptor (Adamou et al. 1995; 
Reubi 2000; 2003; Schulz et al. 2004), VPAC2 signalling prefers phospholipase C 
pathway (Yamada et al. 2004) and not adenlyate cyclase with second messenger cAMP. 
This phenomenon is described for PAC1 signalling. In this case HMEC-1 could not be 
visualised via cAMP, therefore increased Ca
2+
 should be measured.  
As known before (Rubinstein 2005; Sejourne et al. 1997; Sethi et al. 2005; Stark et al. 
2007) enclosed VIP in liposomes are used for systemic application and peptide 
protection of proteases. We tested whether or not liposomes and proticles release VIP 
with a delay and were functional active. Our data indicated that liposomes were a good 
tool for VIP delayed release. We observed lower cAMP level at low proticle #G 
concentration at different time points. This might be because of too less concentration of 
proticles. Liposomes 08I indicated a delay in the first 20 minutes compared to free VIP 
in equal concentrations of PASMCs (fig.46). Also proticles #G revealed an increased 
cAMP response and a delay effect in PANC-1 P8 cells through the first 30min 
compared to free VIP. After 45min no cAMP release was triggered with 1µM proticle 
#G and 10nM VIP (fig.47). 
Both liposomes and proticles indicated a delay of cAMP release after stimulation, 
indicating an advantage for VIP application in patients. 
5.2.2 Fluorescence correlation spectroscopy (FCS) 
FCS of PANC-1 P8 cells revealed a long diffusion component in the membrane area 
and in the cytoplasm for VIP-Cy3 (data not shown), which indicates a strong binding to 
the plasma membrane and inside the cell (fig.48). This phenomenon might be explained 
by hydrophilic properties of Cy3, which immobilize with the molecules on the 
membranes especially at the plasma membrane, endoplasmatic reticulum (ER) or other 
membranes in the cell. To test this theory we changed the conjugate to fluorescein 
which is not as hydrophilic as Cy3. VIP-Fluo revealed much better correlation of 
diffusion (data not shown), we found no long component indicating a membrane 
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association (fig.51). In addition there was less photobleaching with VIP-Fluo (fig.52B1) 
than with VIP-Cy3 (fig.52A1). Controls with Et-Cy3-OH and Cy3-Scr-VIP, with 
random VIP sequence, showed high membrane peaks (Fig.49b, 50b) indicating strong 
membrane binding. No signal in the cytoplasm indicated sequence specific peptide 
internalisation. Haberl et al. (2006) showed the relevance of Cy3 conjugation with a 
ethyl group or a lysine as linker to VIP at N-or C-terminus. Amino terminal and ethyl 
conjugated VIP resulted in less internalisation than the carboxy terminal with lysine 
conjugated VIP. But both conjugates were still active and biological functional.  
My results indicated that VIP conjugates internalised via VPAC receptors because 
controls Et-Cy3-OH, Cy3-Scr-VIP and autofluorescence did not show an internalisation 
into the cell. Et-Cy3-OH and Cy3-Scr-VIP showed fluorescence intensities between 2-
5kHz, which correlated with the autofluorescence of the cell (fig.52A2,B2). Whereas 
VIP-Cy3 and VIP-Fluo showed a rapid internalisation within the first 5 minutes and 
revealed a steady state after VIP-conjugate uptake. An decreasing fluorescence over 20 
minutes of VIP-Cy3, and less of VIP-Fluo was observed because of photobleaching 
induced by the laser (fig.52A1,B1). Therefore we assumed that VIP had a specific 
interaction with VPAC1/2 and PAC1, and Cy3 interacted with the membranes. Cy3 is a 
high hydrophilic molecule which intercalates in hydrophilic structures at the membrane. 
Additionally we tested VIP-Cy3 labelled proticles #G (fig.53), which showed a 
continuously increase of Cy3 signal in the cytoplasm. After 30min no saturation effect 
could be reached, whereas free VIP-Cy3 reached a steady state after 5min (fig.54). As 
seen in fig.47 PANC-1 P8 cells displayed a delay of cAMP release after incubation with 
proticles #G, which was in agreement with FCS data, indicating a delayed release of 
VIP-Cy3 from proticles in the time period of 30min.  
5.2.3 Confocal Laser Scanning Microscopy (CLSM)  
A non-radioactive technique with confocal laser scanning microscopy (CLSM) was 
described by Haberl et al. (2006) and used as a direct method for internalisation in 
living cells. Technical difficulties were observed with nuclear staining with TOPRO-3
®
. 
Partly staining of the cytoplasm or the whole cell was observed in some cell lines 
(fig.56A, 58AC, 62A, 63AC). Others showed only nuclear staining. The staining of the 
dye might work cell line depended or oblique on cell vitality, indicating that TOPRO-3
®
 
might not be the best tool for in vivo staining.  
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We showed that the fluorescently labelled conjugates VIP-Cy3 and (Ala
11,22,28
)-VIP-
FITC internalised in carcinoma cells from different tissue origin (LNCaP fig.55; Capan-
1 fig.56; PANC-1 fig.57; A427 fig.58; Hep3B fig.59; SW1736 fig.60; HT-29 fig.61; 
CaCo-2 fig.62 and HCT-116 fig,63). A high background-signal ratio was seen in with 
(Ala
11,22,28
)-VIP-FITC staining. In spite of blocking with more percent of FBS, FITC 
showed a very high background signal. Because we frequently observed a membrane 
signal when using VPAC1 selective agonists (Ala
11,22,28
)-VIP-FITC even after 1 hour of 
incubation, might indicate that the VPAC1 receptor needed more time for 
internalisation. HT-29 cells were incubated only 15min with (Ala
11,22,28
)-VIP-FITC 
(fig.61C) because of apoptosis of cells with increasing time. 
Ala(
11,22,28
)-VIP internalisation into the cytoplasm indicated a functional VPAC1 
receptor. 
5.3 VIP receptor expression and internalisation function  
Interestingly my confocal data were in agreement with the immunocytochemistry (ICC) 
data. Those cells which did not express VPAC1 receptor (LNCaP fig. 17B, Capan-1 
fig.19B, PANC-1 P8 fig.20F, SW1736 fig.23B and HMEC-1 fig.28B) showed only 
weak or no internalisation of the VPAC1-selective agonist into the cytoplasm (LNCaP 
fig. 55C, Capan-1 fig.56C, PANC-1 P40 fig.57F, SW1735 fig.60C and HCT-116 
fig.63C).  
PANC-1 cells at different age P14 and P40 indicated differences of their internalisation 
pattern. Interestingly ICC staining showed clearly different expression patterns of aged 
PANC-1 cells (fig.34). Some internalisation was observed, possibly the ICC staining 
was less sensitive than the internalisation of fluorescent peptides, alternatively we 
would have to assume that the receptor specific (Ala
11,22,28
)-VIP-FITC is using 
alternative receptors.  
5.4 Peptide conjugates and their cellular effects 
We used three types of ligands with a potential for clinical use. VIP-DOTA-Gd which 
might be applied in MRI diagnostics, VPAC1 selective agonist (Ala
11,22,28
)-VIP for 
specific tumour targeting and VIP-PDT as an application for photodynamic therapy 
(PDT).  
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5.4.1 VIP-DOTA-Gd 
123
I-VIP is known as a chelator for tumour targeting (Virgolini et al. 1994a; 1996; 
1994b) which has been successfully used in tumour search and therapy (Krenning et al. 
2004; Virgolini et al. 1998). Based on this knowledge we designed a DOTA-Gd 
conjugated to VIP for selective VPAC tumour targeting for MRI diagnostics. The 
advantage of DOTA chelated with Gd
3+
 is the loss of cytotoxicity of free Gd
3+
 as 
described by Idee et. al (2006). As shown in fig.45 VIP-DOTA-Gd exposed to tumour 
cells increase the cAMP level. We concluded that the VIP conjugate entered the cell to 
receive this reaction; this implies that the conjugated DOTA with the gadolinium 
entered the cell via the VIP signalling pathway. MTT tests were performed to 
characterise the cell growth behaviour of incubated VIP-conjugates. The MTT assays 
showed no toxicity after incubation with VIP-DOTA or VIP-DOTA-Gd. Both peptide 
conjugates were similar in growth behaviour. LNCaP (fig.31), Capan-1 (fig.33), Hep3B 
(fig.36), SW1736 (fig.37), MGC (fig.38), HCT-15 (fig.39), HT-29 (fig.40), CaCo-2 
(fig.41), HCT-116 (fig.42) and MCF-7 (fig.43) showed no proliferation after treatment. 
Increased cell number of about 20% was observed in PC-3 (fig.32), PANC-1 P8 
(fig.34), A427 (fig.35) and HMEC-1 (fig.44) cells. These cell lines also indicated 
increased proliferation when treated with VIP as a control.  
Free Gd
3+
 is cytotoxic, but chelated to DOTA and linked to VIP, none of all cell lines 
demonstrated cytotoxic effects of VIP-DOTA-Gd in the MTT assays; therefore they 
could be useful for MRI diagnostics as a non-radioactive tool in clinical applied studies. 
5.4.2 (Ala11,22,28)-VIP 
(Ala
11,22,28
)-VIP selective agonist (Nicole et al. 2000) was investigated to for VPAC1 
tumour trageting while blood vessels and smooth muscle cells express dominantly 
VPAC2. Fluorescent labelled and unlabelled (Ala
11,22,28
)-VIP internalisation was shown 
by confocal microscopy, MTT assays were performed to test the proliferative or 
cytotoxic behaviuor of tghe peptide. Following cell lines exhibited no significant inrease 
or decrease in cell growth after treatment with conjugate: LNCaP (fig.31), Capan-1 
(fig.33), Hep3B (fig.36), SW1736 (fig.37), MGC (fig.38), HCT-15 (fig.39), HT-29 
(fig.40), CaCo-2 (fig.41), HCT-116 (fig.42) and MCF-7 (fig.43). An increased cell 
number of about 20% was observed in PC-3 (fig.32), PANC-1 P8 (fig.34), A427 
(fig.35) and HMEC-1 (fig.44) cells. Interestingly HMEC-1 were growth stimulated by 
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VIP and (Ala
11,22,28
)-VIP compared to PACAP, even though HMEC-1 cells 
predominantly express VPAC2 receptor. 
5.4.3 VIP-PDT 
VIP-PDT has the potential to increase the selectivity of photodynamic therapy (PDT), 
because VIP may be a carrier for PDT which targets the PDT to specific VPAC receptor 
expressing cells. First we were interested in the potency of VIP-PDT and photosan 
releasing free radicals and inducing programmed cell death. Different concentrations of 
H2O2, VIP-PDT and photosan in PBS or RPMI 1640 were measured with and without 
radiation. Data showed increased fluorescence in the case of RPMI 1,5 times more than 
with PBS (fig.64-66). A saturation of DCFDA system is possible, because 1µM of 
photosan and VIP-PDT showed less fluorescence than all other concentrations 
(fig.64,65). Photosan induced more reactive oxygen species (ROS) than VIP-PDT. Also 
the oxidative stress level of investigated cell lines was measured (fig.67-72), these 
results revealed no measurable amounts of ROS with DCFDA.  
We did not observe a cytotoxic effect after incubation of 1µM-10pM VIP-PDT with or 
without radiation (fig.73-78). We expect that the VIP-PDT oligomer polymerisation 
during internalisation was destroyed; which means that single hematoporphyrin groups 
has entered the cell. Photofrin
®
/photosan is an oligomer of hematoporphyrin groups, 
which has been more efficient in producing ROS after radiation. May be a defence 
reaction of the cell is activated after exposure to radiation.  
CaCo-2 and HT-29 cells treated with photosan without radiation showed no increased or 
decreased cell viability (fig.73,76), whereas cells treated with 1µM-10pM photosan and 
radiation revealed a significant reduction in growth of about 20% in CaCo-2 (fig.74), 
Capan-1 (fig.75), HT-29 (fig.77,78). Interestingly HT-29 cells displayed massive 
increase in cell number after radiation, only 1µM photosan stops proliferation and 
reduced cell growth of about 20% (fig.77). HT-29 cells needed a high concentration 
(1µM) of photosan to reach a cytotoxic effect with radiation. Capan-1 and HT-29 were 
measured 24 hours after treatment (fig.75,78). These data indicated that programmed 
cell death of 20% was visible after 5h and 20-50% after 24h. Photofrin can induce 
oxidative stress which has been shown by Gomer et al. (1996), and reduces in cell 
growth in colon carcinoma (Yang et al. 2007) and in HT-29 cells (Marchal et al. 2005).  
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Experiments with ROS and cell growth stimulation or cytotoxicity of VIP-PDT and 
photosan after radiation, were not in agreement. ROS induced by photosan showed the 
highest signal at 1µM concentration, whereas cell survival after radiation depended not 
on photosan concentration. An explanation for this phenomenon might be that small 
amount of ROS are enough to activate programmed cell death. Less ROS induction 
could lead to a defence mechanism of the cell, which converts ROS to non-cytotoxic 
products.  
Finaly we conclude that VIP-PDT has not the potential to induce cell death of tumour 
cells, because of missing accumulation of hematoporphyin groups, whereas photosan 
revealed a reduction of cell number of about 20% which depended among the cell lines.  
.
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6 Abstract 
In this work we were interested in the potency of VPAC receptors as target for anti-
cancer drug delivery. There are three subtypes of VPAC receptors, VPAC1, VPAC2 and 
PAC1. They belong to the large superfamily of G-protein coupled receptors (GPCR) 
which play an important role in cell signalling. The two most major specific VPAC 
receptor ligands are neuropeptides, vasoactive intestinal peptide (VIP) and pituitary 
adenlyate cyclase activating polypeptide (PACAP). These small peptides function as 
trophic factor in neurodevelopment, stimulate hormone release, have anti-inflammatory 
effects and benefit tumour proliferation. VIP is an important vasodilator and relaxant of 
smooth muscle cells. Previously VIP´s action for tumour targeting and use in tumour 
diagnostics has been well studied by many groups. Lot of specific agonists and 
antagonists have been developed to target VPAC expressing tumour cells. VIP is widely 
distributed in the most tissue (pancreas, prostate, stomach, thyroid, lung, breast, brain, 
skeletal and smooth muscles and vessels) and VPAC expression pattern showed that 
most endocrine tumours express dominantly VPAC1 receptor and vessels and smooth 
muscles VPAC2, PAC1 is mostly present in the brain. 
We investigated three ideas in this work, on the one hand selective tumour targeting 
with a VPAC1 specific peptide (Ala
11,22,28
)-VIP, because of the VPAC2 expressing 
vessels and muscles cells. This receptor pattern helps use to circumvent the hypotonic 
shock after systemic application and can be used for patients without adverse effects. 
(Ala
11,22,28
)-VIP engulfed in liposomes and loaded with anti-sense RNA or other 
downregulating or destroying drugs could be used as pharmacophor. On the other hand 
we designed a peptide conjugate, VIP-DOTA-Gd, for non-radioactive tumour targeting 
for magnet resonance imaging (MRI) diagnosis. At last a VIP-hematoporphyrin 
conjugate, VIP-PDT, was developed to increase selective photodynamic therapy (PDT) 
for VPAC expressing cancer cells. 
First we characterized 14 human tumour cell lines from different organs and one 
microvascular endothelial cell line for their VPAC receptor expression pattern 
performed with immunocytochemistry (ICC) stainings with specific antibodies. Cell 
culture showed heterogenic expression of VPAC receptors and different expression 
pattern with cell age (PANC-1), therefore living surgically removed human tumour 
tissue should be analysed. Specific interaction of ligand and receptor and the following 
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internalisation into the cytoplasm of VIP conjugates, (Ala
11,22,28
)-VIP, VIP-DOTA-Gd 
and VIP-PDT, were visualised by fluorescence correlation spectroscopy (FCS), 
confocal laser scanning microscopy (CLSM) and cAMP ELISA. Also VIP engulfed in 
liposomes or proticles was tried for delayed VIP release, because VIP is proteolytic 
cleaved in extracellular fluid and therefore its half life time is about 1-2 min. These 
assays performed with cAMP ELISA indicated a 20min to 30min delay of cAMP 
release compared to free VIP. Proliferation properties of VIP-conjugates were obtained 
with MTT assays and analysed for their cytotoxic behaviour. None of the tested 
peptides, VIP, VIP-DOTA-Gd, (Ala
11,22,28
)-VIP and PACAP showed cytotoxic effects, 
some cell lines used VIP or conjugates as proliferative factor. VIP-hematoporphyrin 
conjugate was tested for its potential as selective light sensible chemical substance, 
photo-sensitiser, for PDT. Experiments performed with DCFDA as detection system 
revealed a release of reactive oxygen species (ROS) after incubation of VIP-PDT 
treated with radiation. Cells treated with VIP-PDT and radiation did not increase ROS 
and no reduction of cell growth was observed. As control we used a classical PDT 
substance, Photofrin
®
 (hematoporphyrin oligomer), which indicated apoptosis of 
tumour cells of about 20%-50% after treatment with radiation. So we conclude that 
VIP-PDT with a single hematoporphyrin group is not able to induce enough ROS inside 
the cell, which might depend on defence mechanisms of the cell. 
 
Finally we can say that the development of a selective VPAC1 tumour targeting system 
with (Ala
11,22,28
)-VIP could be useful for anti-cancer drug delivery. Further VIP-DOTA-
Gd can be used to target VPAC positive tumours to increase the sensitivity of tumour 
screenings by MRI. Because we observed inhomogeneous receptor expression in the 
very same cell line and receptor loss in the in vitro models when cells grow over time 
future investigations should employ surgically removed human material and mouse 
models. 
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7 Zusammenfassung 
Diese Arbeit beschäftigt sich mit dem Thema, ob VPAC-Rezeptoren als Schlüssel zur 
Krebsbekämpfung benützt werden können. Es gibt drei Subtypen von VPAC-
Rezeptoren, VPAC1, VPAC2 und PAC1, welche alle zur großen Familie der G-Protein 
gekoppelten Rezeptoren (GPCR) gehören und eine wichtige Rolle in der 
Zellsignaltransduktion spielen. Die zwei wesentlichsten VPAC-Rezeptor Liganden sind 
Neuropeptide, wie das Vasoaktive Intestinale Peptide (VIP) und das Hypophysen-
Adenlyatzyklase-aktivierendes Polypeptid (PACAP). Diese kleinen Peptide üben ihre 
Funktion als Wachstumsfaktor in der Neurogenese und Entwicklung aus, stimulieren 
Hormonausschüttung, vermindern Entzündungen und unterstützen den 
Tumorwachstum. VIP wirkt auch als Vasodilator und relaxiert glatte Muskulatur. 
Frühere Studien vieler Arbeitsgruppen haben sich mit VPAC-Rezeptor 
Tumorerkennung und Diagnostik beschäftigt, wobei viele spezifische Agonisten und 
Antagonisten wurden dabei entwickelt. VIP ist in vielen Geweben weit verbreitet, wie 
zum Beispiel im Pankreas, Prostata, Thyroidea, Lunge, Brust, Skelett-und glatte 
Muskulatur und Gefäßen. Die VPAC Expression in endokrinen Tumorzellen zeigt eine 
Dominanz des VPAC1 Rezeptors, in Gefäßen und Muskelzellen des VPAC2 Rezeptors. 
PAC1 ist hauptsächlich im Hirngewebe zu finden. 
In dieser Arbeit haben wir uns mit drei Fragestellungen beschäftigt. Der selektive 
Agonist (Ala
11,22,28
)-VIP wird für die spezifische VPAC1 Tumorerkennung eingesetzt. 
Mit diesem System können wir den durch Applikation ausgelösten hypotonen Schock 
umgehen und schaffen eine im Patienten angewandte spezifische VPAC1 
Tumorerkennung ohne Nebenwirkungen. (Ala
11,22,28
)-VIP verpackt in Liposome oder 
Proticle ermöglicht die spezifische Eintrittsstelle über den VPAC1 Rezeptor, um 
Chemotherapeutika oder anti-sense RNS oder andere Pharmakophore einzuschleusen. 
Das zweite Thema behandelt sich mit dem Einsatz von VIP-DOTA-Gd in der 
Tumordiagnostik. Ein neuer nicht-radioaktiver Ansatz mit VIP-DOTA-Gd ermöglicht 
die Anwendung des Peptidkonjugates für Tumorscreens in der Magnetresonanz (MRI). 
Der dritte Gedanke beschäftigt sich mit einer selektiveren Anwendung von 
photodynamischer Therapie (PDT) über VPAC-Rezeptoren. Ein VIP-Hematoporphyrin 
Konjugat erkennt spezifisch VPAC positive Tumore und ermöglicht eine selektive 
Bestrahlung von erkranken Gewebe.  
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Am Beginn dieser Arbeit stand die Charakterisierung von 14 humanen Tumorzelllinien 
verschiedener Organe und einer mikrovaskulären endothelialen Zelllinie, welche mittels 
Immunozytochemie (ICC) mit spezifischen Antikörpern durchgeführt wurde. In der 
Zellkultur wurde eine heterogene Expression der VPAC-Rezeptoren gefunden, zB. bei 
PANC-1 Zellen, deshalb sollte eine Charakterisierung auch in lebenden Tumorgewebe, 
dass nach der Operation erhalten wird, durchgeführt werden. Die spezifische Interaktion 
zwischen Ligand und Rezeptor und die anschließende Internalisierung von VIP-
Konjugaten, (Ala
11,22,28
)-VIP, VIP-DOTA-Gd und VIP-PDT, wurde mittels Fluoreszenz 
Korrelationsspektroskopie (FCS), Konfokale Laserscan Mikroskopie (CLSM) und 
cAMP ELISA durchgeführt. VIP eingeschlossen in Liposomen oder Proticle wurden als 
Beförderungsmittel zur Tumorzelle getestet, da VIP im Blut proteolytisch abgebaut 
wird und daher eine sehr geringe Halbwertszeit von 1-2 Minuten hat. Dieser Ansatz 
wurde mit cAMP ELISA nachgewiesen und zeigten Liposome und Protcles eine 20-30 
minütige verzögerte cAMP-Ausschüttung gegenüber freiem VIP. Proliferations-und 
Zytotoxizitätsstudien (MTT-Test) wurden mit allen VIP-Konjugaten durchgeführt. 
Keines der VIP-Konjugate, VIP, VIP-DOTA-Gd, (Ala
11,22,28
)-VIP und PACAP zeigte 
eine zytotoxische Wirkung, manche Zelllinien nützen VIP und Konjugate sogar als 
Wachstumsfaktor. Das VIP-Hematoporphyrin Konjugat wurde auf seine Potenz als 
lichtempfindlicher chemischer Stoff, Photosensibilisator, getestet. Als Detektionssystem 
wurde DCFDA verwendet um die Freisetzung von Sauerstoff-reaktiven Spezies (ROS) 
durch VIP-PDT nach Bestrahlung nachzuweisen. Behandelte Tumorzellen mit VIP-
PDT nach Bestrahlung zeigten keinen Anstieg von Sauerstoff-reaktiven Spezies und 
keine Reduktion des Zellwachstums. Die Apoptose oder Proliferation der Zellen wurde 
mit dem MTT-Test ermittelt. Als Kontrolle wurden die Tumorzellen mit einem 
bekannten Photosenibilisator, Photofrin
®
 (Hematoporphyrin Oligomer), getestet. 
Ungefähr 20% der Zellen gingen nach Bestrahlung in Apoptose, daraus schließen wir, 
dass VIP-PDT mit einer einzelnen Hematoporphyrin Gruppe nicht in der Lage ist 
Sauerstoff-reaktive Spezies in der Zelle zu induzieren. Möglicherweise verhindert ein 
durch Strahlen ausgelöster Abwehrmechanismus der Zelle eine vermehrte Produktion 
von Sauerstoff-reaktiven Spezies. 
Abschließend möchte ich die Wirksamkeit von (Ala
11,22,28
)-VIP, einem selektiven 
VPAC1 Agonisten, hervorheben, welcher zukünftig der Schlüssel zur Einschleusung 
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von Chemotherapeutika oder anderen zellschädigenden Substanzen von VPAC-
Rezeptor expremierenden Krebszellen sein könnte. Weiters hat VIP-DOTA-Gd das 
Potential als nicht-radioaktives Peptidkonjugat VPAC positive Tumore in einem 
Tumorscan mit MRI zu erkennen. Da wir inhomogene VPAC-Rezeptorexpression in 
der Zellkultur gezeigt haben, sollten die zukünftigen Arbeiten zu diesem Thema mit 
postoperativen Lebendtumorgewebe und Mausmodellen durchgeführt werden. 
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Singlet oxygen 
3
O2 Triplet oxygen 
aa Amino acid 
Ab Antibody 
AC Adenlyate cyclase 
Approx. Approximate 
ATCC American Type Culture Collection 
ATP Adenosinetriphosphate 
BBB Blood-brain barrier 
Bidest. Bidestillated 
bp Base pair 
cAMP cyclic Adenosinemonophosphate 
CLSM Confocal laser scanning microscope 
CNS Central nerve system 
conc. Concentration 
CRE cAMP response element  
CREB CRE binding protein 
C-terminus Carboxy terminus 
Cy3 Indocarbocanin 3 
Cy3-Scr-VIP Cy3-scrambled-vasoactive intestinal peptide 
DAG Diacylglycerol 
DCF 2´7´-dichlorofluorescein 
DCFDA Dichlorofluorescin diacetate 
DMEM Dulbecco´s Modified Eagle´s Medium 
DNA Desoxyribonuclein acid 
DOTA 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
DOTA-Gd DOTA-Gadolinium, Gadoteratemeglumine 
DTPA dietyhlenetriaminopentaacetic acid 
EC Extracellular 
EGF Endothelial growth factor 
ELISA Enzyme linked immune sorbent assay 
Abbreviation used 131 
ER endoplasmatic reticulum 
Et-Cy3-OH Ethyl-Cy3-hydroxy 
FBS fetal bovine serum 
FCS Fluorescence correlation spectroscopy 
Fig. Figure 
Fluo Fluorescein 
FMOC-SPPS FMOC solid-phase peptide synthesis 
GALT Gut associated lymphoid tissue 
Gd-DPTA Gadopentetatedimeglumine 
Gd-DTPA-BMA Gadodiamide 
Gd-HP-DO3A Gadoteridol 
GDT Guanine diphosphate 
GH Growth hormone 
GLP-1/2 Glucagon like peptide-1/2 
GPCR G-protein coupled receptors 
Gq Stimulating G protein (activtes PLC-β) 
GRF Growth releasing factor 
GRK G-protein kinases 
Gs stimulatory G protein 
GTP Guanine triphosphate 
h hour 
HRP Horseradish peroxidase 
IBMX 1-methyl-3-(2-methylpropyl)-7H-purine-2,6-dione 
IC Intracellular 
IC50 Half maximum inhibitory concentration 
ICC Immunocytochemistry 
IP3 Inositol-1,4,5-triphosphate 
kDa Kilo Dalton 
LH Luteinizing hormone 
max. Maximum 
MEME Egale´s Minimum Essential with Egale´s Salt 
min Minutes 
Abbreviation used 132 
MRI Magnet resonance imaging 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid test 
NEAA Non-essential amino acids 
NFAT-RE Nuclear factor of activated T-cells response element 
Nle Norleucine 
N-ted Ectodomain 
N-terminus Amino-terminus 
OCT Octreatide 
PAC1 PACAP-preferring receptor subtype 
PACAP Pituitary adenlyate cyclase activating polypeptide 
PAGE Polyacrylamide gel electrophoresis 
PALS Periateriolar lymphocyte sheath 
PBS Phosphate buffer saline 
PCD Programmed cell death 
PDT Photodynamic therapy 
PET Photon emission tomography 
PFA Paraformaldehyd 
PIP2 Phosphatidylinositol biphosphate 
PKA cAMP-depending protein kinase  
PKC Ca
2+
-depending protein kinase 
PLC/PI Inositol phospholipid signalling pathway 
PPi Pyrophosphate 
PRL  Prolactin 
PRP PACAP released peptide 
PS Photosan 
RNS Ribonukleinsäure 
ROS Reactive oxygen species 
RP-HPLC Reverse phase- high pressure liquid chromatographie 
RT Room temperature 
s Seconds 
SCLC Small cell lung cancer 
SCN Suprachiasmatic nucleus 
Abbreviation used 133 
SCR Short consensus repeats 
SDS Sodium dodecyl sulphate 
SP signal peptide 
SQ22,536 [9-(tetrahydro-2-furanyl)-9H-purin-6-amine] 
Std Standard 
T1/2 Half life time 
Tab. Table 
TFA Trifluoracetat salt 
TM Transmembrane domain 
TPBS Tween-phosphate buffer saline 
TTBS Tween-TRIS-buffer saline 
UIPHAR Union of pharmacology 
VIP Vasoactive intestinal peptide 
WB Western Blot 
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Figure 1. Human Amino acid sequence of the different members of the PACAP-VIP-GRF-glucagon 
superfamily. Underlined residues indicate amino acids different from those of VIP. In PACAP-38, GKR (Gly28-
Lys29-Arg30) is the internal cleavage- amidation site. [from (Bachem 2005)] ................................................................ 6 
Figure 2. Schematic illustration of human prepro-VIP, and the localisation SP (signal pepide), mature PHM 
and VIP sequences. Amino acid numbers are shown below. [from (Bachem 2005)] ................................................... 6 
Figure 3. Processing steps from prepro-VIP to 28 amino acids long VIP. The peptides substrates and products are 
indicated on the left and the number of amino acids is indicated in parentheses. The processing enzymes are shown 
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Figure 4. Schematic illustration of the general organisation of human prepro-PACAP, and the localisation of 
mature PRP; PACAP-27 and PACAP-38 sequence. Amino acid numbers are shown below; SP: signal peptide. 
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Figure 5. Schematic model of cell entry behaviour of liposomes, and free VIP. Free random coiled VIP can be 
degraded by proteases. VIP in liposomes is folded in a α-helix, this is the preferred form for receptor recognition, it is 
protected from endogenous proteases in the cytosol. After binding, the ligand-receptor complex is internalised into 
the cell thereby triggering signal transduction via G-proteins and second messengers. VPAC receptors are recycled 
back to the cell surface and can be again loaded with the ligand. [from (Hajos F 2008)] ............................................ 13 
Figure 6. GPCR signalling cascade. The initial stage of GPCR activation occurs via agonist-induced conformational 
changes in the receptor to form an active agonist–receptor complex that is able to interact with heterotrimeric G-
proteins and facilitate its activation via exchange of GDP for GTP at the subunit. (a). Following G-protein activation, 
the dissociated subunit and dimers modulate activity of effector proteins that control the level of intracellular 
signalling molecules. Levels of phosphatidylinositol biphosphate (PIP2) and inositol triphosphate (IP3, b) changes in 
the levels of the intracellular signalling molecules Ca2+ (c). G-protein subunit activation of adenylyl cyclase leads to 
cAMP increase (d). Finally, changes in the levels of these signalling molecules produce alterations in gene 
transcription or protein activity and result in the observed functional response of the cell; transcription factors such as 
CREB (cAMP response element binding protein) and reporter genes under the control of appropriate upstream 
elements (e and f). CRE, cAMP regulatory element, NFAT-RE, Nuclear factor of activated T-cells response element 
and DAG, diacylglycerol. [from (Williams 2004)] ...................................................................................................... 17 
Figure 7. The action mechanism of photosensitising agents in PDT. A photo sensitiser in its singlet ground state 
(PTS) is excited to higher energy levels (PTS*) upon irradiation and absorption of a photon of the appropriate 
wavelength. Deactivation occurs either through the emission of fluorescence or via intersystem crossing leading to 
formation of the excited triplet state (3PTS). Subsequently, energy can be lost in the presence of biological substrates 
and molecular oxygen (3O2), via Type I and Type II reactions leading to the formation of free radicals and ROS (O2
•−, 
HO
•
, H2O2, and 
1O2). These cytotoxic species cause cellular photodamage which can activate a repair mechanism or 
lead to cell death when the damage is beyond repair capacity. [from (Buytaert et al. 2007)] ...................................... 29 
Figure 8. Chemical structure of VIP conjugates used in this study. Cy3 and Fluorescein are fluorescing 
molecules. DOTA, DOTA chelated to gadolinium (Gd) has an application in MRI diagnostic. All conjugates are 
linked to the C-terminus of VIP with lysine as linker. ................................................................................................. 41 
Figure 9. Scheme of immunocytochemistry (ICC) staining. The primary antibody recognizes the antigen. The 
secondary antibody covalently linked to a marker molecule, e.g. enzyme, binds to the primary ab. The marker 
molecule is able to convert a substrate to a visible product. [from (Alberts B 2002)] .................................................. 45 
Figure 10. Sandwich ELISA assembly. Unspecific binding sites are blocked with proteins and antigen. Antigen 
coated surface is detected by primary antibody. Enzyme linked secondary antibody recognizes the primary ab and 
converts a substrate to a coloured product. [from (Nelson D L 2004)] ........................................................................ 48 
Figure 11. VIP signal transduction pathway and the influence of Forskolin, IBMX and SQ22,536. Red arrows 
indicate activation and red dots inhibition of proteins. Forskolin actives the adenlyate cyclase directly (VIP 
independent). SQ22,536 inhibits the adenlyate cyclase. IBMX prevents the degradation of cAMP to 5´AMP by 
blocking cyclic nuclide phosphodiesterase. ................................................................................................................. 49 
Figure 12. EIA loading scheme of 96-well microtiter plate. B blank, NSB non specific binding, 0-3200 fmol 
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Figure 13. Scheme of redox reaction in PDT. The conversion of DCFDA (2´7´-dichlorofluorescein diacetate) to a 
fluorescent product. ...................................................................................................................................................... 54 
Figure 14. Schematic drawing of FCS setup. The exciting radiation provided by a laser beam is directed into a 
microscope objective via a dichroic mirror and focused on the sample. Water immersion objectives with a high 
numerical aperture (ideally > 0.9) are used. The fluorescence light from the sample is collected by the same objective 
and passed through the dichroic mirror and the emission filter. The pinhole in the image plane (field aperture) blocks 
any fluorescence light not originating from the focal region, thus providing axial resolution. Afterwards, the light is 
focused onto the detector, preferably an avalanche photodiode or a photomultiplier. [from (Schwille P 2004)] ......... 57 
Figure 15. Scheme of a Confocal Laser Scanning Microscope (CLSM). A laser beam passes a small pinhole and 
activates the fluorescence in the sample. The emitted fluorescence passes a confocal pinhole, to achieve a z-
resolution, and is detected by the detector. After scanning the beam through the specimen a two dimensional image is 
reconstructed. [from (Alberts B 2002)] ........................................................................................................................ 60 
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Figure 16. ICC staining with primary antibody dilutions, A-D) PC-3 cells, E-F) HCT-116 cells and I-L) LNCaP 
cells. Nuclei are stained very light blue with Mayer´s Hematoxylin. ........................................................................... 62 
Figure 17. ICC staining of prostate carcinoma LNCaP cells. A) Negative control without prim. ab, B) VPAC1 
staining, C) VPAC2 staining and D) PAC1 staining with DAB as a substrate. Cell nuclei are counter stained with 
diluted Mayer´s Hematoxylin. VPAC1 staining reveals an unspecific diffuse signal. VPAC2 and PAC1 show a brown 
staining which indicates a specific receptor expression. .............................................................................................. 63 
Figure 18. ICC staining of prostate carcinoma PC-3 cells. A) Negative control without prim. ab, B) VPAC1 
staining, C) VPAC2 staining and D) PAC1 staining with DAB as a substrate. Nuclei are stained light blue with 
Mayer´s Hematoxylin. VPAC1, VPAC2 and PAC1 show a brown staining which indicates a specific receptor 
expression. ................................................................................................................................................................... 64 
Figure 19. ICC staining of pancreas carcinoma Capan-1 cells. A) Negative control without prim. ab, B) VPAC1 
staining, C) VPAC2 staining and D) PAC1 staining with DAB as a substrate. Nuclei are stained light blue with 
Mayer´s Hematoxylin. No specific VPAC1 signal is visualised. VPAC2 staining shows a heterogeneous distribution 
of receptor in the same population. Specific staining is also revealed when staining PAC1receptor............................ 64 
Figure 20. ICC staining of pancreas carcinoma PANC-1 cells. Nuclei are stained light blue with Mayer´s 
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